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ABSTRACT 
Anthocyanins, a unique class of flavonoid compounds, have recently come to the 
forefront of investigative research aimed at evaluating the potential applications of 
natural products to human health. Evidence demonstrating the beneficial effects of 
anthocyanin consumption has been reported for a myriad of conditions including cancer, 
cardiovascular disease, and lately, neurodegenerative disease. Neurodegenerative 
diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis (ALS) are characterized by the death of specific neuronal populations within the 
brain and spinal cord, leading to cognitive and/or motor impairment. While the etiology 
of many of these diseases is largely unknown, several factors have emerged as 
contributors to the neurodegenerative process. These include conditions such as oxidative 
and nitrosative stress, glutamate excitotoxicity, endoplasmic reticulum stress, protein 
aggregation, and neuroinflammation, which ultimately culminate in the death of 
susceptible neuronal populations. Since anthocyanins have been shown to modulate these 
phenomena in numerous ways, interest in evaluating their use as therapeutic agents for 
neurodegenerative diseases has grown. Additionally, the observation that the 
bioavailability of anthocyanins is very low following consumption relative to that of their 
metabolites suggests that anthocyanin metabolites may also play a significant role of 
mediating the beneficial effects of anthocyanin-rich diets. Therefore, we examined the 
neuroprotective and therapeutic effects of both anthocyanins and phenolic acid 
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metabolites derived from anthocyanins in vitro and in a mouse model of ALS. The results 
of our work reveal that different anthocyanin species possess differential neuroprotective 
effects in vitro against toxicity induced by nitric oxide and define a novel neuroprotective 
mechanism for cyanidin-O-3-glucoside under these conditions. Furthermore, we 
demonstrate that presymptomatic supplementation with an anthocyanin-enriched extract 
from strawberries significantly delays disease onset and extends survival in the transgenic 
G93A mutant Cu, Zn-superoxide dismutase (hSOD1G93A) mouse model of ALS. These 
observations correlate with significant preservation of hind limb grip strength and 
function in mice treated with anthocyanins. Anthocyanin supplementation is also shown 
to improve histopathological indices of disease, reducing reactive astrogliosis in lumbar 
spinal cord tissue, and preserving neuromuscular junctions in gastrocnemius muscle 
tissue. We next illustrate that phenolic acid metabolites derived from anthocyanins 
display distinct and complimentary neuroprotective effects in vitro against a diverse array 
of stressors in cerebellar granule neurons. Lastly, our work shows that treatment with 
protocatechuic acid, a metabolite of cyanidin-O-3-glucoside, beginning at disease onset 
provides significant therapeutic benefit to hSOD1G93A mice, extending survival and 
preserving hind limb grip strength in animals supplemented with this compound. The 
results of this dissertation are the first to evaluate the therapeutic efficacy of anthocyanins 
and their metabolites for the treatment of ALS. Collectively, these data demonstrate that 
both anthocyanins and their metabolites may be of significant clinical benefit for treating 
this insidious disease, and suggest that further preclinical and clinical examination of 
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CHAPTER ONE: INTRODUCTION 
With the advent of rapid medical advance, populations around the world have 
experienced a steady and substantial increase in average life expectancy, and with it, a 
tremendous increase in the incidence of neurodegenerative disease. Cases of Alzheimer’s 
disease and Parkinson’s disease are by far the most prevalent among this increase; 
however recent evidence suggests that less common diseases, such as amyotrophic lateral 
sclerosis (ALS), the focus of this dissertation, may also be on the rise (Ingre et al. 2015).  
Neurodegenerative diseases are characterized by death of specific neuronal 
populations in the brain, brain stem and spinal cord, leading to significant impairments in 
cognitive and/or motor performance, and eventual death. ALS, in particular, is marked by 
the death of both upper and lower motor neurons, which causes severe muscle wasting 
and atrophy, paralysis, and death, usually due to respiratory failure. Two forms of ALS 
are currently recognized: familial forms of the disease, which are caused by inherited 
genetic factors, and sporadic forms of the disease for which the etiology is unknown. Of 
these, sporadic forms of ALS account for the vast majority of all cases, comprising 90% 
of the patient population. Both forms of ALS progress rapidly, and most patients will 
succumb to this insidious disease within 2-5 years of diagnosis, a grim prognosis that has 
not changed in the 75 years since the disease was made famous by Lou Gehrig.  Indeed, 
the development of therapeutic agents for ALS has been extremely limited, and only one 
FDA approved drug, Riluzole, exists to treat both sporadic and familial forms of disease. 
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Riluzole, an anti-glutamatergic compound, modestly extends the lifespan of ALS patients 
by 2-3 months, but has no reported benefit on quality of life (Miller et al. 2012). 
Furthermore, due to a host of side effects, many patients choose to forego treatment with 
this drug entirely and instead seek alternative, often unproven, treatments for their disease 
in the form of dietary supplements. Therefore, it is imperative to identify new therapeutic 
agents that can be used to safely and effectively treat ALS.  
The primary focus of this dissertation is to examine a class of potential 
therapeutic agents known as anthocyanins for their ability to attenuate multiple facets of 
ALS disease pathology while also defining their mechanisms of action. Additionally, the 
therapeutic benefit and effects of these unique compounds on disease progression and 
pathology is explored in vivo in a mouse model of ALS. 
 
1.1 The Pathological Basis of Motor Neuron Death in ALS 
Until recently, the complex nature of ALS was not fully appreciated, making this 
disorder very difficult to treat effectively. However, the multi-faceted nature of 
neurodegeneration has recently become a topic of intense scrutiny in the effort to identify 
new therapeutic targets for this disease. Several common mechanisms are now believed 
to underlie motor neuron death in both sporadic and familial forms of ALS, including 
oxidative stress, excitotoxicity, neuroinflammation, dysregulation of protein homeostasis, 





1.1.1 The Role of Oxidative Damage in ALS 
Oxidative damage is one of the most common features among diverse 
neurodegenerative diseases, including ALS, which has made it an appealing therapeutic 
target. This type of damage occurs when the production of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) in the cell overwhelms endogenous antioxidant 
defenses, resulting in oxidative and nitrosative stress, respectively. Both forms of cellular 
stress lead to severe oxidative damage of vital cellular macromolecules such as lipid 
membranes, proteins, and DNA, which culminates in the induction of neuronal cell death 
(Lin and Beal, 2006). In neurons, the primary sources of oxidative stress are 
dysfunctional mitochondria, commonly thought of as the “powerhouses” of the cell, 
responsible for producing the majority of cellular energy, and functional loss of 
endogenous antioxidant defenses normally involved in the detoxification of ROS and 
RNS.  
Mutations in Cu, Zn-superoxide dismutase (SOD1) are associated with familial 
forms of ALS, with over 150 mutations identified in this gene to date, accounting for 
approximately 20% of all familial cases of this disease (Rosen et al. 1993). To date, 
models utilizing mutant forms of SOD1 are by far the best studied, and a majority of 
what is currently known about the role of oxidative stress in ALS stems from the use of 
these models.  
On their own, mutations in the SOD1 protein can contribute to the induction of 
oxidative stress in that they may induce toxic gain-of-function activities, which enhance 
the production of ROS within the cell (Yim et al. 1996). However, recent evidence has 
indicated that one of the predominate ways by which some forms of mutant SOD1 
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contribute to the induction of oxidative stress within the cell is through selective 
association with mitochondrial membranes, which causes significant mitochondrial 
damage and impaired energy metabolism (Ferri et al. 2006). This in turn causes 
mitochondria to produce greater levels of ROS, which cannot be readily detoxified by the 
cell.  
 Mitochondrial SOD1 aggregates have also been shown to include Bcl-2, a crucial 
pro-survival protein involved in maintaining levels of glutathione (GSH) within 
mitochondria (Pasinelli et al. 2004, Wilkins et al. 2012). This essential antioxidant is 
responsible for scavenging ROS generated by mitochondria through the process oxidative 
phosphorylation in the electron transport chain, as well as maintaining redox homeostasis 
in many other parts of the cell (reviewed by Aoyama and Nakaki, 2015). It is noteworthy 
then, that GSH depletion has been documented in spinal cord mitochondria isolated from 
mice harboring a human mutant SOD1 transgene (Chi et al. 2007, Pesaresi et al. 2011).  
These mice display a significant decrease in the ratio of reduced to oxidized GSH in 
spinal cord mitochondria, indicative of either a decrease in the reduced form of GSH, 
and/or an increase in levels of oxidized glutathione (GSSG), both of which could be 
indicative of a highly oxidizing cellular environment (Pesaresi et al. 2011). Moreover, 
GSH depletion appears to be correlated with disease progression, indicating that the loss 
of antioxidant capacity within affected neuronal populations may play an important role 
in the progression of the disease over time (Babu et al. 2008). This is supported by 
studies in mice expressing the human transgene for a mutant form of SOD1 harboring a 
glycine to alanine mutation at position 93 (mSOD1G93A) in which these mice were 
crossed with mice heterozygous for deletion of the SOD2 gene, which codes for the 
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mitochondrial specific Mn-superoxide dismutase (SOD2) protein. Transgenic mice that 
were also heterozygous for the SOD2 deletion demonstrated a striking shift in disease 
progression, displaying both a significant increase in motor neuron pathology and 
shortened lifespan (Andreassen et al. 2000). Similarly, knockout of the regulatory subunit 
of γ-glutamylcysteine ligase, the rate-limiting enzyme responsible for GSH synthesis, in 
transgenic mSOD1G93A mice accelerated motor neuron disease (Vargas et al. 2011). 
Collectively, these data highlight the role of oxidative damage in ALS pathogenesis, 
particularly as a result of mitochondrially derived ROS, and loss of endogenous 
antioxidant defenses.  
While compelling, evidence for the role of oxidative damage in SOD1 linked 
familial ALS represents only about 2% of all ALS cases; however recent exploration of 
this topic has revealed that oxidative and nitrosative stress are also involved in other 
familial forms of the disease, and in sporadic ALS. Mutations in TAR DNA-binding 
protein-43 (TDP-43) are associated with some familial and sporadic forms of ALS, and 
TDP-43 aggregation in motor neurons is a hallmark of non-SOD1 familial ALS and 
sporadic ALS (Arai et al. 2006, Neumann et al. 2006). Interestingly, aggregation of TDP-
43 can be recapitulated in neuronal cell lines through depletion of GSH, suggesting that 
GSH depletion caused by oxidative stress in ALS may be responsible in part for 
aggregate formation over the course of the disease (Iguchi et al. 2012).  Furthermore, 
TDP-43 overexpression in Drosophila motor neurons enhances indices of oxidative stress 
such as protein carbonylation and elevated levels of antioxidant response enzymes (Zhan 
et al. 2015). Similar findings have also been observed in induced pluripotent stem cells 
derived from ALS patients harboring expansions in the C9orf72 gene, a newly discovered 
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mutation believed to account for as much as 50% of all familial ALS cases (DeJesus-
Hernandez et al. 2011, Renton et al. 2011, Gijselinck et al. 2012).  These cells display 
increased levels of the antioxidant enzyme, catalase, suggestive of enhanced ROS 
production (Kiskinis et al. 2014).  
Lastly, it is important to note that biomarkers of oxidative stress have been 
reported consistently in patients with sporadic ALS, including elevated levels of oxidized 
DNA and lipid peroxidation (Bogdanov et al. 2000, Simpson et al. 2004). Additionally, 
GSH depletion has been reported in erythrocytes and motor cortex from ALS patients, 
indicative of systemic reductions in antioxidant defenses, which are thought to contribute 
to oxidative stress in this disease (Babu et al. 2008, Weiduschat et al. 2014). 
Interestingly, there is also evidence emerging that wild type SOD1 may play a role in 
sporadic ALS as oxidized forms of this protein found in lymphocytes from ALS patients 
behave in a manner that is similar to their mutant SOD1 counterparts, forming 
mitochondrial protein aggregates with Bcl-2 (Guareschi et al. 2012). S-nitrosylation of 
protein disulfide isomerase (PDI), which is involved in protein folding and homeostasis, a 
process that is significantly disrupted in ALS, has also been identified, further illustrating 
that oxidative modification to important cellular components may contribute to ALS 
pathogenesis (Walker et al. 2010).  
 
1.1.2 The Role of Excitotoxicity in ALS 
Excitotoxicity is a phenomenon unique to neurons in which excitatory stimuli 
cause neurons to experience massive calcium influx, membrane depolarization, and 
subsequent death through production of ROS and RNS as well as activation of calcium-
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dependent pro-death factors, such as calpains (Van Damme et al. 2005). Many factors are 
posited to contribute to this process in ALS, including disturbances in excitatory 
signaling by neurotransmitters, increased sensitivity of post-synaptic neurons to 
excitatory stimuli, and reductions in inhibitory signaling by interneurons (reviewed in 
King et al. 2016).  While there is some debate about which of these factors is 
predominately responsible for inducing excitotoxicity in motor neurons, there is little 
doubt as to the involvement of excitotoxicity in ALS disease pathogenesis. This is most 
convincingly evidenced by the fact that to date, the only drug to have shown even modest 
efficacy for the treatment of ALS, Riluzole, is an anti-glutamatergic compound, which is 
thought to act by diminishing aberrant excitatory signaling in motor neurons (Miller et al. 
2012).  
 Glutamate is the primary excitatory neurotransmitter in the central nervous 
system, and evidence for its dysregulation in ALS is abundant.  Early reports suggest that 
glutamate levels are elevated in postmortem tissue and cerebrospinal fluid isolated from 
ALS patients, though recent work has brought these findings into question (Shaw et al. 
1995, Spreux-Varoquaux et al. 2002, Wuolikainen et al. 2011). Nevertheless, emerging 
data have implicated enhanced glutamate release and increased neuronal firing as a 
potential sources of glutamate-induced excitotoxicity. An increased incidence of calcium-
dependent spontaneous neurotransmitter release has recently been linked to endoplasmic 
reticulum (ER) stress, a condition that is garnering significant attention as a major factor 
in ALS (Nosyreva and Kavalali, 2010). It is believed that this spontaneous 
neurotransmission is related to enhanced sensitivity of synaptic vesicle release machinery 
to calcium signaling during activity-dependent depolarization of the cell. While this study 
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did not examine ALS specifically, it suggests that augmented neuronal activity, and 
specifically the release of neurotransmitters such as glutamate, may occur in response to 
ER stress, which could result in the induction of excitotoxicity in post-synaptic cells. This 
assertion is supported by recent data demonstrating that synaptosomes isolated from mice 
expressing the mSOD1G93A human transgene demonstrate heightened glutamate release in 
response to neuronal depolarization and stimulation of metabotropic glutamate receptors 
by receptor agonists (Milanese et al. 2011, Giribaldi et al. 2013). Furthermore, reductions 
in glutamate loading into synaptic vesicles and a consequent decrease in glutamate 
release from pre-synaptic terminals preserves motor neuron viability in a mouse model of 
ALS, although this preservation does not correlate with improvements in disease 
progression and survival (Wootz et al. 2010). 
In addition to evidence suggesting an increase in synaptic glutamate release, 
recent data also demonstrate that the ability of cells in the central nervous system (CNS) 
to clear glutamate from the synaptic cleft after its release is impaired in ALS.  Under 
normal conditions, glutamate is rapidly removed from the synaptic cleft via reuptake by 
both neurons and neighboring astrocytes, glial cells that provide supportive functions to 
neurons in the CNS.  This occurs predominately through the excitatory amino acid 
transporter (EAAT2) expressed by astrocytes; however it has been observed that EAAT2 
expression is significantly reduced in spinal cord of both mice and rats carrying a mutant 
SOD1 transgene, as well as in tissue isolated from both familial and sporadic ALS 
patients (Rothstein et al. 1995, Fray et al. 1998, Sasaki et al. 2000, Allaman et al. 2011).  
Moreover, overexpression of EAAT2 in an ALS mouse model significantly delays 
disease onset, although no effect on survival was observed, which may suggest that 
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aberrant glutamate signaling plays a role in the early stages of the disease (Guo et al. 
2003). 
 It has also been shown that motor neurons in ALS display increased sensitivity to 
glutamate excitotoxicity as a result of multiple factors. Expression levels of the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, one of several types of 
ionotropic glutamate receptor, are intrinsically high in motor neurons (Van Den Bosch et 
al. 2000). These receptors comprise several subunits that differentially affect the 
permeability of each receptor to calcium. In particular, the GluR2 subunit is responsible 
for making AMPA receptors impermeable to calcium ions, thus ablating toxicity 
associated with the massive calcium influx that occurs with excitotoxicity (Van Damme 
et al. 2002). Interestingly, knockdown of this specific subunit in a mouse model of ALS 
significantly accelerates disease progression while overexpression of GluR2 significantly 
delays disease onset (Tateno et al. 2004, Van Damme et al. 2005b). Additionally, reduced 
levels of GluR2 mRNA are observed in spinal cord isolated from ALS patients (Shaw et 
al. 1999). Collectively, these data suggest that altered expression of AMPA subunits may 
sensitize motor neurons to excitotoxic injury. There is also substantial evidence that 
motor neurons in ALS display hyperexcitable activity due to alterations in sodium and 
potassium ion currents, and thus overreact to excitatory stimuli.  For example, 
depolarization of resting membrane potential by enhanced sodium currents can trigger 
calcium influx, causing neurons to become more easily excited (Vucic and Kiernan, 
2006, van Zundert et al. 2008, Vucic et al. 2009, Vucic and Kiernan, 2010). 
Alternatively, repolarization of the neuron and restoration of resting membrane potential 
may be impaired as a result of reductions in outgoing potassium currents such that 
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neurons remain depolarized following an excitatory stimulus (Bostock et al. 1995, Kanai 
et al, 2006, Vucic and Kiernan, 2006, Vucic et al. 2009, Wainger et al. 2014). This 
overreaction to excitatory stimuli is thought to further sensitize motor neurons to 
excitotoxicity. 
 Conversely, a number of studies have implicated a loss of inhibitory signaling to 
motor neurons by interneurons as a potential source of excitotoxicity in ALS. In mice 
expressing a mutant form of SOD1, for example, inhibitory interneurons are observed to 
degenerate in parallel with motor neurons (Morrison et al. 1998). Furthermore, inhibitory 
interneurons in the spinal cord of mice overexpressing TDP-43 or mutant SOD1 are 
found to accumulate ubiquitinated inclusions in early stages of the disease, resulting in 
subsequent degeneration, which precedes motor neuron loss (Martin et al. 2007, 
Wegorzewska et al. 2009). Similar observations have been made in cortical and spinal 
cord tissue derived from ALS patients, which show reductions in the number of 
interneurons, although ubiquitination within neurons in these populations is rare (Ince et 
al. 1993, Stephens et al. 2001, Stephens et al. 2006). These studies correlate with recent 
data collected from ALS patients demonstrating that intracortical inhibitory signaling is 
impaired, which could reflect a loss in cortical interneurons (Ziemann et al. 1997, Zanette 
et al. 2002a, 2002b, Vucic et al. 2009). Taken together, these data may be indicative of a 
loss of inhibitory signaling to downstream motor neurons, which would normally 
attenuate the response of these cells to excitatory stimuli. Consequently, in the absence of 
inhibitory signals in an ALS disease state, motor neurons may overreact to excitatory 
signals, resulting in excitotoxic injury, and subsequent neuronal death.  
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1.1.3 The Role of Neuroinflammation in ALS 
 ALS is commonly thought of as a disease of motor neurons, implying that motor 
neuron death occurs through pathways that are intrinsic to these cells (i.e. cell-
autonomous death); however, in the past two decades, it has become abundantly clear 
that motor neuron death is driven in large part by deviations in the normal activity of 
surrounding glial cells within the CNS (i.e. non-cell-autonomous death). Although glial 
cells, such as astrocytes and microglia, are capable of providing trophic support and 
protection from foreign pathogens to surrounding neurons, they are also capable of 
causing significant injury to neighboring cells in response to aversive stimuli. This 
process, in which glial cells in the CNS become neurotoxic and promote neuronal injury, 
is known as neuroinflammation.  
 Neuroinflammation is mediated primarily through the activity of reactive 
astrocytes and activated microglia. In healthy tissue, astrocytes are involved in providing 
structural and trophic support to neighboring neurons, in addition to regulating neuronal 
responses to synaptic transmission (reviewed by Sofroniew and Vinters, 2010). In ALS, 
however, astrocytes adopt a reactive phenotype in which they secrete a number of toxic 
factors, including cytokines and chemokines such as interleukin (IL)-6, and withdraw 
trophic support, ultimately culminating in neuronal death (Farina et al. 2007). Astrocytic 
activation in ALS has been shown in vitro to occur in response to several factors, 
including GSH depletion within astrocyte cell bodies, and expression of mutant SOD1 
(Hensley et al. 2006, Nagai et al. 2007, Marchetto et al. 2008, Lee et al. 2010). 
Furthermore, there is ample evidence to suggest that astrocytes expressing mutant forms 
of SOD1 are not only capable of inducing death in co-cultured motor neurons, but also 
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seem to possess an increased propensity for expression of pro-inflammatory cytokines 
including TNF-α and Fas ligand (FasL), and display an enhanced expression of these 
genes in response to cytokine stimulation in comparison to wild type astrocytes (Hensley 
et al. 2006). Astrocytes derived from neural progenitors isolated from both familial and 
sporadic ALS patient tissue have also been demonstrated to be neurotoxic to co-cultured 
motor neurons (Haidet-Phillips et al. 2011). It is also apparent that astrocytes play a 
significant role in modulating disease progression in ALS. This is most clearly 
demonstrated by studies of chimeric mice with a selective deletion of G37R mutant 
SOD1 in astrocytes, which yielded no delay in disease onset and progression, though 
early disease stage was modestly slowed (Yamanaka et al. 2008). However, late disease 
progression was significantly delayed. An identical experiment in astrocytes using the 
G85R form of mutant SOD1, which, unlike G37R SOD1, does not possess any dismutase 
activity, produced the opposite results, delaying onset and the progression of early 
disease phase, but not late disease phase (Wang et al. 2011). This apparent conflict can be 
attributed to differences in the two variants of mutant SOD1 used in these experiments, 
and indicates that disease progression is not consistent for all familial forms of the 
disease. Nonetheless, these results indicate that astrocytes participate in ALS disease 
processes and possess the ability to significantly alter disease progression. 
Microglia are the resident immune cells of the brain, possessing a common 
myeloid lineage with macrophages. These cells exist primarily in a resting state in which 
they participate in many important functions that are essential to neuronal support and 
survival, in addition to playing a role in synaptic pruning (Turrin and Rivest, 2006, 
Paolicelli et al. 2011). When signs of neuronal distress are detected, microglia adopt an 
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inflammatory phenotype aimed at eliminating foreign invaders or removing damaged 
cells. While beneficial in the short term, prolonged activation of microglia is capable of 
causing neuronal injury and death in a manner comparable to that observed with reactive 
astrocytes. Intriguingly, microglial activation occurs in two stages, which alter 
throughout ALS disease progression. At disease onset, microglia possess a 
neuroprotective “M2” phenotype in which cells secrete an abundance of anti-
inflammatory factors, such as brain derived neurotrophic factor (BDNF), which aid in 
promoting neuronal survival (Seeburger and Springer, 1993, Liao et al. 2012). However, 
as the disease progresses, microglia are known to undergo a deleterious transition to a 
neurotoxic “M1” phenotype in which the production of pro-inflammatory cytokines and 
chemokines, such as IL-6, TNF-α, FasL, IL-8, and monocyte chemoattractant protein-1 
(MCP-1), is significantly enhanced, and pro-inflammatory mediators such as inducible 
nitric oxide synthase (iNOS), NADPH-oxidase-2 (NOX-2), and cyclooxygenase-2 (COX-
2) are upregulated. Notably, many of these factors are found in spinal cord tissue and 
cerebrospinal fluid from ALS patients, in addition to spinal cord tissue isolated from mice 
expressing mutant forms of SOD1 (Almer et al. 1999, Almer et al. 2001, Hensley et al. 
2003, Henkel et al. 2006, Raoul et al. 2006, Wu et al. 2006, Rentzos et al. 2007, Kuhle et 
al. 2009, Meissner et al. 2010, Liao et al. 2012). It is also noteworthy that extracellular 
mutant SOD1 is capable of causing microglial activation and enhancing production of 
pro-inflammatory cytokines (Zhao et al. 2010). As mutant SOD1 has been shown to be 
secreted by motor neurons through association with chromogranin A and B, this suggests 
that microglia in ALS may adopt an inflammatory phenotype in response to mutant 
SOD1 release in some familial forms of ALS (Urushitani et al. 2006, Zhao et al. 2010). 
14 
Like astrocytes, microglia are known to significantly alter disease progression as 
selective knockout of mutant SOD1 or replacement of mutant SOD1 with wild type 
SOD1 in cells of myeloid lineage, including microglia, significantly delays progression 
through the late phase of the disease, though no effect on disease onset is observed (Beers 
et al. 2006, Boilée et al. 2006). Moreover, increased numbers of microglia have been 
observed in close proximity to dying motor neurons in spinal cord tissue taken from both 
sporadic and familial ALS patients (Henkel et al. 2004). Altogether, these data indicate 
that neuroinflammation mediated by microglia and astrocytes plays a substantial role in 
modulating the progression of ALS. 
 
1.1.4 The Role of Protein Dysregulation in ALS 
Disruptions to proteostasis occur at multiple levels in ALS, evidenced by 
accumulation and aggregation of mutated proteins, induction of the unfolded protein 
response (UPR), and perturbances in the clearance of mutant or damaged proteins (Ilieva 
et al. 2009). As discussed previously, mutant forms of SOD1 and TDP-43, as well as 
several other mutant proteins known to cause familial forms of ALS such as fused in 
sarcoma (FUS) and C9orf72, participate in extensive protein aggregation (Mori et al. 
2013, Turner et al. 2013). Notably, wild type TDP-43 and FUS aggregation, and 
aggregation of oxidized wild type SOD1, has also been reported in sporadic cases of ALS 
(Bosco et al. 2010, Mackenzie et al. 2010). While the mechanisms causing protein 
aggregation in ALS are not well understood, there is growing evidence that accumulation 
of these proteins in aggregates plays a major role in inducing cell death by associating 
with organelles. As previously discussed, accumulation of mutant forms of SOD1 at 
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mitochondria enhances the propensity of these organelles to produce ROS, contributing 
to conditions of oxidative stress (Pasinelli et al. 2004). More recently, data have emerged 
demonstrating that mutant SOD1 also accumulates at the ER, disrupting the ability of this 
organelle to perform crucial functions in maintaining protein homeostasis (Kikuchi et al. 
2006). Ultimately, accumulation of protein aggregates at the ER results in ER stress and 
induction of the UPR, which, if not corrected, causes cell death. 
Expression of markers associated with ER stress are observed in spinal cord 
motor neurons of transgenic mice expressing mutant forms of SOD1 before protein 
aggregation, onset of disease symptoms, and muscle denervation (Saxena et al. 2009). 
Accumulation of SOD1 aggregates at the ER then occurs after disease onset and is 
observed to increase throughout the progression of the disease, reaching its greatest 
prevalence at end stage (Kikuchi et al. 2006). Translocation of mutant SOD1 to the ER is 
associated with induction of the UPR, and mutant SOD1 has been shown to directly 
interact with binding immunoglobulin protein (BiP), thereby initiating the ER stress 
response. Caspase-12, which is involved in mediating ER stress-induced apoptosis, has 
been shown to be activated under these conditions, suggestive of motor neuron death in 
response to ER stress. Similarly, SOD1 has also been shown to interact with Derlin-1, 
preventing it from fulfilling its role as a critical mediator of ER- associated degradation 
of misfolded proteins (Nishitoh et al. 2008). This interaction eventually leads to 
activation of apoptosis signal-regulating kinase 1 (ASK1) by inhibiting transport of 
misfolded proteins to the cytoplasm, and death of the cell. This is corroborated by recent 
findings demonstrating that mutant SOD1 inhibits protein transport from the ER to the 
Goli apparatus, promoting ER stress and Golgi fragmentation (Atkin et al. 2014). Further 
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evidence for the involvement of ER stress and the UPR in ALS comes from studies 
demonstrating that mutant SOD1 mice deficient in pro-death mediators of the UPR such 
as ASK1, puma, and bim display enhanced motor neuron viability and delays in disease 
onset and progression (Hetz et al. 2007, Kieran et al. 2007, Nishitoh et al. 2008). As 
further evidence for the involvement of ER stress in ALS, numerous ER stress markers 
are shown to be significantly elevated in spinal cord tissue from ALS patients including 
BiP, protein kinase RNA-like endoplasmic reticulum kinase (PERK), an ER stress sensor, 
and C/EPB homologous protein (CHOP), a mediator of cell death activated in response to 
ER stress and the UPR (Ilieva et al. 2007, Atkin et al. 2008, Hetz et al. 2009, Ito et al. 
2009, Vajayalakshmi et al. 2011). Furthermore, ER from sporadic ALS patient spinal 
cords shows pronounced structural abnormalities that may correlate with significant 
alterations in ER function (Oyangi et al. 2008, Sasaki, 2010). 
Aggregation of mutant proteins can also induce cell death though other pathways. 
Several hypotheses have been put forth to explain the toxicity of such aggregates 
including proteasome inhibition, sequestration or depletion of chaperone proteins, and 
general inclusion of vital cellular components (Bruening et al. 1999, Niwa et al. 2002, 
Urushitani et al. 2002). Intriguingly, inhibition of the proteasome by sustained expression 
of mutant SOD1 has been demonstrated, as hypothesized by Niwa et al. (2002) with 
continuous production and degradation of mutant SOD1 ‘choking’ the proteasome and 
preventing its continued function (Urushitani et al. 2002, Niwa et al. 2002). This could 
lead to further accumulation of dysfunctional mutant proteins, further aggregation, and 
ultimately neuronal death. Similarly, overexpression of chaperone proteins such as Hsp70 
was shown to offer limited neuroprotection from cell death induced by mutant SOD1, 
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which might suggest that mutant SOD1 toxicity is in part mediated by a depletion of 
chaperone proteins (Bruening et al. 1999). Collectively, this evidence suggests that 
collection of mutant SOD1 into aggregates might function to induce toxicity through a 
variety of mechanisms unrelated to aggregation phenomena at the mitochondria or in the 
ER. This is further supported by the observation that reductions in protein aggregation 
through either genetic or pharmacological upregulation of autophagy has been shown to 
enhance survival in ALS mice in several recent studies (Hetz et al. 2009, Wang et al. 
2012, Castillo et al. 2013).  
 
1.1.5 The Role of Apoptosis in ALS 
Though it is evident that ALS is a multi-faceted disease, with many factors 
contributing to its etiology and progression, these factors ultimately converge at the 
induction of cell death. In particular, the role of apoptosis, a type of programmed cell 
death, is well-described in ALS, and many of the processes involved in the disease, such 
as those discussed above, are known to culminate in activation of pro-apoptotic 
pathways. Commitment of the cell to apoptosis cannot be reversed; thus modulation of 
apoptotic signaling pathways represents the final point at which therapeutic intervention 
can occur to prevent neuronal loss.  
Apoptosis can be triggered in a myriad of different ways, but typically proceeds 
through one of two pathways: the extrinsic apoptotic cascade, which is triggered by 
binding of pro-apoptotic ligands to death receptors on the cell surface, and the intrinsic 
apoptotic cascade in which intracellular events trigger the release of apoptogenic factors 
from mitochondria (Kajta, 2004, Krantic et al. 2005). Extrinsic apoptosis occurs upon 
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binding of death receptor ligands to their cognate receptors on the plasma membrane, 
leading to activation of the initiator caspase, caspase-8, which in turn stimulates cleavage 
and activation of caspase-3, one of three executioner caspases that mediates controlled 
degradation of vital cellular components, most notably DNA (Sakahira et al. 1998). Pro-
inflammatory cytokines, such as TNF-α and FasL, which are produced by enflamed 
microglia and astrocytes in ALS, are known to bind to death receptors on the plasma 
membrane, triggering apoptotic cell death in neighboring neurons via the extrinsic 
apoptotic cascade (Kajta, 2004).  
Similarly, events such as oxidative and nitrosative stress, calcium overload caused 
by excitotoxicity, and ER stress can all induce apoptosis through the intrinsic apoptotic 
pathway. In this pathway, aberrant calcium signaling, and the accumulation of ROS and 
RNS cause release of cytochrome c from mitochondria and caspase-9 activation. 
Together with apoptosis protease-activating factor-1 (APAF-1), these proteins interact to 
form the apoptosome and activate caspase-3, resulting in death very similar to that 
observed in the extrinsic cascade (Slee et al. 1999, Luetjens et al. 2000, Ott et al. 2007). 
ER stress, on the other hand, is believed to activate caspase-8, 9 and 12, causing 
subsequent activation of caspase 3 and induction of apoptosis (Nakagawa et al. 2000, 
Jimbo et al. 2003).  As caspase 12 levels are known to be elevated in spinal cord from 
mice expressing mutant SOD1, this suggests that ER stress may play a major role in 
apoptosis signaling in ALS (Wootz et al. 2004). Apoptosis driven by mitochondria can 
also proceed in a p53-dependent manner, in which cellular stress causes activation of p53 
and its downstream effectors puma, noxa, and Bax, pro-apoptotic Bcl-2 family members 
(Amaral et al. 2010). Additionally, p53 activity is known to inhibit pro-survival proteins, 
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such as Bcl-2, levels of which are reduced in spinal cord tissue from ALS patients (Mu et 
al. 1999). Together, these factors can result in cytochrome c release, caspase activation, 
and subsequent death. As p53 activity is enhanced in cells overexpressing mutant SOD1 
and in brain and spinal cord from ALS patients, activation of this pathway could play a 
role in promoting neuronal cell death in ALS (Martin, 2000, Barbosa et al. 2010, 
Ranganathan and Bowser, 2010). 
Evidence has also arisen demonstrating that apoptosis in ALS may occur through 
mitochondrially-linked mechanisms independent of caspase activation. Apoptosis-
inducing factor (AIF) is a pro-apoptotic protein released from mitochondria in response 
to mitochondrial damage and dysfunction (Daugas et al. 2000). Upon release, AIF 
translocates to the nucleus where is triggers DNA fragmentation and chromatin 
condensation as a part of apoptotic cell death. Recent studies have found that AIF 
accumulates in the nuclei of spinal cord motor neurons in mice carrying a mutant SOD1 
transgene, and that nuclear AIF levels increase as the disease progresses (Oh et al. 2006). 
Collectively, these data indicate that AIF likely plays a role in initiating apoptotic cell 
death of motor neurons in ALS. 
The complex nature of ALS has presented a great challenge to the development of 
effective therapeutics for the disease. In the past, many strategies have targeted only one 
facet of disease pathology, as is the case with the drug Riluzole; however as our 
understanding of ALS has grown, so too has the consensus that effective therapeutic 
strategies must target multiple factors contributing to ALS etiology and progression. In 
this context, anthocyanins are emerging as promising therapeutic agents for the treatment 
20 
of neurodegenerative disease, although their efficacy for the treatment of ALS 




Figure 1.1. Molecular mechanisms contributing to ALS pathogenesis. A, The role of 
excitotoxicity in ALS. Glutamate is released from pre-synaptic neuron terminals in 
elevated quantities and binds to glutamate receptors such as NMDA and AMPA 
receptors. Receptor binding causes massive calcium influx in post-synaptic neurons and 
activates pro-apoptotic signaling cascades, in addition to inducing mitochondrial 
dysfunction and ER stress responses. B, The role of neuroinflammation in ALS. Glial 
cells such as astrocytes and microglia become chronically enflamed in disease states and 
secrete oxidative species, such as nitric oxide, and pro-inflammatory cytokines. 
Cytokines bind to death receptors on the cell surface and activate pro-apoptotic signaling 
cascades. C, The role of oxidative stress and mitochondrial dysfunction in ALS. 
Mitochondrial dysfunction occurs as a result of several factors in ALS, causing 
mitochondria to produce elevated levels or reactive oxygen and nitrogen species (ROS 
and RNS). Enhanced production of ROS and RNS exacerbates mitochondrial 
dysfunction, eventually causing release of the pro-apoptotic signaling protein, 
cytochrome c (CytC). Cytochrome C contributes to formation of the apoptosome, which 
in turn cleaves procaspase-3 to form active caspase-3, stimulating apoptosis. D, The role 
of protein dysregulation in ALS. ER stress occurs as a result of multiple factors in ALS, 
causing accumulation of misfolded proteins and activation of the unfolded protein 
response (UPR). As misfolded and aggregated proteins accumulate, the proteasome 
becomes clogged, leading to proteasome inhibition and further accumulation of protein 
aggregates. Protein aggregation and ER stress trigger pro-apoptotic signaling cascades. 




1.2 The Use of Anthocyanins as Novel Neuroprotective and Therapeutic Agents in 
Neurodegenerative Disease 
Flavonoids are a large class of polyphenolic compounds found in many fruits, 
vegetables, spices and herbs that are best known for their high levels of intrinsic 
antioxidant activity. However, in recent years the beneficial effects of flavonoid-rich 
diets have been found to influence a diverse array of functions, including modulation of 
inflammatory and apoptotic signaling pathways. Anthocyanins in particular have 
garnered significant attention in this regard, and reports describing their therapeutic 
benefit for a variety of conditions such as cardiovascular disease and cancer have 
emerged (reviewed by Wallace 2011, Wang and Stoner 2008). These unique cationic 
compounds are found in high concentrations in a number of fruits, vegetables, and 
flowers, and are responsible for creating the red, blue, and purple pigmentation observed 
in many of these species. Common anthocyanins are composed of one of six 
anthocyanidin bases, which differ in molecular structure at the B-ring, and a sugar moiety 
attached at the third position of the C-ring (Fig. 1.2). They are appealing as therapeutic 
agents for many reasons, one of the most notable being that they are among the most 
commonly consumed flavonoids in a normal diet and, for this reason, they are generally 




Figure 1.2. Common anthocyanin structures. A, General flavonoid structure. 
Flavonoids possess a characteristic three-ring structure that is conserved across all family 
members. Several classes of flavonoids exist, including anthocyanins, which differ 
depending on substitutions of the A, B, and C-rings. B, Structures of the six most 
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common anthocyanins. Anthocyanins possess a cationic structure that differs between 
species predominately in substitutions of the B-ring. Anthocyanins also possess a sugar 
moiety as a part of their structure, represented as R. Common sugar moieties include but 
are not limited to glucose, galactose, and rutinose. All structures included in this 
dissertation were created using MarvinSketch (ChemAxon, Cambridge, MA).  
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The ability of anthocyanins to attenuate disorders of the CNS is currently under 
exploration, although data regarding their effects on neurodegeneration are still relatively 
limited. Nevertheless, several findings have emerged to suggest that anthocyanins 
ameliorate many of the damaging effects of processes implicated in neurodegeneration 
such as oxidative and nitrosative stress, excitotoxicity, glial inflammation, protein 
aggregation, and induction of apoptotic signaling proteins. Furthermore, evidence has 
accumulated showing that anthocyanins are capable of crossing the blood brain barrier 
(BBB), suggesting that these compounds may mediate these effects directly in the CNS 
where neuronal death takes place (Youdim et al. 2003, Andres-Lacueva et al. 2005, El 
Mohsen et al. 2006, Williams et al. 2008). Limited data have also been reported 
demonstrating that anthocyanins may be effective therapeutic agents for Parkinson’s 
disease, Alzheimer’s disease, and aging, which share many common pathological 
features with ALS. These studies are discussed in detail below. 
 
1.2.1 Absorption and Blood Brain Barrier Permeability of Anthocyanins 
Following ingestion, anthocyanins are swiftly taken up and absorbed into the 
blood stream where they are transported to target tissues (El Mohsen et al. 2006, Milbury 
and Kalt, 2010, Vanzo et al. 2011). The rapid kinetics of anthocyanin absorption into 
systemic circulation suggests that initial absorption likely takes place in the stomach 
(Passamonti et al. 2003). This process is thought to be mediated by a bilitranslocase 
transporter as anthocyanins have been shown to interact with this transporter in several 
studies (Maestro et al. 2010, Vanzo et al. 2008). A similar mechanism is thought to be 
responsible for the uptake of these compounds into the CNS as bilitranslocase, possessing 
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a bilirubin binding motif, is present in the endothelial cells that help form the BBB 
(Battiston et al. 1999). Furthermore, the interaction between bilitranslocase and 
anthocyanins is mediated by hydrogen bonding, which provides a compelling level of 
specificity for this mechanism. There is also some evidence that flavonoids, such as 
anthocyanins, may interact with p-glycoprotein transporters, and gain entrance into the 
brain in this manner (Youdim et al. 2004). 
Upon transport into the CNS, anthocyanins have been shown to accumulate in 
brain tissue at levels up to 0.21nmol/g of tissue in rodent models (Passamonti et al. 2005; 
Talavera et al. 2005). Accumulation occurs in several tissues, including brain endothelial 
cells, brain parenchymal tissue, as well as striatum, hippocampus, cerebellum, and cortex 
(Youdim et al. 2003, Andres-Lacueva et al. 2005, El Mohsen et al, 2006). This finding is 
of particular interest in that several of these brain regions are known to contain vulnerable 
neuronal populations whose loss is implicated in several forms of neurodegenerative 
disease (Andres-Lacueva et al. 2005).  
 
1.2.2 Antioxidant Effects of Anthocyanins 
Anthocyanins, like many flavonoids, are unique antioxidants in that they are able 
to scavenge damaging ROS and RNS directly, as evidenced by their high oxygen radical 
absorption capacity (ORAC) values, in addition to enhancing the cell’s intrinsic 
antioxidant defenses (Shih et al. 2007, Zafra-Stone et al. 2007, Zhu et al. 2010, Hwang et 
al. 2011). Direct scavenging of various ROS including 1,1-diphenyl-2-picrylhydrazyl 
(DPPH), alkyl, and hydroxyl radicals has been reported using electron spin resonance 
spectroscopy (Hwang et al. 2012). Similarly, the major anthocyanin constituents of plum 
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extract have been shown to scavenge superoxide radicals at a higher capacity than other 
flavonoids such as quercetin, which is thought to play a role in mediating the 
neuroprotective effects of these compounds (Chun et al. 2003). Indeed, many studies 
utilizing both anthocyanin-rich fruit extracts and pure anthocyanins in vitro have 
demonstrated that these compounds provide potent protection from hydrogen peroxide 
toxicity in a variety of neuronal cell lines (Heo and Lee 2005, Ghosh et al. 2006, Tarozzi 
et al. 2007, Spada et al. 2009). As both superoxide and hydrogen peroxide are the 
products of many physiological processes, and are known to be elevated in the context of 
neurodegeneration by processes such as mitochondrial dysfunction and glial 
inflammation, the ability of anthocyanins to scavenge these ROS suggests that they may 
be well suited to ameliorate oxidative damage in diseases like ALS. This is further 
supported by an in vivo study in which rats were injected with carbon tetrachloride, an 
agent that causes generation of free radicals and oxidative damage within several tissues, 
including brain, after chronic consumption of anthocyanin-rich grape juice (Dani et al. 
2008). Rats that received grape juice supplementation displayed a significant reduction in 
markers of oxidative damage such as lipid peroxidation and protein carbonylation 
compared to rats treated with carbon tetrachloride alone. 
Indirect mitigation of oxidative and nitrosative stress by anthocyanins occurs in 
several ways and is due primarily to an increase in the levels and activities of antioxidant 
enzymes. Several reports have documented that treatment with pure anthocyanins or 
anthocyanin-rich extracts enhances levels of the enzymes catalase, which scavenges 
hydrogen peroxide, and SOD1 both in vitro and in vivo (Heo and Lee 2005, Ghosh et al. 
2006, Dani et al. 2008, Tarozzi et al. 2007, Spada et al. 2009, Poulose et al. 2016). 
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Additionally, anthocyanins have been shown to enhance levels of GSH within neuronal 
cultures in addition to directly enhancing the activity of glutathione peroxidase, which 
plays a vital role in detoxifying hydrogen peroxide using GSH (Kelsey et al. 2011). 
Moreover, both pure anthocyanins and anthocyanin-rich extracts have been shown to 
reduce mitochondrial oxidative stress and dysfunction induced by either Bcl-2 inhibition 
or rotenone toxicity (Kelsey et al. 2011, Strathearn et al. 2014).  These activities are 
thought to be modulated in part by the ability of anthocyanins to induce nuclear factor 
erythroid 2-related factor 2 (Nrf2) activity, which acts as a master regulator of many 
antioxidant genes including catalase and the regulatory subunit of gamma-
glutamylcysteine ligase, the enzyme responsible for carrying out the rate limiting step of 
GSH synthesis, in addition to a host of other phase II detoxification enzymes (Hwang et 
al. 2011, Shih et al. 2007). This is supported by a recent study demonstrating that aged 
rats fed an anthocyanin-rich acai pulp diet showed significantly elevated Nrf2 levels in 
hippocampus and prefrontal cortex in addition to enhanced levels of antioxidant enzymes 
such as SOD1 and glutathione S-transferase (Poulose et al. 2016). Collectively, these data 
suggest that the neuroprotective effects of anthocyanins are mediated through both direct 






Figure 1.3. Antioxidant effects of anthoycanins. Anthocyanins modulate damage 
produced by reactive oxygen and nitrogen species (ROS and RNS) by several 
mechanisms. These include direct enhancement of glutathione peroxidase activity, direct 
scavenging of ROS and RNS, and activation of Nrf2 transcription of antioxidant 
enzymes. Genes activated by Nrf2 include those for catalase, Cu, Zn-superoxide 
dismutase (SOD1), and gamma-glutamylcysteine ligase (γ-GCL), which increases 
synthesis of the critical antioxidant, glutathione. Collectively, these mechanisms detoxify 
ROS and RNS to prevent apoptosis.  
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1.2.3 Anthocyanins in Calcium Homeostasis and Excitotoxicity 
Maintaining calcium homeostasis is an essential part of preventing neuronal cell 
death induced by excitotoxicity. Although the mechanism by which anthocyanins 
preserve calcium homeostasis is not well understood, several lines of evidence have 
recently emerged demonstrating that these compounds have significant effects on calcium 
flux in response to many neurotoxic agents. For example, cells treated with amyloid beta, 
one of the neurotoxic species thought to underlie the development of Alzheimer’s 
disease, display significant disturbances in calcium homeostasis leading ultimately to 
excitotoxicity. However, several studies have reported that anthocyanin treatment in both 
neuronal cell lines and primary hippocampal cells prevents increases in intracellular 
calcium caused by this insult (Ye et al. 2010, Shih et al. 2011, Badshah et al. 2015). 
Anthocyanins have also been shown to promote restoration of calcium levels following 
depolarization induced by dopamine treatment in primary rat hippocampal neurons 
(Poulose et al. 2014). 
The direct effects of anthocyanins on excitotoxic insult have also been described 
both in vitro and in vivo. In one study, anthocyanins were shown to attenuate increases in 
intracellular free calcium in both primary hippocampal cells and the HT22 hippocampal 
cell line in response to treatment with kainate, a glutamate receptor agonist (Ullah et al. 
2014). This effect was responsible in part for reducing excitotoxic cell death in these 
cells. In a similar manner, treatment with the pure anthocyanin, cyanidin-O-3-glucoside, 
inhibited glutamate-induced increases in calcium concentration in rat hippocampal 
neurons (Yang et al. 2015). These effects have also been observed in vivo using a model 
of retinal ganglion cell degeneration. Intraocular injection of mice with N-methyl-D-
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aspartate (NMDA) induced excitotoxicity by stimulating calcium influx through 
ionotropic glutamate receptors, causing wide-spread cell death in injected mice; however 
simultaneous injection with anthocyanin-rich bilberry extract dramatically attenuated 
these effects, demonstrating that anthocyanins may be capable of mitigating 






Figure 1.4. Effects of anthocyanins on calcium homeostasis and excitotoxicity. 
Binding of the excitatory compounds, glutamate or kainate, to their cognate receptors on 
the cell membrane causes massive calcium influx into neurons, causing ER stress, 
mitochondrial dysfunction and oxidative stress, and activation of pro-apoptotic factors 
such as calpain, leading to cell death. Anthocyanins protect neurons from excitotoxicity 
by preventing increases in intracellular calcium caused by glutamate and kainate 
signaling.   
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1.2.4 Anti-neuroinflammatory Activity of Anthocyanins 
The anti-inflammatory effects of anthocyanins are well established in non-
neuronal systems, particularly those related to cardiovascular disease (reviewed by 
Wallace, 2011). However, their role in reducing neuroinflammation is less understood 
and the topic of current exploration. Several recent studies have assessed the anti-
inflammatory effects of anthocyanins and anthocyanin-rich extracts on the BV2 mouse 
microglial cell line. These studies have demonstrated that anthocyanin treatment is 
capable of significantly reducing induction of pro-inflammatory proteins such as iNOS 
and COX-2 in response to stimulation with lipopolysaccharide (LPS), a component of 
bacterial cell walls that is known to induce a pronounced inflammatory response. 
Furthermore, these studies demonstrated that treatment with anthocyanin-rich extracts 
significantly attenuates production and secretion of nitric oxide, IL-1β and TNF-α (Lau et 
al. 2007, Poulose et al. 2012, Carey et al. 2013, Jeong et al. 2013). Modulation of pro-
inflammatory signaling pathways is also reported as levels of active c-Jun-N-terminal 
kinase (JNK), p38-mitogen activated protein kinase (p38-MAPK), extracellular signal-
regulated kinase 1/2 (ERK1/2), and Akt, are all significantly reduced (Lau et al. 2007, 
Poulose et al. 2012, Carey et al. 2013, Jeong et al. 2013). Reduction in the activity of 
these signaling pathways correlates with reductions in activated nuclear factor-κB (NF-
κB), and prevention of its translocation to the nucleus, where it is capable of mediating 
the transcription of many pro-inflammatory genes. Though few in number, these studies 
clearly demonstrate that treatment with anthocyanins or anthocyanin-rich extracts is 
capable of ameliorating many of the inflammatory effects of microglial activation. 
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These findings are mirrored in vivo in an experiment demonstrating that mice 
receiving anthocyanins from purple sweet potatoes displayed a marked decrease in 
neuroinflammatory markers following injection with LPS (Wang et al. 2010). Levels of 
both iNOS and COX-2 were significantly reduced in the brains of anthocyanin-treated 
mice, correlating with significant improvements in cognition and memory tasks. Other 
studies have indicated that anthocyanin-rich extracts from acai and black soybeans 
effectively attenuate inflammation induced in models of natural and artificial aging, the 
latter achieved by treatment with D-galactose (Poulose et al. 2016, Rehman et al. 2016). 
Acai-rich diets significantly reduced levels of both NOX-2 and NF-κB in a model of 
natural (chronological) aging, in good agreement with in vitro studies with isolated 
microglia (Poulose et al. 2016). Black soybean anthocyanin extract displayed similar 
results in a D-galactose model of neuroinflammation and artificial aging as rats receiving 
anthocyanin treatment displayed reduced levels of iNOS and NF-κB activity, as well as 
reductions in TNF-α and ROS production, and lipid peroxidation. Moreover this study 
reported reduced levels of reactive astrocytes and activated microglia in hippocampal 
tissue of anthocyanin-treated rats, indicating that these unique compounds are capable of 





Figure 1.5. Effects of anthocyanins on neuroinflammation. Inflammatory stimuli 
cause activation of extracellular regulated signal kinase 1/2 (ERK1/2), Akt, and p38-
mitogen-activated protein kinase (p38-MAPK), which subsequently activate nuclear 
factor-κB (NF-κB) in microglia. NF-κB then translocates to the nucleus and initiates 
transcription of pro-inflammatory genes including, but not limited to inducible nitric 
oxide synthase (iNOS), cyclooxygenase-2 (COX-2) NADPH-oxidase-2 (NOX-2), and 
tumor necrosis factor-α (TNF-α). It is thought anthocyanins inhibit this pathway by 
blocking activation of ERK1/2, Akt, and p38-MAPK.  
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1.2.5 Anthocyanins and Regulation of Protein Homeostasis 
Though limited, new data are emerging to suggest that anthocyanins may also 
exert neuroprotective effects by directly preventing protein aggregation and by 
stimulating autophagy. As protein aggregation has been suggested to play a significant 
role in neuronal death for many diseases, the ability of therapeutic agents to inhibit 
protein oligomerization into toxic plaques and fibrils is desirable (Table 1.1). The pure 
anthocyanin cyanidin-O-3-glucopyranoside has been shown to directly interfere with 
oligomerization of amyloid beta peptides, one of the major constituents of senile plaques 
observed predominately in Alzheimer’s disease (Tarozzi et al. 2010). Similarly, the 
aglycon, malvidin, and its glucoside conjugate have also been reported to potently inhibit 
amyloid beta oligomerization into toxic fibrils (Rivière et al. 2008). Though the 
mechanism by which anthocyanins inhibit aggregate formation is currently unknown, the 
ability of these compounds to disrupt the formation of toxic oligomers is promising for 
their therapeutic efficacy. Further data is needed to determine if anthocyanins are also 
able to disrupt toxic aggregate formation of other protein species such as mutant SOD1. 
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Major Constituents of Protein 
Aggregates 
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Glenner and Wong, 1984 
Masters et al. 1985 
Selkoe et al. 1986 
Bancher et al. 1989 








Mori et al. 2013 
Vance et al. 2009 
Ling et al. 2010 
Burijn et al. 1998 
Bosco et al. 2010  
Johnson et al. 2009 
Mackenzie et al. 2007 
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Recent studies have also reported the ability of anthocyanin-rich extracts from 
acai fruit pulp to modulate autophagy. This process, in addition to proteasomal 
degradation, is vital for clearing toxic aggregates and misfolded proteins from the 
intracellular space (Poulose 2014, Poulose et al. 2016). Treatment of HT22 cells with the 
autophagy inhibitors wortmanin and bafilomycin A1 caused significant accumulation of 
poly-ubiquitinated proteins, which was corrected by treatment with acai pulp extracts 
(Poulose 2014). Additionally, these extracts significantly enhanced turnover of 
autophagosomes and enhanced activation of mammalian target of rapamycin (mTOR), 
one of several regulators of the autophagy pathway. These results were confirmed in vivo 
in the brains of aged rats treated with acai pulp extracts, demonstrating upregulation of 
autophagy markers, such as mTOR activation (Poulose et al. 2016). Taken together, these 
results suggest that anthocyanins and anthocyanin-rich extracts may modulate processes 
such as protein aggregation and autophagy to correct disruptions in protein homeostasis 
observed in neurodegenerative disease, though further data is needed to confirm this 
hypothesis. 
There is also some evidence to suggest that anthocyanins may regulate ER stress 
in vivo, thereby preventing ER stress-induced apoptosis. In a mouse model of cognitive 
impairment induced by domoic acid, mice experienced a significant increase in levels of 
ER stress markers such as PERK and ASK1 in hippocampal tissue (Lu et al. 2012). 
However, treatment with purple sweet potato extract entirely mitigated this effect, 
returning these markers to normal levels and preventing ER stress-induced apoptosis. 
Though this is the only study to date exploring the effect of an anthocyanin-rich extract 
on neuronal ER stress in vivo, it demonstrates that these compounds may show some 
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benefit in disorders like ALS for which ER stress and concomitant protein dysregulation 






Figure 1.6. Effects of anthocyanins on protein dysregulation and homeostasis. 
Protein homeostasis is disrupted in several ways in neurodegenerative disease. Increased 
levels of ER stress cause significant decreases in protein trafficking to other organelles 
such as the Golgi apparatus. Decreased protein trafficking results in accumulation of 
misfolded and mutant proteins, causing protein aggregates to form. Formation of these 
toxic aggregates then contributes to induction of neuronal apoptosis. Anthocyanins 
modulate this process by reducing ER stress, directly inhibiting the formation of toxic 
protein aggregates, and stimulating autophagy processes to clear aggregates formed 
within the neuron.  
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1.2.6 Anti-apoptotic Effects of Anthocyanins 
Anthocyanins are known to modulate several signaling pathways involved in cell 
death and survival. Their effects on apoptosis specifically are well documented and have 
been shown to occur in both caspase-dependent and caspase-independent manners 
(Reddivari et al. 2007). For example, in a D-galactose mouse model of aging, treatment 
with purple sweet potato extract suppressed activation of pro-apoptotic proteins such as 
JNK while also preventing mitochondrial release of cytochrome c and subsequent 
execution of apoptotic signaling pathways (Lu et al. 2010, Ye et al. 2010). These effects 
were mediated by activation of phosphoinositide-3-kinase (PI3K), which is an upstream 
activator of Akt, a major regulator of pro-survival signaling. In agreement with these 
findings, it was also reported that anthocyanins attenuate p53 and JNK-dependent 
apoptosis in a model of ischemic injury induced by cerebral artery occlusion, which 
shares many pathological features with neurodegenerative disease such as oxidative 
stress, excitotoxicity, neuroinflammation, and ultimately neuronal death (Shin et al. 
2006). There are also reports that anthocyanins are capable of modulating the expression 
of Bcl-2 family members. Indeed, in a cellular model of 6-hydroxydopamine (6-OHDA) 
toxicity, a chemical often used to induce a Parkinsonian phenotype in mice and rats, 
treatment with an anthocyanin-rich extract from mulberry elevated expression of pro-
survival Bcl-2 protein while suppressing expression of the pro-apoptotic Bax protein 
(Kim et al. 2010). Finally, anthocyanins have also demonstrated the ability to prevent 
release of AIF from mitochondria, likely accounting for the ability of these compounds to 
effectively mitigate caspase-independent apoptosis (Min et al. 2011). In sum, these data 
indicate that anthocyanins are not only capable of ameliorating many factors implicated 
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in causing neuronal death in ALS, but also pro-apoptotic signaling itself, thus targeting 





Figure 1.7. Effects of anthocyanins on pro-survival and pro-apoptotic signaling 
pathways. Anthocyanins modulate several signaling pathways involved in cell survival 
and death. Anthocyanins inhibit the activity of c-Jun N-terminal kinase (JNK) and p53, 
which are responsible for activating pro-apoptotic family members of the Bcl-2 family of 
proteins, Bim, Bad, Puma, and Noxa. Bim, Puma, and Noxa are known to inhibit the pro-
survival functions of Bcl-2, causing activation of the pro-apoptotic protein, Bax. Bax can 
also be activated by interaction with Bad. Bax then forms pores in the mitochondrial 
membrane, allowing the release of cytochrome c from mitochondria. Cytochrome c 
interacts with apoptosis protease activating factor-1 (APAF-1) and caspase-9 to form the 
apoptosome.  The apoptosome then cleaves procaspase-3 to form active caspase-3, 
stimulating apoptosis. Anthocyanins also enhance the activity of the phosphoinositide-3-
kinase (PI3K)/Akt pro-survival signaling pathway, which inhibits activity of pro-
apoptotic Bcl-2 family members including Bim, Bad, and Bax, in addition to inhibiting 
the activity of p53. This activity inhibits entry of neurons into caspase-dependent 
apoptosis. Alternatively, anthocyanins have also been shown to inhibit caspase-
independent apoptosis by blocking the translocation of apoptosis inducing factor (AIF) 




1.2.7 Anthocyanins as Therapeutic Agents in Neurodegenerative Disease Models 
Since anthocyanins display impressive pleiotropic effects, combating multiple 
facets of neurodegeneration, it has been recently hypothesized that they may be effective 
therapeutic agents for the treatment of neurodegenerative disease.  Though no studies 
have been conducted in models of ALS specifically, several reports have indicated that 
anthocyanin-enriched extracts are capable of relieving the motor and cognitive deficits 
associated with Parkinson’s disease and Alzheimer’s disease, respectively.  
Parkinson’s disease is often modeled chemically using injection of the toxin  
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which has been shown to induce 
the death of nigrostriatal dopaminergic neurons, the major neuronal population affected 
in Parkinson’s disease. In mice that were treated with mulberry extract before MPTP 
injection, however, this effect was significantly reduced and dopaminergic neurons were 
preserved (Kim et al. 2010). This observation correlated with decreases in pro-apoptotic 
protein expression and significant improvements in Parkinsonian symptoms. A similar 
effect was described in another chemical model of Parkinson’s disease using rats injected 
with 6-OHDA. Studies using 6-OHDA have demonstrated that this compound causes 
significant oxidative damage and neuronal death in relevant neuronal populations 
associated with Parkinson’s disease (Simola et a. 2007). Rats injected unilaterally with 6-
OHDA showed decreased numbers of dopaminergic neurons within the lesioned 
substantia nigra and elevation in levels of lipid peroxidation (Roghani et al. 2010). These 
effects were essentially ablated, however, by administration of the aglycon anthocyanin 
derivative, pelargonidin, which corresponded to significant improvements in motor 
function.   
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 Positive findings have also been shown for the treatment of Alzheimer’s disease 
and age-related cognitive impairment with anthocyanin-rich extracts. A recent study in 
the APP/PS1 mutant mouse model of Alzheimer’s disease, which expresses the 
transgenes for both mutant amyloid precursor protein (APP) and mutant presenilin-1 
(PS1), demonstrated that transgenic mice develop significant cognitive impairments in 
spatial working memory and accumulation of amyloid beta in brain tissue (Vepsäläinen et 
al. 2013). This accumulation was significantly reduced by treatment with anthocyanins 
isolated from bilberry and black currant, and both extracts were able to prevent cognitive 
decline and improve behavioral abnormalities. Similarly, a recent study by Qin et al. 
(2013) demonstrated that treatment with cyanidin-O-3-glucoside prevented cognitive 
impairment induced by amyloid beta intra-cerebro-ventricular injection. Positive findings 
were also reported by Badshah et al. (2015) in anthocyanin-treated rats injected with 
amyloid beta, which showed significant reductions in markers of apoptosis and 
Alzheimer’s disease. These findings are in good agreement with a study conducted in 
senescence accelerated mouse prone 8 (SAMP8) mice, which are used as a model of 
accelerated aging. These mice experience significant cognitive impairment, which 
correlates with deposition of amyloid beta plaques, reminiscent of those observed in 
Alzheimer’s disease. Additionally, these mice display elevated levels of stress kinase 
signaling in the brain mediated by JNK and p38-MAPK. Treatment with an anthocyanin-
rich extract from mulberry preserved cognitive function and significantly reduced 
amyloid plaque burden and stress kinase signaling in the brains of treated mice (Shih et 
al. 2010). Human studies in older adults at risk for dementia have also yielded promising 
results with regards to anthocyanin consumption. The dietary introduction of blueberries 
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and Concord grape juice, which are rich in anthocyanins, significantly improved mild 
memory impairment in treated individuals (Krikorian et al 2010a, 2010b).  
 While preclinical and clinical findings on the use of anthocyanins for the 
treatment of neurodegenerative disease are currently limited in number, they provide 
compelling evidence for the potential therapeutic efficacy of these compounds. 
Moreover, as diseases such as Parkinson’s disease and Alzheimer’s disease share many 
common pathogenic features with ALS, these studies strongly suggest that anthocyanins 
may also show beneficial effects in preclinical models of this disease. As such, further 
study into the mechanism of action and effectiveness of these compounds is warranted. 
 
1.3 The Use of Anthocyanin Metabolites as Novel Neuroprotective and Therapeutic 
Agents in Neurodegenerative Disease 
While anthocyanins have proven to be promising therapeutic candidates in a 
preclinical context, it is important to note that the overall bioavailability of parent 
anthocyanins is very low despite their high degree of bioactivity. Indeed, the 
concentrations that are needed to achieve neuroprotection in cultured neurons far exceed 
physiological concentrations of anthocyanins observed in brain tissue from supplemented 
animals (Del Rio et al. 2010, Woodward et al. 2009). Furthermore, several reports have 
indicated that anthocyanins are rapidly and thoroughly metabolized in the gut such that 
very little of the parent compounds are able to be absorbed in their native state (Fleschhut 
et al. 2006, Woodward et al. 2009, Forester and Waterhouse, 2010). This has led to the 
hypothesis that anthocyanin metabolites are likely to mediate many of the biological 
effects observed following anthocyanin ingestion in vivo. Thus, it is of great import to 
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investigate the therapeutic properties of these metabolites in order to better understand 
their potential role in attenuating neurodegenerative disease 
 
1.3.1 Metabolism, Absorption and Bioavailability of Anthocyanin Metabolites  
 Following consumption, anthocyanins are detected systemically in several forms, 
including sulfated, methylated, glucuronidated, and glycosylated conjugates (Gonthier et 
al. 2003, Manach et al. 2005). Additionally, metabolism by gut microflora has been 
shown to produce considerable amounts of phenolic acid and aldehyde metabolites that 
share many structural characteristics with their respective parent anthocyanins (Fleschhut 
et al. 2006; Woodward et al. 2009; Forester and Waterhouse, 2010). These metabolites 
are often more stable than parent anthocyanins supporting the idea that they are likely the 
bioactive components of an anthocyanin-rich diet (Keppler and Humpf, 2005, Kay et al. 
2009). 
It is generally accepted that anthocyanins and related polyphenols begin 
metabolism in the small intestine where glycoside linkages are hydrolyzed to produce the 
aglycon form (Day et al. 2000, Gee et al. 2000). Anthocyanins and aglycons that are not 
absorbed in the small intestine then pass on to the colon, where they are further 
metabolized by the resident microflora. Metabolism by gut microflora is perhaps the best 
characterized method by which anthocyanins are degraded and has been described by 
several studies. In this paradigm, anthocyanins incubated with intestinal microflora has 
been reported to lead to almost complete degradation of anthocyanins, resulting in the 
formation of phenolic acids and a universal aldehyde metabolite (Fig. 1.8; Fleschhut et al. 
2006, Woodward et al. 2009, Forester and Waterhouse, 2010). The phenolic acids 
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derived from this process are the result of hydrolysis of the B-ring and largely retain their 
structure after separation from the anthocyanin skeleton (Fig 1.9). Phenolic acid 
metabolites can be further modified by glucuronidation; however, unaltered phenolic 
acids have been observed in vivo following anthocyanin ingestion (Woodward et al. 
2011). In particular, the phenolic acid metabolite of cyanidin-based anthocyanins, 
protocatechuic acid (PCA), has been found in circulation, achieving a concentration eight 
times higher than that of parent anthocyanins in rat plasma (Azzini et al. 2010). 
Interestingly, PCA also appears to remain in tissue longer than its parent anthocyanin 





Figure 1.8. Metabolism of anthocyanins. A generic anthocyanin with a glucoside 
moiety is pictured. Parent anthocyanin species are first converted to an aglycon 
(anthocyanidin) form by hydrolysis of glycoside linkages in the small intestine. Upon 
entry into the large intestine, the anthocyanidin is further metabolized by gut microflora 
to produce a universal aldehyde metabolite, phloroglucinol aldehyde, and a phenolic acid 




Figure 1.9. Common phenolic acid metabolites derived from anthocyanins. A, 
Common anthocyanin bases and their phenolic acid metabolites. B, Molecular structures 
of the six most common phenolic acid metabolites derived from anthocyanins.   
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While high circulating concentrations of some metabolites suggests that they may 
play a significant role in mediating the various health benefits of anthocyanin 
consumption, it is currently unknown if all anthocyanin metabolites are able to cross the 
BBB to be absorbed by relevant CNS tissues. However, a growing pool of evidence 
suggests that phenolic acids are indeed able to gain access to the CNS. One study has 
reported that PCA can be detected in cortical tissue from rats after oral administration of 
Danshen extract (Zhang et al. 2011). Gallic acid has also been detected in brain tissue 
following oral treatment with grape seed extract, and appears to accumulate in plasma 
and brain tissue with chronic dosing, strongly suggesting that these compounds are 
capable of crossing the BBB  (Ferruzzi et al. 2009). Nevertheless, further exploration of 
this topic is required to assess the therapeutic efficacy of anthocyanin metabolites in vivo 
in order to characterize the bioavailability of these phenolic acids in the CNS.  
 
1.3.2 In Vitro Neuroprotective Effects of Anthocyanin Metabolites 
To date, studies assessing the neuroprotective effects of anthocyanin metabolites, 
particularly in primary cell cultures, are lacking; however the few studies that have been 
conducted show encouraging results for the use of these compounds in mitigating several 
factors associated with neuronal death in neurodegeneration. The large majority of these 
studies have examined the beneficial effects of the compounds PCA and gallic acid (GA), 
the phenolic acid metabolites of cyanidin- and delphinidin-based anthocyanins 
respectively (Fig. 1.9, Fleschhut et al. 2006, Woodward et al. 2009, Forester and 
Waterhouse, 2010).  
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Like its parent anthocyanins, PCA has been shown to have significant antioxidant 
capacity, which is believed to mediate some of its neuroprotective effects (Sroka and 
Cisowski, 2003). For example, treatment of neuronal cell lines with hydrogen peroxide 
induced a significant degree of cell death, which was entirely attenuated by treatment 
with PCA (An et al. 2006, Guan et al. 2006a, Shi et al. 2006, Tarozzi et al. 2007). This 
effect was likely mediated in part by the intrinsic free radical scavenging abilities of 
PCA; however it was also reported that PCA-treated PC12 cells challenged with 
hydrogen peroxide possessed higher levels of GSH and catalase activity, suggesting that 
this compound may also regulate intrinsic antioxidant defenses within the cell (Guan et 
al. 2006a). Similar results were observed in PC12 cells treated with the nitric oxide 
donor, sodium nitroprusside (SNP), with PCA preserving cellular viability to a significant 
degree (An et al. 2006).  
PCA has also been examined for its ability to attenuate neuronal death induced by 
treatment with 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of MPTP, 
which acts as a mitochondrial complex I inhibitor to induce neurotoxicity (Nicklas et al. 
1985). These studies have indicated that PCA effectively protects PC12 cells from 
MPP+-induced toxicity by preventing mitochondrial dysfunction and elevating levels of 
antioxidant enzymes such as catalase, SOD1, and glutathione peroxidase, in addition to 
enhancing levels of the pro-survival protein, Bcl-2 (An et al. 2006, Guan et al. 2006b, 
Zhang et al. 2009). Similar results were observed when this study was repeated using 
rotenone, another inhibitor of complex I (Liu et al. 2008). GA and another anthocyanin 
metabolite, syringic acid, which is derived from malvidin-based anthocyanins, were also 
evaluated in vitro for their ability to attenuate 6-OHDA toxicity. This study found that 
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both GA and syringic acid were effective neuroprotective agents in this model, though 
the mechanism of protection was not well defined (Lu et al. 2006). 
The impact of anthocyanin metabolites has also been evaluated for cellular 
models of neurotoxicity observed in Alzheimer’s disease. PCA has been shown to 
mitigate the neurotoxic effects of amyloid beta in primary rat cortical neurons by 
attenuating increases in ROS and intracellular calcium levels, in addition to preventing 
glutamate release caused by this insult (Ban et al. 2007). Evidence has also accumulated 
suggesting that GA effectively defends neuronal cells from amyloid beta toxicity in a 
manner very similar to that of PCA, reducing accumulation of intracellular ROS and 
calcium, and preventing glutamate release (Bastianetto et al. 2006, Ban et al. 2008). 
Interestingly, regulation of calcium signaling has also been reported in one study utilizing 
GA to blunt kainate-induced excitotoxicity in PC12 cells. Indeed, GA treatment 
significantly attenuated increased calcium levels in addition to mitigating ROS 
accumulation and preventing the induction of pro-inflammatory enzymes such as COX-2 
and p38-MAPK (Huang et al. 2012). Collectively, these studies indicate that PCA and 
GA may be effective treatments to regulate disruptions in calcium homeostasis observed 
in diseases like ALS. 
GA has also been shown to ablate the neurotoxic effects of microglial 
inflammation induced by amyloid beta in a co-culture system utilizing either primary 
microglia or BV2 microglia and the neuro2A cell line (Kim et al. 2011). Treatment with 
GA significantly reduced production of pro-inflammatory cytokines, and induced 
acetylation of NF-κB, thereby decreasing inflammatory gene expression.  This translated 
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into preservation of neuronal viability, suggesting that some anthocyanin metabolites 
may be effective anti-neuroinflammatory agents. 
There is also a growing number of reports indicating that anthocyanin metabolites 
interfere with oligomerization of proteins such as amyloid beta and α-synuclein into toxic 
fibrils, which are characteristic of Alzheimer’s and Parkinson’s disease pathology, 
respectively (Table 1.1). GA was shown to interfere with amyloid beta fibril formation in 
primary rat hippocampal cells, which was thought to contribute to its protective effects 
against amyloid beta toxicity, though the mechanism of this effect is undefined 
(Bastianetto et al. 2006). In a similar fashion, both PCA and GA were found to inhibit the 
formation of toxic α-synuclein fibrils (Zhang et al. 2009, Liu et al. 2014). Though it is not 
clear how PCA carries out this function, GA was found to inhibit fibril formation by 
transient interaction with α-synuclein in its extended native structure, which prevented its 
collapse and subsequent formation of toxic fibrils (Liu et al. 2014). While further 
exploration is needed to determine if this effect can be reproduced with other anthocyanin 
metabolites, it is a promising finding for their use as therapeutic agents in 
neurodegeneration for which protein aggregation is a major contributing factor. 
 
1.3.3 Anthocyanin Metabolites as Therapeutic Agents in Neurodegenerative Disease 
and Aging Models  
Studies into the efficacy of anthocyanin metabolites for treating 
neurodegeneration have gained momentum in the past five years, and several reports 
have emerged describing the use of these compounds in preclinical disease models. 
While the data are sparse and focused almost exclusively around the in vivo 
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neuroprotective effects of PCA and GA, these initial reports have so far yielded 
encouraging findings. For example, the therapeutic potential of PCA was recently 
evaluated in the MPTP mouse model of Parkinson’s disease. This study found that 
treatment with PCA prior to MPTP injection significantly ameliorated the detrimental 
effects of this insult, preventing loss of tyrosine hydroxylase-positive dopamine neurons 
in the substantia nigra and preserving levels of dopamine and its metabolites in striatum 
in comparison to mice receiving MPTP alone (Zhang et al. 2010). These observations 
correlated with improved motor function in rotarod testing. Similar results were reported 
in a study utilizing GA in the 6-OHDA rat model of Parkinson’s disease. Rats that 
experienced 6-OHDA lesion displayed dramatic deficits in memory and learning 
performance, measured by passive avoidance testing, which correlated with increased 
lipid peroxidation and reduced antioxidant defenses in both hippocampus and striatum 
(Mansouri et al. 2013). These effects were significantly attenuated by GA treatment in a 
dose-dependent manner. These studies suggest that PCA and GA may be useful for the 
treatment of Parkinson’s disease and other related disorders. 
The therapeutic benefits of PCA and GA treatment were also explored in models 
of Alzheimer’s disease and aging. In the APP/PS1 mutant mouse model of Alzheimer’s 
disease, PCA treatment was found to reduce amyloid beta deposition in hippocampal 
tissue, in addition to reducing expression of APP, from which amyloid beta is generated 
(Song et al. 2014). PCA also reduced the presence of inflammatory markers in tissue 
homogenates from hippocampus and cerebral cortex including several inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, and IL-8, while increasing production of pro-
survival signaling factors such as brain-derived neurotrophic factor (BDNF). Mice that 
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received PCA treatment also displayed marked improvements in learning and memory 
tasks in comparison to untreated APP/PS1 mice (Song et al. 2014). These findings were 
corroborated in a study utilizing the D-galactose mouse model of aging, which reported 
similar anti-inflammatory effects following administration of PCA (Tsai and Yin, 2012). 
These included decreased levels of pro-inflammatory cytokines and reductions in COX-2 
and NF-κB expression. Moreover, PCA treatment was also reported to reduce oxidative 
damage in the brains of treated mice. GA has been shown to have similar effects in mice 
treated with amyloid beta by intra-cerebro-ventricular injection. Amyloid beta injection 
caused significant impairments in learning and memory tasks in mice, in addition to 
enhancing pro-inflammatory markers including iNOS and COX-2 expression and 
production of IL-1β (Kim et al. 2011). NF-κB acetylation and nuclear translocation were 
also examined and found to be significantly enhanced in this model. Pre-treatment with 
GA, however, potently inhibited these effects, likely through suppression of NF-κB 
activity (Kim et al. 2011). These in vivo results support the assertion that phenolic acid 
metabolites of anthocyanins may be good candidates for the therapeutic treatment of 
Alzheimer’s disease. 
While the effects of anthocyanin metabolites have never been assessed in the 
context of ALS, the studies that have been conducted in other preclinical disease models 
indicate that these compounds may be effective therapeutic agents for ALS due to the 
common pathological features underlying these diseases. Nonetheless, further exploration 
is needed to fully understand the possible therapeutic value of phenolic acid metabolites 
for various neurodegenerative diseases. 
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1.4 Cellular Models for the Study of Neuroprotection and Neuroinflammation 
The use of in vitro models is an essential step in the screening process for 
potential therapeutics. Cell culture models for neuroprotection and neuroinflammation 
provide relatively simple systems to assess the efficacy of a variety of compounds in a 
manner that is timely and cost-effective. Furthermore, cell culture models represent an 
easy way to gain insight into the mechanistic qualities of potential neuroprotective and 
anti-inflammatory compounds before introducing them into animal models of 
neurodegenerative disease.  This makes them valuable tools for studying and identifying 
novel neuroprotective and anti-inflammatory compounds such as anthocyanins and their 
metabolites. Our approach uses two in vitro cell culture systems to assess the therapeutic 
potential of compounds in terms of their neuroprotective and anti-neuroinflammatory 
activity to inform subsequent in vivo analyses of promising therapeutic candidates in 
preclinical models of ALS. These systems are described in detail below. 
 
1.4.1 An In Vitro Model of Neuroprotection: Cerebellar Granule Neurons 
Cerebellar granule neurons (CGNs) are a widely used cell culture model to study 
the neuroprotective action of pharmacological, and more recently, nutraceutical 
compounds. Established over 40 years ago, CGN cultures represent a unique in vitro 
system to study neuronal death and survival, and have become one of the best 
characterized cell culture systems in neuroscience research. CGNs are among the most 
homogenous primary neuronal cultures, yielding purities of up to 95%, which is a 
desirable characteristic for studies attempting to define the mechanistic actions of a 
particular pharmacological or nutraceutical agent (Linseman et al. 2001). Furthermore, 
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treatment of CGNs with various insults (or cellular stressors) has been shown to 
recapitulate many of the individual molecular factors associated with neurodegeneration 
and cell death in vivo, including oxidative and nitrosative stress, excitotoxicity, 
dysregulation of protein homeostasis, and apoptosis. Indeed, treatment with hydrogen 
peroxide, 6-OHDA, an inducer of oxidative stress, or nitric oxide donors has been shown 
to induce apoptotic death of CGNs in a caspase-dependent manner (Leist et al. 1997, Wei 
et al. 2000, Lin et al. 2003, Noelker et al. 2005). Stimulation of CGNs with glutamate has 
also been shown to result in neuronal death due to excitotoxic mechanisms such as 
enhanced free-radical production and activation of calpains (Manev et al. 1991, Ciani et 
al. 1996). Additionally, CGNs have been shown to undergo apoptotic death in response to 
induction of ER stress by blocking transport of proteins from the ER to the Goli 
apparatus using Brefeldin A, and proteasome inhibition (Pasquini et al. 2000, Brewster et 
al. 2006, Ma and D’Mello, 2010). It is also notable that we have previously demonstrated 
that CGNs challenged with agents inducing mitochondrial oxidative stress displayed 
significant cell death consistent with apoptosis, which was almost entirely mitigated by 
treatment with pure anthocyanin compounds (Kelsey et al. 2011).  
Thus, though many more studies exist demonstrating the value of CGNs in 
modeling different neuronal stressors, and the neuroprotective effects of pharmacological 
interventions, this small sampling of data indicate that CGNs are a versatile system for 
assessing the neuroprotective effects of anthocyanins against a variety of stressors (Fig 
1.10).  Moreover, data gained from this evaluation will provide valuable insight into the 
neuroprotective capacity and mechanism of action of these compounds to assess their 




Figure 1.10. Cerebellar granule neurons as a model of cell death and survival. Cells 
were observed under normal culture conditions (Control) or in the presence of apoptotic 
stimuli (Apoptosis). Healthy control cells display large, round nuclei (blue) and elaborate 
tubulin networks (green) whereas cells that have undergone apoptosis possess condensed 
and fragmented nuclei and fragmented tubulin networks.  
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1.4.2 An In Vitro Model of Neuroinflammation: The BV2 Microglial Cell Line 
As the primary mediators of the neuroinflammatory response, microglia play a 
critical role in the neurodegenerative process, and thus, many models of microglial 
inflammation have been developed. While the use of primary microglial cultures has 
been described for this purpose, the use of microglial cell lines represents a more cost-
effective and timely way to screen for potential anti-inflammatory agents. The BV2 
microglial cell line in particular is a widely used model of neuroinflammation as these 
cells retain many of the most important features of primary microglia (Horvath et al. 
2008, Henn et al. 2009, Stansley et al. 2012). BV2 microglia were originally derived 
from primary mouse microglia immortalized by retroviral infection carrying the v-raf and 
v-myc oncogenes (Blasi et al. 1990). These cells were shown to maintain markers of a 
microglial phenotype, while lacking markers for other cell types  such as glial fibrillary 
acidic protein (GFAP) and  galactocerebroside, markers for astrocytes and 
oligodendrocytes respectively (Blasi et al. 1990). Furthermore, these cells behave in the 
same way as primary microglia and maintain the ability to mount an inflammatory 
response in the presence of LPS and interferon-γ, and perform phagocytosis (Blasi et al. 
1990, Kopec and Carroll, 1998). Indeed, 90% of the genes activated by LPS stimulation 
in primary microglia are also activated in BV2 microglia, albeit to a lesser extent (Henn 
et al. 2009). Moreover, BV2 microglia retain the ability to secrete pro-inflammatory 
factors such as cytokines and nitric oxide, though overall levels are lower than those 
observed in primary microglia, and their use in co-culture systems with primary neurons 
has been shown to induce apoptotic neuronal death upon microglial activation in a 
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manner similar to that hypothesizied to occur in vivo during neurodegeneration (Bi et al. 
2014, Henn et al. 2009, Horvath et al. 2008). 
The use of BV2 microglia to evaluate the anti-neuroinflammatory effects of 
anthocyanin-rich extracts and at least one anthocyanin metabolite has recently been 
described and treatment with these substances was shown to have  a positive impact on 
microglial inflammation (Lau et al. 2007, Kim et al. 2011, Poulose et al. 2012, Carey et 
al. 2013, Jeong et al. 2013). With this in mind, BV2 microglia are a viable system to 
further evaluate the therapeutic benefits of anthocyanins and their metabolites in vitro 







Figure 1.11. BV2 microglia as a model of neuroinflammation. BV2 cells were 
observed under normal culture conditions (Control) or after treatment with 
lipopolysaccharide (LPS) for 24h. Control cells possess a spindle-shaped morphology 
characterized by long processes extending from the cell body. Cells treated with LPS 
display a rounded, amoeboid morphology, and a loss of processes extending from the cell 
body, characteristic of inflammatory microglia.  
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1.5  Preclinical Assessment of Therapeutic Agents: The G93A mutant hSOD1 Mouse 
Model of ALS 
Mutations in SOD1 were first described by Rosen et al. in 1993 as the first genetic 
causes of autosomal dominant familial ALS. Shortly following this discovery, the first 
transgenic mutant mouse model of ALS, the hSOD1G93A mouse, was developed in an 
effort to better our understanding of ALS disease course (Gurney et al. 1994). This mouse 
model has become the most widely used preclinical model of ALS, and a majority of 
what we currently understand about ALS pathophysiology and the treatment of this 
disease has been derived from this model.  
Mice overexpressing the hSOD1G93A transgene faithfully recapitulate many 
clinical manifestations of ALS disease progression. These mice experience early disease 
onset at approximately three to four months of age depending on the background of the 
strain, which is characterized as hind limb weakness, measured by the inability of mice to 
splay their hind limbs when suspended by the tail, and weight loss (Fig. 1.12; Gurney et 
al. 1994, Ludolph et al. 2007, Scott et al. 2008). Disease progression is aggressive in this 
model, occurring over the course of approximately three to four weeks during which time 
mice experience continued loss of strength in the hind limbs, significant loss of body 
weight, muscle atrophy, and paralysis until end stage of disease is reached, defined as the 
point at which a mouse placed on its side can no longer right itself to a sternal position 




Figure 1.12. Clinical indices of disease in the hSOD1G93A mouse model of ALS. A, 
Transgenic hSOD1G93A mice display significant weakness in hind limb muscles measured 
by leg splay. Non-transgenic wild type (WT) mice splay their hind limbs when suspended 
by their tail whereas hSOD1G93A (G93A) mice cannot splay their hind limbs due to 
muscle weakness and paralysis. B, Transgenic hSOD1G93A mice display muscle atrophy 
and weight loss. WT mice show healthy weight and muscle mass, whereas hSOD1G93A 
mice show marked reductions in body weight and significant muscle atrophy, particularly 
in the hind limbs.   
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In addition to clinical symptoms of ALS, hSOD1G93A mice display several 
histopathological markers of ALS disease pathophysiology. Among these, the most 
notable is rapid and extensive degeneration of motor neurons (particularly spinal motor 
neurons) resulting in motor neuron axonopathies, and eventual death (Gurney et al. 1994, 
Dal Canto and Gurney 1994). As loss of motor neurons is a defining characteristic of 
ALS disease pathology, this represents solid evidence that mice harboring the mSODG93A 
transgene do develop ALS-like disease. Furthermore, hSODG93A mice also develop 
mitochondrial dysfunction and oxidative stress, markers of excitotoxicity, markers of ER 
stress, reactive gliosis, and loss of functional neuromuscular junctions in a manner that 
appears similar to that experienced by ALS patients (Dal Canto and Gurney, 1994, Hall et 
al. 1998a, Hall et al. 1998b, Kong and Xu, 1998, Mattiazzi et al. 2002, Saxena et al. 
2009, Wootz et al. 2010, Milanese et al. 2011, Giribaldi et al. 2013). These mice also 
develop SOD1-positive aggregates consistent with histopathological data from familial 
ALS patient tissue (Turner et al. 2013). As discussed above, all of these features have 
been observed in patients with both sporadic and familial forms of ALS, suggesting that 
findings in the hSOD1G93A mouse model could be applicable to both forms of the disease 
observed in ALS patients.  
Because the hSOD1G93A mouse model of ALS appears to share many pathological 
features with human disease and displays a well-characterized disease course, it has 
become the model of choice for rapid preclinical screening and characterization of 
numerous proposed therapies to treat ALS. In recent years, interest in nutraceutical 
treatments for ALS has grown owing largely to the observation that many nutraceutical 
compounds display impressive antioxidant abilities, and several notable studies have 
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been conducted examining their efficacy as therapeutic agents. Vitamin E is arguably one 
of the most studied nutraceuticals yet examined for the treatment of ALS. Aimed at 
reducing oxidative damage, particularly in lipid membranes, presymptomatic vitamin E 
supplementation in the hSODG93A mouse significantly delayed disease onset, though no 
extension in survival of treated mice was noted (Gurney et al. 1996). Subsequent clinical 
trials with vitamin E in ALS patients have been conducted, though the efficacy for this 
nutraceutical in treating ALS remains unclear (Butterfield et al. 2002). We recently 
obtained similar results using a non-denatured whey protein supplement, Immunocal®, 
which is known to boost GSH levels in vivo (Ross et al. 2014). Transgenic hSOD1G93A 
mice treated presymptomatically with this supplement displayed a significant delay in 
disease onset and preservation of skeletal muscle function, although no extension in 
survival was observed (Ross et al. 2014). This correlated with preservation of GSH levels 
in blood and spinal cord tissue isolated from treated hSOD1G93A mice, though 
Immunocal® treatment was not able to rescue GSH deficits specifically in the 
mitochondrial compartment of spinal cord tissue. Though modest therapeutic benefits 
were observed in both of these studies, they highlight the use of the hSOD1G93A mouse as 
a viable and sensitive model in which to test the mechanism and efficacy of novel 
therapeutic candidates for ALS treatment. Therefore, the hSOD1G93A mouse model of 
ALS represents a powerful tool to evaluate the therapeutic value of anthocyanins and 








CHAPTER TWO: CHEMICAL BASIS FOR THE DISPARATE 
NEUROPROTECTIVE EFFECTS OF THE ANTHOCYANINS, CALLISTEPHIN 
AND KUROMANIN, AGAINST NITROSATIVE STRESS 
 
2.1 Abstract 
Oxidative and nitrosative stress are major factors in neuronal cell death 
underlying neurodegenerative disease. Thus, supplementation of antioxidant defenses 
may be an effective therapeutic strategy for diseases such as amyotrophic lateral 
sclerosis, Parkinson’s disease, and Alzheimer’s disease. In this regard, treatment with 
nutraceutical antioxidants has garnered increasing attention; however, the differential 
neuroprotective effects of structurally similar nutraceuticals, which may affect their 
suitability as therapeutic agents, has not been directly examined. In this study we 
compare the ability of two anthocyanins, callistephin (pelargonidin-O-3-glucoside) and 
kuromanin (cyanidin-O-3-glucoside) to protect cerebellar granule neurons from damage 
induced by either oxidative or nitrosative stress. These anthocyanins differ by the 
presence of a single additional hydroxyl group on the B-ring of kuromanin, forming a 
catechol moiety. While both compounds protected neurons from oxidative stress induced 
by glutamate excitotoxicity, a stark contrast was observed under conditions of nitrosative 
stress. Only kuromanin displayed the capacity to defend neurons from nitric oxide (NO)-
induced apoptosis. This protective effect was blocked by addition of Cu, Zn-superoxide 
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dismutase, indicating that the neuroprotective mechanism is superoxide dependent. Based 
on these observations, we suggest a unique mechanism by which slight structural 
variances, specifically the absence or presence of a catechol moiety, lend kuromanin the 
unique ability to generate superoxide, which acts as a scavenger of NO. These findings 
indicate that kuromanin and compounds that share similar chemical characteristics may 
be more effective therapeutic agents for treating neurodegenerative diseases than 
callistephin and related (non-catechol) compounds. 
 
2.2 Introduction 
Conditions of oxidative and nitrosative stress are well documented factors 
contributing to the pathophysiology of a number of neurodegenerative diseases 
(Calabrese et al. 2000, Lin and Beal 2006, Gu et al. 2010, Radi et al. 2014). In recent 
years, it has become apparent that these conditions arise largely as a consequence of 
diverse initiating mechanisms, including excitotoxicity, mitochondrial dysfunction, and 
neuroinflammation, which produce large quantities of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). Accumulation of ROS, such as superoxide, hydrogen 
peroxide, and hydroxyl radicals, or RNS, such as nitric oxide and peroxynitrite, results in 
significant damage to vital cellular components, culminating in neuronal cell death. It is 
therefore unsurprising that strategies aimed at mitigating the damaging effects of ROS 
and RNS are being actively pursued as potential therapeutic treatments for a number of 
neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and 
amyotrophic lateral sclerosis (ALS). In this respect, flavonoids, naturally occurring 
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compounds found in a number of highly consumed fruits and vegetables, are promising 
therapeutic candidates due to their impressive antioxidant, anti-inflammatory and anti-
apoptotic properties, which make them well suited to combat multiple facets of the 
neurodegenerative process (Ishikawa et al. 2000, Hirano et al. 2001, Schroeter et al. 
2001, Kwon et al. 2004, Kumazawa et al. 2006, Hamalaninen et al. 2007, Vauzour et al. 
2007, Vauzour et al. 2008). 
In particular, anthocyanins, a class of flavonoid compounds responsible for the 
brilliant red, blue, and purple coloration of many fruits, vegetables and flowers, have 
garnered significant attention as potent antioxidants and anti-inflammatory agents. Their 
positive effects on a myriad of health conditions, such as heart disease and cancer, have 
been extensively documented (reviewed by Wang and Stoner 2008, Wallace 2011, Ross 
et al. 2012). However, while promising, the use of these compounds in the context of 
neurodegenerative disease is novel and warrants further exploration.  
While several studies have explored the benefits of anthocyanins in both in vitro 
and in vivo models of neurodegeneration, neuroinflammation, and aging (Poulose et al. 
2012, Ross et al. 2012, Carey et al. 2013, Jeong et al. 2013, Ross et al. 2013), interpreting 
the results of these studies is often complicated by the use of anthocyanin-enriched 
extracts, which contain multiple anthocyanins and small amounts of other (poly)phenolic 
compounds. While such studies have been invaluable as a starting point for identifying 
anthocyanins as new drug candidates, the presence of multiple compounds within a single 
extract severely limits the ability of investigators to discern which compounds are 
ultimately responsible for any observed health benefits, and eliminates the possibility of 
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dissecting the mechanism of action of any particular compound. Interpretation of results 
is further confounded by the possibility that any positive effects observed after treating 
with an anthocyanin-enriched extract may actually be due to synergism between several 
unique compounds, rather than the activity of a single agent. Indeed, a recent study by 
Carey et al. (2013) compared the anti-neuroinflammatory effects of two pure anthocyanin 
species to an extract derived from blueberries using the BV2 microglial cell line. Their 
data revealed that a much higher concentration of pure anthocyanins was required to 
achieve significant reductions in inflammatory markers when compared to the blueberry 
extract, suggesting a high degree of synergism between its constituents. 
In this regard, conclusions drawn using anthocyanin-enriched extracts alone are 
restricted at best to a particular family of compounds, which contains several members, 
or at worst, to the use of a particular extract itself. However, despite these limitations, 
studies using pure anthocyanin species in models of neurodegeneration and 
neuroprotection are few in number, and almost exclusively limited to in vitro assessment 
(Tarozzi et al. 2007, Tarozzi et al. 2008, Kim et al. 2009, Tarozzi et al. 2010, Kelsey et 
al. 2011, Shih et al. 2011). Indeed, to the best of our knowledge, only two studies have 
been conducted in vivo, one using the pure anthocyanidin, pelargonidin, in a 6-
hydroxydopamine lesioned rat model of hemi-Parkinsonism, and one using cyanidin-O-3-
glucoside to preserve spatial memory in rats treated with beta-amyloid peptide (Roghani 
et al. 2010, Qin et al. 2013). Furthermore only one in vitro study previously conducted by 
our lab with pure anthocyanins has compared the neuroprotective effects of distinct 
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anthocyanin species (Kelsey et al. 2011). However, this study was limited to the 
evaluation of anthocyanins only in the context of mitochondrial oxidative stress.  
While our previous work indicated that the two pure anthocyanins, callistephin 
(pelargonidin-O-3-glucoside) and kuromanin (cyanidin-O-3-glucoside), protect primary 
neurons equally from the Bcl-2 inhibitor and mitochondrial glutathione depleting agent, 
HA14-1, reports comparing the properties of different anthocyanins and related 
flavonoids in non-neuronal systems have indicated that subtle differences in molecular 
structure, particularly the number of hydroxyl groups located on the B-ring, have 
measurable effects on the ability to interact with lipid membranes, absorption, and free 
radical scavenging activities (Yi et al. 2006, Brown and Kelly, 2007, Kelsey et al. 2011). 
With this in mind, we sought to determine if structurally similar, yet distinct anthocyanin 
species also differ in their ability to confer neuroprotection against a more diverse array 
of insults related to neurodegenerative processes, such as excitotoxicity and nitric oxide 
toxicity.  Our results revealed a striking contrast in the neuroprotective abilities of the 
anthocyanins callistephin and kuromanin against nitric oxide-induced nitrosative stress, 
with only kuromanin significantly preserving cell viability. As these compounds are 
structurally similar, differing only by the presence of a single hydroxyl group on the B-
ring of kuromanin (Fig. 2.1), we determined that slight alterations in molecular structure 
can have a profound effect on neuroprotective capacity under conditions of nitrosative 
stress. Here, we propose a novel neuroprotective mechanism by which anthocyanins 
containing a catechol moiety on their B-ring, such as kuromanin, are able to effectively 





Figure 2.1. Molecular structures of callistephin (left) and kuromanin (right). Note 




2.3.1 Reagents  
Callistephin chloride (≥ 97% purity), kuromanin chloride (≥ 95% purity), 
glutamic acid, glycine, potassium chloride, Hoechst 33258, paraformaldehyde, 
polyethyleneglycol-conjugated superoxide dismutase 1 (PEG-SOD), Cu, Zn-superoxide 
dismutase (SOD1) from bovine erythrocytes, DT diaphorase (quinone oxidoreductase 1; 
QR1), quininone oxidoreductase 2 (QR2), tween 20, and monoclonal antibody against β-
tubulin were purchased from Sigma-Aldrich (St. Louis, MO). Sodium nitroprusside 
(SNP) was obtained from Calbiochem (San Diego, CA). 2-Methyl-6-(4-Methoxyphenyl) 
-3,7-Dihydroimidazo[1, 2-A]pyrazin-O-3ne, Hydrochloride (MCLA) was purchased from 
Molecular Probes (Grand Island, NY). Basal Medium Eagle’s solution, L-glutamine 
solution, penicillin/streptomycin solution, fetal bovine serum (FBS), and lipofectamine 
2000 transfection reagent was purchased from Invitrogen (Grand Island, NY). Anti-
mouse FITC-conjugated secondary antibody was obtained from Jackson Immunoresearch 
Laboratories (West Grove, PA). Nitric Oxide Assay kit (EMSNOTOT) was obtained 
from Thermo Scientific (Rockford, IL). MTT assay kit was purchased from Bioassays 
Systems (Hayward, CA). Nutri-Fruit freeze-dried strawberry and blackberry powders 
were purchased from the Scenic Fruit Company (Gresham, OR).  
 
2.3.2 Extraction and HPLC Analysis of Freeze-Dried Fruit Powders 
Anthocyanin enriched extracts from strawberry (SAE) and blackberry (BAE) 
were prepared using commercially available freeze-dried fruit powders. Extracts were 
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prepared as described by Rodriguez-Saona and Wrolstad (2001) using acidified 
methanol. Fifty grams of freeze-dried fruit powder was placed in a large flask and 
macerated with acidified methanol (0.01% HCl) for 1 hour at room temperature to create 
a crude extract of phenolic species. Methanol containing the extracted (poly)phenols was 
then collected by vacuum filtration using Whatman no. 1 filter paper. The remaining 
powder collected in a Buchner funnel, was then re-extracted with acidified methanol until 
a faint colored extract was obtained. The crude extract was pooled together and boiled 
under vacuum at a temperature of approximately 40°C to remove the methanol until the 
extract had become viscous. This extract was then purified for anthocyanins using a C18 
column prepared with acidified water (0.01% HCl). The extract was loaded onto the 
column then washed sequentially with one column volume each of acidified water and 
ethyl acetate, and then eluted into a collection flask using acidified methanol (0.01% 
HCl). This extract, containing purified anthocyanins, was then boiled once more under 
vacuum at a temperature of approximately 40°C until a highly viscous and strongly 
pigmented solution was obtained. 
HPLC analyses were conducted using HPLC-UV/Vis with an Agilent model 
HP1100 series II with programmable diode array detector (Avondale, PA). Separation of 
anthocyanins was carried out using a C18 bonded silica column (3µm, 3 x 150mm) from 
Dionex Inc. (Sunnyvale, CA). Mobile phases consisted of A, 0.1% trifluoroacetic acid 
(TFA) in water, and B, 70% acetonitrile in water, which were combined in a step-wise 
gradient over the course of the separation. Gradient conditions were as follows: initial 
conditions were composed of 90% mobile phase A and 10% mobile phase B; from time  
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5-10 minutes, the gradient changed to 30% mobile phase B; from 14.5-16 minutes, the 
gradient changed to 50% mobile phase B; from 20-21 minutes, the gradient was returned 
to 10% mobile phase B. Analysis was carried out on 10µL injections at 25˚C using a flow 
rate of 0.6mL/min, and anthocyanins were detected at 520nm over the course of 25 
minutes with a post run time of 5 minutes to clear and equilibrate the column for 
subsequent runs.  
The concentration of the primary anthocyanin constituent in both SAE and BAE 
was determined by creating a standard curve from commercially available anthocyanin 
standards for both callistephin chloride and kuromanin chloride. For each anthocyanin, a 
1mg/mL solution was prepared initially in 0.1% TFA in water, and diluted to 3/5, 2/5, 
1/5, and 1/10 of the original concentration. Standards were injected individually and run 
under the HPLC conditions described above to create linear curves (R2 ≥ 0.999) for each 
anthocyanin species.  
  
2.3.3 Cell Culture 
Cerebellar granule neurons (CGNs) were isolated as previously described 
(Linseman et al. 2001) from seven day-old Sprague-Dawley rat pups, including both 
sexes. Cells were plated on poly-L-lysine coated six-well plates (35mm-diameter), with a 
density of approximately 4x106 cells/well in Basal Medium Eagle’s supplemented with 
25mM potassium chloride, 10% FBS, 2mM L-glutamine, and penicillin/streptomycin 
(100U/mL/100µg/mL). Twenty-four hours after CGNs were plated, 10µM cytosine 
arabinoside was added to the culture medium to inhibit the growth of non-neuronal cells. 
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Granule neurons were subsequently incubated at 37˚C in 10% CO2 for six to seven days 
in culture prior to experimentation. At this point, cultures were ~95% pure for CGNs. 
Neuro2A cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS, 2mM L-glutamine, and penicillin/streptomycin 
(100U/mL/100µg/mL) at 37˚C in 10% CO2. Cells were plated in 6-well plates (35mm-
diameter), and allowed to reach approximately 80% confluency before transfection and 
treatment.  
 
2.3.4 Transfection of Neuro2A cells  
Neuro2A cells were plated at 50% confluency and transfected the following day 
when the cells had reached approximately 80% confluency using the Lipofectamine 2000 
reagent according to the manufacturer’s instructions. Briefly, culture medium was 
removed and replaced with OptiMEM transfection medium. Plasmids encoding either 
enhanced green fluorescent protein (EGFP) or an EGFP-Cu, Zn-superoxide dismutase 
(SOD1) fusion construct were incubated for 20 minutes in OptiMEM containing 
Lipofectamine 2000 at a dilution of 1:1000. This mixture was then added to culture 
dishes containing Neuro2A cells in OptiMEM transfection medium and cells were 
allowed to incubate for 6 hours at a temperature of 37˚C. Following the 6 hour 
incubation, the transfection medium was removed and replaced with culture medium at 




2.3.5 Treatment of cell cultures 
Cell culture medium was removed and replaced with serum free medium in order 
to avoid any potential protective effects of the serum that might limit apoptosis. Cells 
were then treated with either 100µM glutamate (final solution contained 100µM glutamic 
acid and 10µM glycine co-factor) or 100µM SNP alone or in combination with 0.15% 
SAE, 0.25% BAE, 100µM callistephin, or 100µM kuromanin for 24 hours prior to 
quantification of apoptosis. For those experiments utilizing Cu, Zn-superoxide dismutase 
(SOD1), cells were treated as described above with the addition of either PEG-SOD or 
unconjugated SOD1 at a concentration of 30U/mL unless otherwise indicated. For all 
experiments, an untreated control was used for comparison in assaying cell death.  
 
2.3.6 MTT Assay  
An MTT assay kit was used to determine the viability of cells treated with SAE 
and BAE per the manufacturer’s instructions. Briefly, MTT reagent was added to each 
well of a 6-well culture dish following treatment with SAE and BAE at a final 
concentration of 2mM, and cells were then incubated at 37˚C for 4 hours. Following this 
incubation, the purple formazan precipitate was solubilized using 2mL of dimethyl 
sulfoxide (DMSO) by gently rocking the culture dishes for 1 hour at room temperature 
until all of the precipitate had dissolved. This solution was then transferred to a 96-well 
plate, and the absorbance of the sample was determined at 570nm, and expressed as a 




2.3.7 Immunocytochemistry and Assay of Apoptosis  
Following treatment, CGNs were washed with phosphate buffered saline (PBS; 
pH=7.4) and fixed for one hour in 4% paraformaldehyde. Cells were then washed with 
PBS and incubated in blocking solution containing 5% bovine serum albumin (BSA) in 
0.2% triton-X in PBS for 1 hour at room temperature. This was followed by overnight 
incubation at 4˚C with primary antibody against β-tubulin, prepared in a 1:200 dilution in 
2% BSA in 0.2% triton-X in PBS. The following day, CGNs were washed, and then 
incubated for 1 hour at room temperature with FITC-conjugated secondary antibody 
prepared as a 1:250 dilution in 2% BSA in 0.2% triton-X in PBS with Hoechst stain at 
10mg/mL. Neuro2A cells were similarly washed with PBS following transfection and 
treatment, then fixed for one hour at room temperature. These cells were then stained 
with Hoechst to visualize nuclear morphology. All cells were imaged using a Zeiss 
Axiovert-200M epi-fluorescence microscope. Five images per well were captured to 
assay apoptosis, with either duplicate or triplicate wells for each treatment comprising 
one experiment. Cells were counted and scored as either living or apoptotic based on 
nuclear morphology using images showing decolorized Hoechst fluorescence. Cells 
having condensed or fragmented nuclei were scored as apoptotic, and a minimum of 50 
cells per treatment per experiment were scored overall. 
 
2.3.8 Nitric Oxide Assay 
Nitric oxide assay was performed using a Nitric Oxide Assay kit from Thermo 
Fisher Scientific (Rockford, IL) by the Griess method per the manufacturer’s instructions. 
This assay was used to determine the total amount of both nitrate and nitrite ions in 
 
81 
solution, which are generated as the major degradation products of nitric oxide. Samples 
were prepared in sealed 1.5-mL mirocentrifuge tubes in the absence of cells in serum free 
medium containing 25mM KCl, and either 100µM callistephin or kuromanin ± 100µM 
SNP.  Samples containing only medium, or SNP only in medium were prepared in 
parallel for comparison. All samples were placed in an Eppendorf thermomixer, and 
allowed to incubate overnight at 37˚C and 300 rpm before assaying nitric oxide 
concentration. Since the culture medium does not contain nitrates or nitrites, readings 
from a sample containing culture medium only were subtracted as background from the 
total absorbance for all of the remaining samples before calculating the concentration of 
nitric oxide in solution. Absorbance for samples containing callistephin and kuromanin 
without SNP were similarly subtracted from samples containing both anthocyanins and 
SNP in order to correct for the absorbance of these compounds when assaying for nitric 
oxide production. 
 
2.3.9 Superoxide Assay 
Superoxide production was assayed using MCLA luminescence as an indicator 
for the presence of superoxide radical. Samples were prepared in a total volume of 1mL 
in PBS containing 100µM MCLA and either 100µM kuromanin alone, or in combination 
with 5U/mL QR1 or QR2. Reactions containing QR1 also contained 200µM NADH to 
serve as a cofactor, while reactions containing QR2 also contained 200µM of 1-methyl-1, 
4-dihydronicotinamide cofactor. A 30U/mL SOD1 aliquot was added to one sample for 
each experiment containing kuromanin and QR2 as a control to confirm that MCLA 
luminescence was due to superoxide, and not production of another reactive radical 
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species. Luminescence was recorded every 15 seconds for a period of 8 minutes. A 
baseline was recorded for the first 4 minutes of each experiment at which time 
kuromanin, or kuromanin in combination with SOD1 was added to the reaction mixture. 
For those experiments in which the effects of QR1 or QR2 were assessed, these enzymes 
were added 1 minute after the addition of kuromanin or kuromanin in combination with 
SOD1. Luminescence was measured using a TD-20/20 model luminometer from Turner 
Designs (Sunnyvale, CA). 
 
2.3.10 Data Analysis 
Each experiment was performed using either duplicate or triplicate wells for each 
treatment, with each experiment being performed at least three times. Data represent the 
means ± standard error of the mean (SEM) for the total number (n) of experiments 
carried out. All data, unless otherwise noted, were analyzed using a one-way analysis of 
variance (ANOVA) with a post hoc Tukey’s test. Data collected for the MCLA 
superoxide assay were analyzed using two-way ANOVA for repeated measures with a 
post hoc Bonferroni’s test to compare all groups. A p-value <0.05 was considered 





2.4.1 Anthocyanin-Enriched Extracts from Strawberries and Blackberries Display 
Differential Neuroprotective Effects Against Oxidative and Nitrosative Stress 
Anthocyanin-enriched extracts were prepared from freeze-dried strawberry and 
blackberry powder and characterized by HPLC. Anthocyanins were detected at a 
wavelength of 520 nm and the identity of the primary anthocyanin constituent of each 







Figure 2.2. Representative HPLC chromatograms of anthocyanin-enriched extracts 
from strawberry (SAE) and blackberry (BAE).  A, Purified anthocyanin extract from 
freeze-dried strawberry powder was analyzed by HPLC with UV/Vis detection at 520nm 
(top panel) and compared to a pure callistephin standard (bottom panel) for peak 
identification of the major anthocyanin constituent. Callistephin appears at rt=13.22min 
for SAE and rt=13.22min for the pure standard; B, Purified anthocyanin extract from 
freeze-dried blackberry powder was analyzed by HPLC with UV/Vis detection at 520nm 
(top panel) and compared to a pure kuromanin standard (bottom panel) for peak 
identification of the major anthocyanin constituent. Kuromanin appears at rt=12.56min 




By this method, it was determined that the primary anthocyanin constituent of 
strawberry anthocyanin extract (SAE) was callistephin, which made up 91% of the 
enriched extract, while blackberry anthocyanin extract (BAE) was composed primarily of 
kuromanin, which made up approximately 87% of the enriched extract (Table 2.1). Once 
the identity of the primary anthocyanin constituents of each extract had been determined, 
the concentration of this component was determined for both SAE and BAE by 
comparison to a standard curve created using varying concentrations of either callistephin 
or kuromanin accordingly. For SAE, callistephin was determined to have a concentration 
of 5mM. For BAE, the concentration of kuromanin was calculated to be 3mM (Table 
2.1). In experiments using these extracts, the concentrations of SAE and BAE were 
adjusted on a percentage basis to yield equivalent concentrations (7.5µM) of their 




Table 2.1. Composition and concentration of primary anthocyanin constituents in 

























Strawberry Callistephin 91% 5mM 0.15% 7.5µM 





As anthocyanins are known to be potent antioxidants, we next characterized the 
neuroprotective profile of the two extracts against distinct neurotoxic insults. 
Excitotoxicity, during which neurons become over stimulated by glutamate signaling, 
leading to massive calcium influx, and subsequent activation of multiple cell death 
processes, was used as a model of oxidative stress as increased production of ROS is a 
hallmark of this process (Luetjens et al. 2000). Moreover, neuronal cell death associated 
with excitotoxicity is thought to play a role in several neurodegenerative diseases such as 
ALS, Parkinson’s disease and Alzheimer’s disease, highlighting the relevance of this 
insult for screening potential neuroprotective compounds (Miguel-Hidalgo et al. 2002, 
Sun et al. 2006, Helton et al. 2008). Alone, exposure to glutamate diminished cellular 
viability in CGNs by almost 50%, as assessed by MTT assay. However, co-treatment of 
the cells with either 0.15% SAE or 0.25% BAE abrogated this effect, preserving cell 
viability at a level that was comparable to untreated control cells (Fig. 2.3A).  
While excitotoxicity is known to contribute to neurodegenerative disease 
processes, and particularly to oxidative stress, other factors, such as neuroinflammation, 
also play major roles in promoting cell death through production of free radical species. 
Indeed, a key aspect of neuroinflammation is the release of toxic nitric oxide radicals by 
astrocytes and microglia, which are capable of promoting conditions of nitrosative stress 
in neighboring neurons that ultimately culminate in the activation of cell death signaling 
cascades (Di Filippo et al. 2010). Since these processes do not occur independently of 
other disease factors such as excitotoxicity, it is important that potential therapeutics for 
neurodegeneration are capable of mitigating both oxidative and nitrosative stress in order 
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to target multiple facets of disease pathology. To this end, we next tested the ability of the 
two anthocyanin extracts to defend cells from sodium nitroprusside (SNP), a nitric oxide 
donor, meant in this context to simulate conditions of nitrosative stress. Cells treated with 
SNP alone showed a drastic reduction in viability of 95%, and treatment with 0.15% SAE 
demonstrated no ability to preserve cellular viability in the presence of this insult (Fig. 
2.3B). In striking contrast, treatment with 0.25% BAE significantly preserved neuronal 





Figure 2.3. Effects of SAE and BAE on glutamate excitotoxicity and nitric oxide 
toxicity induced by sodium nitroprusside (SNP). A, Primary rat cerebellar granule 
neurons (CGNs) were treated with 100µM glutamate alone or in combination with 0.15% 
SAE or 0.25% BAE for 24h. Cell viability was then assessed by MTT assay; B, CGNs 
were treated with 100µM SNP alone or in combination with SAE or BAE for 24h. Cell 
viability was then assessed by MTT assay. All data are represented as mean ± SEM. *** 
indicates p<0.001 compared to untreated control cells, ††† represents p<0.001, †† 
represents p<0.01, and † represents p<0.05 in comparison to cells treated with the insult 







2.4.2 Both Callistephin and Kuromanin, the Primary Anthocyanin Constituents of 
SAE and BAE, Protect CGNs from Glutamate Excitotoxicity 
The differential protective effects of the two anthocyanin extracts were thought to 
be attributed to differences in the neuroprotective potential of their respective primary 
anthocyanin constituents. However, given that neither extract was composed purely of a 
single anthocyanin, the possibility that the differential neuroprotective abilities were due 
to other compounds contained in the extract, or synergism between several compounds, 
could not be excluded. Therefore, in order to confirm that the observed differences in 
neuroprotection corresponded to the differing properties of the two primary anthocyanins, 
callistephin and kuromanin, we next examined the neuroprotective capabilities of the two 
pure anthocyanins.  
Pure preparations of both callistephin and kuromanin were obtained commercially 
and tested for their ability to protect CGNs from glutamate excitotoxicity. Because pure 
anthocyanins were used at a higher concentration than either of the extracts and produced 
deeply pigmented solutions with absorbance in the same range as MTT products, cells 
were fixed following treatment, and nuclear morphology was observed in order to 
quantify apoptosis. In general, cells displaying condensed and/or fragmented nuclei were 
scored as apoptotic. In a preliminary dose response, it was found that pure anthocyanins 
were less efficient neuroprotective agents than the extracts, requiring a dose of either 
75µM or 100µM for kuromanin and callistephin respectively in order to significantly 
protect CGNs from excitotoxic insult (Winter and Linseman, unpublished data). Given 
this observation, a dose of 100µM was selected to complete all subsequent analyses. 
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Treatment with glutamate alone produced death in approximately 50% of CGNs, 
consistent with our previous observations using the MTT assay (compare Fig. 2.3A and 
2.4B). These cultures displayed a much higher proportion of cells with condensed or 
fragmented nuclei in addition to a compromised tubulin network when compared to 
untreated controls (Fig. 2.4A). This result is consistent with induction of neuronal 
apoptosis. Intriguingly, treatment with either callistephin or kuromanin significantly 
reduced the number of cells displaying apoptotic nuclei and fragmented tubulin (Fig. 
2.4A). Quantitatively, callistephin and kuromanin reduced CGN apoptosis to 20% and 
15% respectively, which is in good agreement with our previous observations using SAE 
and BAE against glutamate excitotoxicity (compare Fig. 2.3A and 2.4B). Collectively, 
these results suggest that callistephin and kuromanin, the primary anthocyanin 
constituents of SAE and BAE, respectively, are capable of mediating similar 
neuroprotective effects against glutamate-induced excitotoxicity to those observed using 





Figure 2.4. Both pure callistephin and kuromanin protect CGNs from glutamate-
induced excitotoxicity. A, Representative fluorescent micrographs showing untreated 
control CGNs, or CGNs  treated with 100µM glutamate alone or in combination with 
100µM callistephin (Calli) or 100µM kuromanin (Kuro) for 24 hours. Top panels show 
immunocytochemistry for β-tubulin (green) and Hoechst stain (blue). Panels on the 
bottom show decolorized Hoechst fluorescence to visualize nuclear morphology. Scale 
bar=10μm; B, Quantitative assessment of cellular apoptosis CGNs treated as described in 
(A). Cells were counted and scored as either living or apoptotic based on nuclear 
morphology, and the percent of cells showing apoptotic nuclei (either condensed or 
fragmented morphology) was determined. Data are represented as the mean ± SEM. *** 
indicates p<0.001 compared to untreated control cells and ††† represents p<0.001 in 
comparison to cells treated with glutamate alone, as determined by one-way ANOVA 




2.4.3 Kuromanin, But Not Callistephin, Protects CGNs from Nitric Oxide-Induced 
Toxicity 
 In order to further compare the neuroprotective capacity of pure anthocyanin 
compounds to neuroprotection mediated by SAE and BAE, callistephin and kuromanin 
were next assessed for their ability to defend CGNs from nitric oxide-induced toxicity. 
CGNs that were treated with SNP alone uniformly displayed condensed and fragmented 
nuclear morphology as well as extensive disintegration of tubulin networks in 
comparison to untreated controls (Fig. 2.5A). Quantification of condensed nuclei 
revealed that 95% of cells exposed to SNP alone underwent apoptosis in concurrence 
with our previous results using MTT (compare Fig. 2.3B and 2.5B). Interestingly, cells 
that were co-treated with both callistephin and SNP displayed the same features as cells 
treated with SNP alone, and no significant reduction in the number of apoptotic nuclei 
was observed (Fig. 2.5A, B). In stark contrast to this observation, co-treatment with 
kuromanin dramatically mitigated these effects, preserving tubulin networks and 
maintaining healthy nuclear morphology (Fig. 2.5A). These cells showed a reduction in 
apoptosis of nearly 70% in comparison to cells treated with SNP alone, or SNP with 
callistephin, consistent with the protective effect if BAE against SNP demonstrated using 





Figure 2.5. Pure kuromanin, but not callistephin, protects CGNs from nitric oxide-
induced toxicity. A, Representative fluorescent micrographs showing untreated control 
CGNs, or CGNs  treated with 100µM SNP alone or in combination with 100µM 
callistephin (Calli) or 100µM kuromanin (Kuro) for 24 hours. Top panels show 
immunocytochemistry for β-tubulin (green) and Hoechst stain (blue). Panels on the 
bottom show decolorized Hoechst fluorescence to visualize nuclear morphology. Scale 
bar=10μm; B, Quantitative assessment of cellular apoptosis in CGNs treated as described 
in (A). Cells were counted and scored as either living or apoptotic based on nuclear 
morphology, and the percent of cells showing apoptotic nuclei (either condensed or 
fragmented morphology) was determined. Data are represented as the mean ± SEM. *** 
indicates p<0.001 compared to untreated control cells and ††† represents p<0.001 in 
comparison to cells treated with SNP alone, as determined by one-way ANOVA with a 




2.4.4 Kuromanin, But Not Callistephin, Reduces Nitric Oxide Concentration in a 
Cell Free System and Produces Superoxide 
 Given the stark contrast between the abilities of callistephin and kuromanin to 
prevent the harmful effects of nitrosative stress in neurons, a nitric oxide assay was used 
to determine the final concentration of nitric oxide in cell-free medium incubated with 
callistephin or kuromanin and SNP. Analysis using a Griess assay to measure total nitrite 
and nitrate, decomposition products of nitric oxide, demonstrated that culture medium 
incubated overnight with SNP produced a substantial amount of nitric oxide in solution 
(Fig. 2.6A). Consistent with its inability to defend CGNs from nitric oxide toxicity, co-
incubation with callistephin did not reduce the concentration of nitric oxide in solution 
(Fig. 2.6A). Incubation with kuromanin, however, significantly decreased the amount of 
nitric oxide that remained in solution following generation by SNP, suggesting that this 
anthocyanin is able to scavenge nitric oxide in some capacity (Fig. 2.6A).  
We next aimed to determine the chemical mechanism by which kuromanin is able 
to scavenge nitric oxide, and prevent subsequent toxicity, in contrast to callistephin. 
These anthocyanins share a significant degree of structural homology at the molecular 
level, differing only by the presence of a single hydroxyl group on the B-ring of 
kuromanin (Fig. 2.1). Given that these two compounds are otherwise identical, we 
postulated that the presence or absence of this catechol moiety on the B-ring is 
responsible for the differential neuroprotection of the anthocyanins against nitric oxide-
induced cell death.  
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One unique aspect of catechol chemistry is the ability of catecholic compounds, 
such as kuromanin, to auto-oxidize and generate superoxide (Chichirau et al. 2005). The 
superoxide produced from these reactions is highly reactive and combines readily with 
other radical species such as nitric oxide. Therefore, we next assessed the ability of 
kuromanin to generate superoxide in a cell free system.  
2-Methyl-6-(4-Methoxyphenyl) -3,7-Dihydroimidazo[1, 2-A]pyrazin-O-3ne, 
Hydrochloride (MCLA) luminescence was used to detect the presence of superoxide in 
solutions containing 100µM kuromanin alone or in combination with quinone 
oxidoreductase 1 (QR1) or quinone oxidoreductase 2 (QR2) in a cell free system. At this 
concentration, kuromanin alone did not produce detectable concentrations of superoxide 
in solution (Fig. 2.6B).  Given that this assay was performed in the absence of cells and 
associated reducing factors that would allow kuromanin to undergo multiple auto-
oxidation reactions, this result was not altogether unexpected. Without these reducing 
factors, each molecule has the potential to undergo only one auto-oxidation reaction, and 
detection would be limited by the rate at which this reaction occurred. QR1 and QR2 
were added to the reaction to act as generic reducing factors for the quinone formed when 
kuromanin is fully oxidized, creating the potential for each molecule of kuromanin to 
undergo multiple oxidation reactions. Addition of QR1 to the system produced a modest 
luminescence signal while addition of QR2 significantly enhanced MCLA luminescence 
(Fig. 2.6B). Neither QR1 nor QR2 produced an appreciable luminescence signal when 
incubated alone (Winter and Linseman, unpublished data). Addition of SOD1 to solutions 
containing kuromanin and QR2 completely quenched MCLA luminescence, confirming 
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that superoxide, and not another reactive radical species, was responsible for the observed 





Figure 2.6. Kuromanin, but not callistephin scavenges nitric oxide present in culture 
medium following incubation with SNP through a superoxide dependent 
mechanism. A, 100µM SNP was incubated in fresh, serum free, culture medium at 37°C 
alone or in combination with 100µM callistephin (Calli) or 100µM kuromanin (Kuro) for 
24 hours to mimic cell culture conditions. The amount of total nitrate and nitrite was then 
assessed in culture medium using the Griess assay to quantify the amount of nitric oxide 
remaining after anthocyanin addition. Each experiment was run in parallel with a sample 
containing only culture medium and no SNP. The culture medium did not contain any 
nitrates or nitrites that would be detected by the assay, but was calculated to have an 
average nitrate/nitrite concentration of approximately 15.704µM due to absorbance by 
phenol red in the culture medium. This value was therefore subtracted from the total 
concentration of nitric oxide detected by the Griess Assay for the three remaining 
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samples. These adjusted values are reported here. Data are represented as the mean ± 
SEM. * indicates p<0.05 compared to culture medium containing SNP alone by one-way 
ANOVA with  post hoc Tukey’s test; B, Superoxide production by kuromanin was 
monitored using MCLA luminescence assay. MCLA luminescence was recorded at 
intervals of 15 seconds for a total of 8 minutes. A baseline was recorded for the first 4 
minutes of the assay (data not shown) before addition of 100µM  kuromanin alone or in 
combination with 30U/mL Cu, Zn-superoxide dismutase (SOD1). MCLA luminescence 
was then assessed for 1 minute before the addition of 5U/mL of either quinone 
oxidoreductase 1 or 2 (QR1/2) and their appropriate co-factors. Time points at which 
additions were completed are indicated below the x-axis of the graph. *** indicates 
p<0.001, ** indicates p<0.01, and * indicates p<0.05 compared to MCLA luminescence 
with kuromanin alone, ††† indicates p<0.001 compared to MCLA luminescence in 
sample containing kuromanin, QR2, and SOD1, and ‡‡‡ indicates p<0.001 compared to 
samples containing kuromanin and QR2. All statistics were conducted using two-way 




2.4.5 Kuromanin Protects Neurons from Nitric Oxide Toxicity in a Superoxide-
Dependent Manner 
To validate the data obtained using a cell free approach, we next examined the 
role of superoxide production in defending cultured neurons from nitric oxide toxicity. 
As before, CGNs were cultured with SNP alone, or in the presence of kuromanin, and 
evaluated for apoptosis. In addition to these treatment groups, cells were also treated with 
kuromanin and SNP in the presence of PEG-SOD, a cell permeable conjugate of SOD1, 
to scavenge any superoxide generated in culture. In agreement with our previous results, 
cells treated with SNP alone displayed fragmented tubulin networks and condensed 
nuclei indicative of widespread apoptosis, in comparison to untreated control cells (Fig. 
2.7A). Kuromanin effectively mitigated these effects, preserving tubulin networks and 
healthy nuclear morphology. However, in the presence of PEG-SOD, the neuroprotective 
effects of kuromanin were completely ablated. Cells treated with PEG-SOD showed 
extensive disintegration of tubulin networks and condensed nuclei similar to cells that 
were treated with SNP alone (Fig. 2.7A). This effect was concentration dependent, as low 
concentrations of PEG-SOD had essentially no influence on the protective abilities of 
kuromanin, while concentrations of 30U/mL or more completely abolished kuromanin-
mediated neuroprotection (Fig. 2.7B). At these concentrations, up to 97% of cells 
possessed condensed or fragmented nuclei, and no significant difference was observed 
between the percentage of apoptotic cells under these conditions in comparison to cells 
treated with SNP alone (Fig. 2.7B). Moreover, treatment with PEG-SOD alone at the 
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concentrations tested in these experiments had no effect on cellular viability (Winter and 
Linseman, unpublished data). 
Following these experiments, we next sought to determine if superoxide 
generation by kuromanin occurred at the extracellular or intracellular level by comparing 
the effects of PEG-SOD and unconjugated SOD1, which is not cell permeable. As before, 
kuromanin protected CGNs from nitric oxide-induced toxicity, and these effects were 
blocked by concomitant treatment with PEG-SOD. However, treatment with 
unconjugated SOD1 had no significant effect on the neuroprotective capacity of 
kuromanin, suggesting that these effects occur at the intracellular level (Fig. 2.7C). 
To confirm this observation using a molecular approach, we transfected Neuro2A 
mouse neuroblastoma cells with either a control vector expressing EGFP or a vector 
expressing EGFP-tagged, wild type SOD1, and treated them with SNP alone or in the 
presence of kuromanin. We then assessed the number of transfected cells displaying 
condensed or fragmented nuclei indicative of cell death. Cells transfected with the EGFP 
vector and treated with SNP alone underwent significant cell death in comparison to 
untreated EGFP-transfected controls, while cells that were co-treated with both SNP and 
kuromanin displayed a significant reduction in cell death in comparison to cells treated 
with SNP alone (Fig. 2.7D). In contrast, cells transfected with SOD1 and treated with 
SNP and kuromanin displayed the opposite result. Indeed, SOD1 overexpressing cells 
showed a marked increase in cell death in comparison to EGFP-transfected cells that 
were treated with SNP and kuromanin, and this level of death was comparable to that 




Figure 2.7. Delivery of SOD1 intracellularly blocks the neuroprotective effects of 
kuromanin against SNP. A, Representative fluorescent micrographs showing untreated 
control CGNs, CGNs treated with 100µM SNP alone or in combination with 100µM 
kuromanin (Kuro), and CGNs treated with SNP, kuromanin, and PEG-SOD at the 
indicated concentrations (U/mL) for 24h. Top panels show immunocytochemistry for β-
tubulin (green) and Hoechst stain (blue). Panels on the bottom show decolorized Hoechst 
fluorescence to visualize nuclear morphology. Scale bar=10μm; B, Quantitative 
assessment of cellular apoptosis for CGNs treated as in (A). Cells were counted and 
scored as either living or apoptotic based on nuclear morphology, and the percent of cells 
showing apoptotic nuclei (either condensed or fragmented morphology) was determined; 
C, Quantitative assessment of cellular apoptosis for untreated control CGNs, CGNs  
treated with SNP alone or in combination with kuromanin, and CGNs treated with SNP, 
kuromanin, and either unconjugated SOD1 or PEG-SOD for 24 hours; D, Quantitative 
assessment of apoptosis in Neuro2A cells transfected with either EGFP or EGFP-tagged 
SOD1 and treated with 200µM SNP alone or in combination with 100µM kuromanin. 
Transfected (EGFP-positive) cells were counted and scored as either living or apoptotic 
based on nuclear morphology, and the percent of cells showing apoptotic nuclei (either 
condensed or fragmented morphology) was determined.  Data are represented as the 
mean ± SEM. *** indicates p<0.001 compared to untreated control cells, ††† represents 
p<0.001 in comparison to cells treated with SNP alone, and ‡‡‡ indicates p<0.001 in 
comparison to cells treated with kuromanin and SNP in combination as determined by 




2.5 Discussion  
Initially, two anthocyanin-enriched extracts were prepared from freeze-dried 
strawberry or blackberry powder in order to preliminarily characterize the 
neuroprotective effects of two distinct anthocyanin compositions. These fruits were 
chosen as their primary anthocyanin constituents, callistephin and kuromanin, have been 
previously described and are known to compose a majority of the anthocyanin profiles of 
strawberries and blackberries, respectively (Elisia et al. 2007, Baiamonte et al. 2010). 
This increased the likelihood that any observed protective effects would be due to these 
two anthocyanins and not another phenolic species within the extracts. While it was 
found that treatment with either SAE or BAE was sufficient to defend primary neurons 
from excitotoxic insult, a stark contrast in neuroprotective ability between these two 
extracts was observed in cells treated with the nitric oxide donor, SNP. While BAE was 
able to significantly protect neurons from nitric oxide toxicity, SAE had no observable 
effect against this insult, suggesting that there is a distinct difference between the 
neuroprotective effects of the primary anthocyanin constituents of the two extracts. 
Similar effects were observed when pure preparations of both callistephin and kuromanin 
were assessed for their neuroprotective potential, confirming that these two compounds 
were likely responsible for the results observed when using enriched fruit extracts. 
However, it was notable that the protective concentration of kuromanin and callistephin 
in the extracts was much lower than that observed for the pure compounds. This may 
suggest synergism with other anthocyanin species or contaminating phenolics within the 
extract which was not observed when treating with the individual anthocyanins, and 
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illustrates one of the confounding factors of assessing the neuroprotective potential of 
particular species within enriched extracts. Taken as a whole, these results indicate that 
subtle molecular differences between callistephin and kuromanin, specifically the 
absence or presence of a catechol moiety on the B-ring, was responsible for the 
differential neuroprotective effects observed under conditions of nitric oxide toxicity. 
This hypothesis was supported by the observation that kuromanin, which contains a 
catechol as part of its B-ring, was able to scavenge nitric oxide in solution to a significant 
degree, while callistephin, which lacks a catechol, was not.  
Interestingly, the chemistry of anthocyanins and many other natural products is 
such that these potent antioxidants can behave as pro-oxidants under certain conditions, 
such as at high concentrations (Yen et al. 2003, Prochazkova et al. 2011). In particular, 
catechol containing compounds such as kuromanin are thought to execute their pro-
oxidant functions through the process of auto-oxidation. This reaction proceeds using 
molecular oxygen as an electron acceptor to produce first a semiquinone and then a 
quinone molecule with a net production of one superoxide radical (Fig. 2.8; Chichirau et 
al. 2005). Within the cell where there are multiple reducing factors that may regenerate 
the original parent compound, this auto-oxidation cycle could proceed many times for a 





Figure 2.8. Proposed auto-oxidation reaction of kuromanin to produce superoxide. 
Kuromanin reacts with molecular oxygen to produce a semiquinone and one superoxide 
radical (HO2). Superoxide produced from this reaction is consumed to produce hydrogen 
peroxide (H2O2), while molecular oxygen interacts with the semiquinone radical to form 
more superoxide. This results in the net production of one molecule of H2O2, one 
superoxide radical, and the oxidized quinone form of kuromanin. The superoxide radical 
produced from this reaction is then able to scavenge nitric oxide (NO) radicals to form 
peroxynitrite (ONOO-). The oxidized quinone form of kuromanin is then recycled to the 
reduced catechol by a quinone reductase or other reducing factor (QR). This mechanism 




This hypothesis is consistent with our observation that kuromanin produces 
superoxide, but this radical reached detectable concentrations only when kuromanin was 
incubated in the presence of a quinone reductase. Moreover, Chichirau et al. (2005) 
propose that this reaction may only occur while the parent catechol is in its anionic form, 
which accounts for only a small proportion of aqueous anthocyanins at a given time, 
further hampering detection of superoxide. While both quinone reductases used in our 
experiments caused some increased superoxide production by kuromanin, the largest 
increase in superoxide production was observed in the presence of QR2. These results are 
consistent with the observation that QR1 works best on meta- and para-quinones, with a 
low affinity for ortho-quinones, while QR2 preferentially reduces ortho-quinones, as 
would be formed by kuromanin (Fu et al. 2008). This also lends further support to the 
idea that catechol-containing species like kuromanin are not only capable of generating 
superoxide, but may do so with an enhanced capacity in the presence of appropriate 
reducing factors, as might occur within a cell.  
Pro-oxidant processes are thought to be partially responsible for the anti-
carcinogenic properties of anthocyanins and other nutraceuticals, and have spurred the 
development of the “quercetin paradox.” This paradox suggests that by performing their 
antioxidant function, flavonoids and other polyphenols produce reactive species that are 
capable of depleting endogenous antioxidants like glutathione, ultimately causing 
cytotoxicity (Weisburg et al. 2004, Lee et al. 2005, Boots et al. 200, Feng et al. 2007). It 
is noteworthy, then, that both callistephin and kuromanin were previously demonstrated 
to preserve neuronal viability and glutathione levels in the presence of the glutathione-
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depleting agent, HA14-1, which may suggest that anthocyanin chemistry is uniquely 
suited to avoid glutathione depletion, unlike quercetin (Boots et al. 2007, Kelsey et al. 
2011). This is further supported by the observation that an anthocyanin-rich diet 
stimulates promoter activity for γ-glutamylcysteine ligase, the rate limiting enzyme in 
glutathione synthesis, and increases glutathione levels in kidney, liver, and brain tissue in 
vivo (Carlsen et al. 2003, Hassimotto et al. 2011).  Most impressive is the observation 
that in the context of nitric oxide toxicity and subsequent nitrosative stress, superoxide 
generated through auto-oxidation of kuromanin appears to play the unexpected role of a 
neuroprotective nitric oxide scavenger rather than that of a toxic free radical, illustrating a 
role for the pro-oxidant activity of anthocyanins in mitigating this facet of 
neurodegenerative disease. Indeed, incorporation of excess SOD1 into the cell culture 
completely abolished the neuroprotective effect of kuromanin against nitric oxide, 
indicating that this process is superoxide-dependent. Moreover, this phenomenon was 
observed only when SOD1 was able to enter the cell, either as a cell-permeable form of 
the enzyme, PEG-SOD, or through transfection with wild type SOD1, demonstrating that 
nitric oxide scavenging by superoxide takes place at the intracellular level. This is 
significant in that damage from nitric oxide occurs largely at the intracellular level 
throughout many neurodegenerative processes, either by induction of nitric oxide 
synthase (NOS) through inflammatory cytokine signaling, or through diffusion into 
neuronal cells from neighboring glia (Raoul et al. 2006, Uehara et al. 2006).   
Combination of superoxide and nitric oxide results in the formation of 
peroxynitrite. While high levels of peroxynitrite can also be toxic, this compound has a 
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very short half-life and is readily scavenged by a number of endogenous antioxidants, 
such as glutathione, in addition to flavonoids such as kuromanin and quercetin, that 
possess a catechol as a part of their B-ring (Heijnen et al. 2001). Strikingly, there is also 
evidence to suggest that, in moderation, peroxynitrite is neuroprotective against nitric 
oxide toxicity in primary cortical neurons (Garcia-Nogales et al. 2003, Delgado-Esteban 
et al. 2007). These effects are due to stimulation of the pentose phosphate pathway, 
which generates an abundance of NADPH that can be used in the synthesis of important 
antioxidants such as glutathione, and other cellular defenses (Garcia-Nogales et al. 2003). 
Additionally, oxidative modification of phosphatase tensin homolog (PTEN) by 
peroxynitrite has been shown to elicit a neuroprotective response by enhancing activation 
of the PI3K/Akt pro-survival pathway (Delgado-Esteban et al. 2007). Taken together, 
these data lead us to conclude that peroxynitrite generated through the proposed 
scavenging mechanism illustrated in Figure 8 is not only non-toxic, but may in fact 
contribute to the neuroprotective effect of kuromanin against nitric oxide.  
Our structure-activity analysis of callistephin and kuromanin indicates that 
although all anthocyanins bear a high degree of structural homology, the absence or 
presence of a catechol moiety on the B-ring of the compound is necessary for it to 
mitigate nitric oxide toxicity and subsequent cell death. This may also be true of 
delphinidin-based anthocyanins, and compounds such as epigallocatechin gallate, which 
possess a pyrogallol moiety as part of their structure. Such compounds are also capable of 
producing superoxide and reactive ortho-quinones through the process of auto-oxidation, 
similar to kuromanin (Li, 2012). However, it should be noted that while these compounds 
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may undergo similar processes, and therefore protect similarly from nitric oxide toxicity, 
various anthocyanins also display differences in their abilities to interact with other 
oxidative species. For example, increasing hydrophilicity in anthocyanins through 
addition of hydroxyl groups lowers the ability of these compounds to interact with lipid-
rich environments, hampering their ability to prevent other prominent features of 
neurodegeneration such as lipid peroxidation (Brown and Kelly, 2007). It is also notable 
that while most common anthocyanins are known to cross the blood-brain barrier (BBB), 
highly hydrophilic anthocyanins interact less with lipid-rich environments, and cross the 
BBB at a lower rate than their more lipophilic flavonoid relatives in an in vitro model of 
the BBB (Youdim et al. 2003, Brown and Kelly, 2007, Faria et al. 2014) This decreases 
the likelihood that anthocyanins that contain a high number of hydroxyl groups, 
particularly on the B-ring, can effectively mitigate oxidative damage in the brain. While 
further evidence is required to confirm this observation in vivo, it has been previously 
observed that the rate of transport across the basolateral membrane during digestion is 
directly correlated with the lipophilicity of the anthocyanin in question (Yi et al. 2006). 
As a result, compounds such as delphinidin-based anthocyanins may prove to be less 
effective therapeutics than other more lipophilic anthocyanins like kuromanin.  
This highlights the importance of choosing a drug candidate with versatile 
chemistry to target multiple aspects of neurodegenerative disease in the most effective 
way possible. For this reason, mechanistic studies examining individual compounds for 
their efficacy in various systems that mimic neurodegenerative conditions are 
advantageous. Moreover this approach also lends itself to the creation of a multi-agent 
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treatment paradigm, which may ultimately be required to combat complex 
neurodegenerative diseases, as highly effective compounds with complimentary chemical 
properties can be readily identified and combined in high through-put screens to assess 
potential synergism. This allows for the rapid assessment and development of new drug 
combinations for further preclinical testing.  
While it is true that some element of the multi-agent strategy is present in the use 
of enriched fruit extracts, it is often the case that a single extract may contain compounds 
that directly hinder one another’s performance, compromising its effectiveness. 
Additionally, such extracts are difficult to standardize and purify sufficiently to ensure 
safety during consumption for clinical development. Lastly, understanding the 
mechanistic aspects of neuroprotection for a single compound, such as kuromanin, may 
allow for the identification or design of similar substances that are able to perform the 
same functions with even greater efficiency, which cannot be accomplished using 
extracts. In the case of anthocyanins, this may be especially true of their phenolic acid 
metabolites, which are derived from the B-ring of the parent compounds, and appear at 
concentrations in the body that far exceed that of the parent anthocyanin following 
ingestion (Tsuda et al. 1999, Azzini et al. 2010). Thus, it will be of great interest in the 
future to determine if anthocyanin metabolites behave in a manner similar to their parent 
compounds, as these derivatives may ultimately be responsible for the observed benefits 
of anthocyanin consumption in vivo due to their higher bioavailability. 
Collectively, our data demonstrate that some anthocyanins may be more uniquely 
suited than others to combat the multi-faceted nature of neurodegenerative disorders. 
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Indeed, while anthocyanins appear to be universally capable of mitigating conditions of 
oxidative stress to some degree, our observations clearly show that this ability does not 
extend to all anthocyanin family members under conditions of nitrosative stress. This 
understanding is vital for determining which anthocyanin species have the highest 
potential as preventative and therapeutic agents in the context of neurodegeneration, and 










CHAPTER THREE: AN ANTHOCYANIN-ENRICHED EXTRACT FROM 
STRAWBERRIES DELAYS DISEASE ONSET AND EXTENDS SURVIVAL IN 




Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease 
that results from the death of motor neurons in the brain, brain stem, and spinal cord. 
While the etiology of ALS is poorly defined, recent data indicate that there are many 
pathological contributors to disease progression such as oxidative stress, 
neuroinflammation, and neuronal apoptosis. Anthocyanins are flavonoid compounds 
derived from many common fruits and vegetables that possess pleiotropic effects, acting 
as antioxidant, anti-inflammatory, and anti-apoptotic agents. Thus, these unique 
compounds may provide therapeutic benefit for the treatment of ALS. Here, we used the 
G93A mutant human SOD1 (hSOD1G93A) mouse model of familial ALS to assess the 
effects of an anthocyanin-enriched extract from strawberries (SAE) on disease onset and 
progression. Transgenic hSOD1G93A mice that received SAE supplementation 
presymptomatically experienced a marked (~17 day) delay in disease onset and a 
statistically significant (~11 day) extension in survival in comparison to untreated 
hSOD1G93A mice. Additionally, hSOD1G93A mice treated with SAE displayed a 
 
113 
significant preservation in paw grip strength throughout disease progression in 
comparison to their untreated mutant counterparts. Histopathological analysis showed 
that SAE supplementation significantly reduced astrogliosis in spinal cord, and preserved 
neuromuscular junctions in gastrocnemius muscle. These data are the first to demonstrate 
that anthocyanins have significant impact as therapeutic agents in a preclinical model of 
ALS. Therefore, further study of these compounds is warranted in additional preclinical 
models and patients suffering from ALS and possibly other neurodegenerative diseases. 
 
3.2 Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterized by the death of motor neurons in the motor cortex, brainstem and spinal 
cord. Recent evidence suggests that oxidative stress and inflammation of glial cells 
within the CNS are major contributing factors to the apoptotic death of motor neurons in 
ALS.  Markers of oxidative stress are observed in tissue collected from both sporadic and 
familial ALS patients. These include reduced levels of the critical antioxidant, 
glutathione, in blood and brain, and elevations in oxidative damage to DNA and lipids 
(Bogdanov et al. 2000, Simpson et al. 2004, Babu et al. 2008, Weiduschat et al. 2014).  
Similarly, indices of neuroinflammation are also found in abundance in tissue from both 
ALS patients and mouse models of the disease. Microglia and astrocytes have been 
shown to play  significant roles in modulating ALS disease progression in mutant SOD1 
mouse models (Beers et al. 2006, Boilée et al. 2006, Yamanaka et al. 2008, Wang et al. 
2011). These findings are supported by data collected from spinal cord tissue and 
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cerebrospinal fluid from ALS mouse models and patients which display significant 
elevations in a number of pro-inflammatory cytokines and enzymes, such as tumor 
necrosis factor-α, cyclooxygenase-2 and inducible nitric oxide synthase, products of 
inflamed glial cells known to cause motor neuron death (Almer et al. 1999, Almer et al. 
2001, Hensley et al. 2003, Raoul et al. 2006).  
Both oxidative stress and neuroinflammation are thought to be significant 
contributors to the induction of apoptosis in affected motor neurons, highlighting the 
complex nature of this disease. However, the exploration of new treatments for ALS thus 
far has largely been targeted at mitigating only a single aspect of ALS pathology, a 
strategy that has proven unsuccessful up to this point. For example, the only drug 
approved to treat ALS, Riluzole, is aimed specifically at attenuating the damaging effects 
of excitotoxicity; however, its effect on disease course is modest, extending lifespan only 
2-3 months (Miller et al. 2012). As such, focus on treating ALS has recently begun to 
shift towards the use of agents that, via their molecular mechanism of action, target 
multiple aspects of the underlying disease pathology.  
Anthocyanins are a unique class of flavonoid compounds responsible for the red, 
blue, and purple coloration of many fruits, vegetables and flowers. These compounds 
have been shown to possess a considerable antioxidant capacity in vitro and have been 
demonstrated to display neuroprotective effects against oxidative insults such as 
hydrogen peroxide (Ghosh et al. 2006, Heo and Lee 2005, Tarozzi et al. 2007, Zafra-
Stone et al. 2007, Spada et al. 2009, Zhu et al. 2010).  Furthermore, anthocyanins have 
recently garnered attention as anti-inflammatory agents, significantly reducing 
 
115 
inflammatory responses induced by lipopolysaccharide stimulation in BV2 microglial 
cells (Lau et al. 2007, Poulose et al. 2012, Carey et al. 2013, Jeong et al. 2013). 
Anthocyanins have also been shown to directly modulate pro-survival and pro-apoptotic 
signaling pathways, further contributing to their neuroprotective effects (Shin et al. 2006, 
Reddivari et al. 2007, Lu et al. 2010, Kim et al. 2010, Ye et al. 2010, Min et al. 2011). 
The pleiotropic nature of these compounds makes them highly appealing as potential 
therapeutics for the treatment of diseases like ALS that possess a complex etiology and 
progression characterized by both oxidative stress and inflammation.  We have 
previously shown that an anthocyanin-enriched extract from strawberries (SAE) and its 
primary anthocyanin constituent, callistephin, display significant neuroprotective effects 
against glutamate excitotoxicity and mitochondrial oxidative stress in vitro (Kelsey et al. 
2011, Chapter 2, Section 2.4). Therefore, we sought to explore the therapeutic potential 
of SAE in the G93A mutant human Cu, Zn-superoxide dismutase (hSOD1G93A) mouse 
model of familial ALS. 
 
3.3. Materials and Methods 
3.3.1 Anthocyanin Extraction and HPLC Analysis 
Anthocyanins were extracted from commercially available Nutri-Fruit freeze-
dried strawberry powder (Scenic Fruit Co., Gresham Oregon) using the protocol 
established by Rodriguez-Saona and Wrolstad (2001).  Briefly, 500g of freeze-dried 
powder was macerated in a large flask with acidified methanol (0.01% HCl)  to obtain a 
crude extract of all (poly)phenolic species. The extract was collected by filtration using 
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Whatman no. 1 filter paper, and the remaining powder was re-extracted with acidified 
methanol until a faintly colored solution was obtained.  The crude extract was pooled 
together, then boiled under vacuum to remove the methanol until a viscous solution was 
obtained. This solution was then purified for anthocyanins using a C18 column prepared 
with acidified water (0.01% HCl) by loading one column volume of the crude extract 
onto the column followed by sequential washes with one column volume each of 
acidified water and ethyl acetate.  Anthocyanins were then eluted into a separate 
collection flask by passing one column volume of acidified methanol (0.01% HCl) 
through the column. This extract, containing purified anthocyanins, was then boiled 
under vacuum until a strongly pigmented and viscous solution was obtained. 
The purified strawberry anthocyanin extract (SAE) was analyzed and the primary 
anthocyanin constituent was identified using HPLC.  All analyses were conducted using 
HPLC-UV/Vis with an Agilent model HP1100 series II with programmable diode array 
detector (Avondale, PA). Separation of anthocyanins was carried out using a C18 bonded 
silica column (3µm, 3 x 150mm) from Dionex Inc. (Sunnyvale, CA).  Mobile phases 
consisting of 0.1% trifluoroacetic acid in water (A) and 70% HPLC-grade acetonitrile (B) 
were prepared and combined in a stepwise gradient over the course of the separation. 
Gradient conditions were as follows:  initial conditions were composed of 90% mobile 
phase A and 10% mobile phase B; from time 5-10 minutes, the gradient changed to 30% 
mobile phase B; from 14.5-16 minutes, the gradient changed to 50% mobile phase B; 
from 20-21 minutes, the gradient was returned to 10% mobile phase B. Anthocyanins 
were detected  in 100µL injections  of a 1% solution prepared in mobile phase A  at a 
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temperature and flow rate of 25ºC and 0.6mL/min respectively, and a wavelength of 
520nm over the course of 25 minutes. A post run time of 5 minutes was then observed to 
clear and equilibrate the column for subsequent runs.  
It has been previously reported that pelargonidin-O-3-glucoside (callistephin) is 
the major anthocyanin constituent of strawberry fruit (Baiamonte et a. 2010). This was 
confirmed by comparing a pure callistephin chloride standard (97% pure, Sigma Aldrich, 
St. Louis, MO) to the extract (Fig. 3.1).  The concentration of callistephin in SAE was 
then determined by constructing a standard curve using the pure callistephin standard. A 
1mg/mL solution was prepared initially in mobile phase A, and then diluted to 3/5, 2/5, 
1/5, and 1/10 of the original concentration. Standards were injected individually and run 
under HPLC conditions as described above to create a linear curve (R2 ≥ 0.990) of peak 







Figure 3.1. Representative HPLC chromatograms of an anthocyanin-enriched 
extract from strawberries (SAE) and pure callistephin standard. Purified 
anthocyanin extract from freeze-dried strawberry powder was analyzed by HPLC with 
UV/Vis detection at 520nm (A) and compared to a pure callistephin standard (B) for peak 
identification of the major anthocyanin constituent. Callistephin appears at rt=9.304min 




3.3.2 hSOD1G93A  Mouse Model of ALS 
All procedures were performed in accordance with a protocol approved by the 
institutional animal care and use committee (IACUC) at the University of Denver. 
FVB/NJ mice harboring a human transgene coding for a mutated form of SOD1 with a 
glycine to alanine substitution at position 93 were obtained from The Jackson Laboratory 
(Bar Harbor, ME). Mice were bred and maintained at the University of Denver animal 
facility under a standard 12 hour night and day cycle with food and water provided ad 
libitum. Genotyping to identify transgenic mice was carried out by a third party company, 
Transnetyx Inc. (Cordova, TN). 
Mice were divided into three groups of 9 mice each. These groups consisted of 
non-transgenic wild type (WT) littermate controls, untreated hSOD1G93A littermate 
controls, and hSOD1G93A mice receiving SAE supplementation. Approximately equal 
numbers of males and females composed each group. Mice were age and sex-matched to 
ensure an accurate comparison of clinical indices of disease onset and survival across the 
three groups. Mice receiving SAE supplementation were dosed twice daily by oral 
gavage with 0.25mL of a 5% SAE solution prepared in sterile drinking water beginning 
at the presymptomatic age of 60 days-old. This dose equated to 2mg/kg/day of the 
primary anthocyanin constituent, callistephin, assuming an average body mass of 25g. 





3.3.3 Clinical Tests 
Mice were assessed for signs of disease onset daily beginning at 60 days of age. It 
was determined that mice had experienced disease onset upon the appearance of hind 
limb trembling or the inability to extend one or both hind limbs when suspended by the 
tail. Onset was not determined in a blinded fashion; however, onset was evaluated by at 
least two investigators independently in order to reduce subjectivity.  
Mice were also evaluated for grip strength in the hind limbs using the paw grip 
endurance (PaGE) test as described by Weydt et al. (2003). Briefly, mice were placed on 
top of a standard wire cage lid, and given a few seconds to acclimate. The lid was then 
inverted in one smooth motion to prompt the mouse to grip the wire with both its fore and 
hind limbs. Care was taken to avoid jostling the lid during inversion, which might have 
caused the mouse to fall. Once inverted, the lid was held suspended a few inches above 
the bench top and a stopwatch was used to determine the time it took for the mouse to 
release its grip on the wire lid with its hind limbs after becoming fully inverted. Time was 
stopped the moment the mouse’s hind limbs detached from the cage, or after 30s with no 
detachment. This time was recorded as latency to fall with a maximum achievable score 
of 30s. Mice were given three scored attempts, and final scores are reported as the 
average of the three scores ± standard error of the mean (SEM) for each time point. This 
testing regimen was performed twice weekly. Time points correspond to the age of the 
animal at the time that testing was performed, and are reported as a range of five days due 
to the fact that multiple sets of animals having slightly different ages were tested 
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concomitantly. Animal weight was also assessed at the time of PaGE testing, 
immediately following the three scored attempts for each mouse. 
Throughout testing, mice were monitored and assessed daily for the point at 
which end-stage of the disease was reached. End-stage was defined as the point at which 
a mouse placed on its side failed to right itself to a sternal position within 20s. When it 
was determined that a mouse had reached end-stage, the animal was immediately 
euthanized by inhaled isoflurane overdose and secondary decapitation. 
 
3.3.4 Tissue Preparation and Immunohistochemistry 
For analysis of disease pathology, a separate set of mice from those used to assess 
onset and survival was euthanized at 105 days of age, the time point at which the greatest 
difference in clinical indices of disease was observed. After euthanasia the 
thoracicolumbar portion of the spinal column, containing the lumbar spinal cord, and 
gastrocnemius muscle were isolated. Tissue was immediately frozen in optimal cutting 
temperature (OCT) compound to prepare it for cryosectioning and stored at -80°C until 
sectioning took place. 
For spinal column, 18μm coronal sections were cut, collecting every fourth tissue 
section onto the surface of Fisherbrand Superfrost coated slides (Thermofisher Scientific, 
Rockford, IL) to ensure an accurate representation of the entire lumbar region of the 
spinal cord. Tissue was then fixed at room temperature for forty minutes using 4% 
paraformaldehyde. Once fixed, tissue was incubated at room temperature in blocking 
buffer, containing 5% (w/v) bovine serum albumin (BSA) and 0.2% triton-X100 in 
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phosphate buffered saline (PBS). Primary antibody to glial acidic fibrillary protein 
(GFAP; Abcam, Cambridge, MA) was then prepared as a 1:250 dilution in PBS 
containing 0.2% triton-X100 and 2% BSA (w/v) respectively. Tissue sections were then 
incubated in primary antibody overnight at 4°C. Tissue was next washed five times with 
PBS to remove unbound primary antibody. FITC-conjugated secondary donkey-anti-
rabbit antibody (Jackson Immunoresearch Laboratories, West Grove, PA), was then 
prepared at a 1:250 dilution (v/v) in PBS containing 0.2% triton-X100 and 2% BSA (w/v) 
and Hoechst nuclear stain (Sigma-Aldrich, St. Louis, MO) at a 1:500 dilution to detect 
GFAP primary antibodies and to label nuclei, respectively. Sections were incubated with 
secondary antibodies for 1h at room temperature, then washed five times in PBS. Slides 
were then sealed with cover slips using mounting medium composed of a 1:3 of PBS to 
glycerol (v/v) and p-phenylenediamine (Sigma-Aldrich, St. Louis, MO) to preserve 
fluorescence. Tissue was then imaged using a Zeiss Axiovert-200M epi-fluorescence 
microscope to capture a single image of each ventral horn using equal exposure times for 
all tissue sections. At least 13 ventral horns per animal were imaged and analyzed for 
fluorescence intensity using Adobe Photoshop CS4 software by determining the average 
green fluorescence intensity of pixels in the ventral horn region and multiplying the 
intensity by the total number of pixels that were measured. This analysis was done on 
four animals for each of the three treatment groups. 
For gastrocnemius muscle, 18μm longitudinal sections were cut, collecting every 
third tissue section on Superfrost coated slides to gain an accurate representation of the 
size and health of neuromuscular junctions (NMJs). To accomplish this, muscle tissue 
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was fixed for 40min in 4% paraformaldehyde, and then incubated for 1h in blocking 
buffer as described above. A 5μg/mL solution of α-bungarotoxin (BTx) conjugated to 
Alexa Fluor® 594 (ThermoFisher Scientific Inc., Rockford, IL) was then prepared in 
blocking buffer containing Hoechst nuclear stain at a dilution of 1:500, and sections were 
incubated for 1h at room temperature. Muscle sections were then washed five times with 
PBS and sealed with glass cover slips as described above. NMJs were imaged and 
assessed for size using Adobe Photoshop CS4 software. Size was measured by 
determining the total area occupied by individual NMJs, and a complete distribution of 
sizes was created for each of the three treatment groups. At least 50 NMJs per animal 
were analyzed. NMJs were considered healthy if their morphology was observed to be 
large and complex, while fragmented and small NMJs were considered to be unhealthy, 
reflecting a lack of innervation and muscle atrophy (Rudolf et al. 2014). This analysis 
was done on three animals per each of the three treatment groups. 
 
3.3.5 Nissl Staining for Spinal Motor Neurons 
 Coronal spinal column sections of 18µm each were cut, and every fourth tissue 
section was collected on Superfrost coated slides. Tissue sections were fixed for 40min in 
4% paraformaldehyde, and then washed with PBS. Subsequently, tissue was prepared by 
incubation in 70% ethanol for 3min, followed by incubation in 95% ethanol for 3min, and 
finally two incubations in 100% ethanol for 3min and 5 min respectively, changing the 
ethanol between each incubation. Slides were then rinsed briefly in deionized water 
several times. A 1% cresyl violet solution (Ambion, Foster City, CA) was then prepared 
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in deionized water and applied to the slides for approximately 30s. Slides were rinsed 
with deionized water several times, and then de-stained to differentiate neuronal cell 
bodies. To de-stain, tissue sections were dipped briefly into 70mM acetic acid solution. 
This process was repeated until white space between stained cells was observed under a 
bright field microscope. Once sections were sufficiently de-stained, the slides were rinsed 
with deionized water several times, and then incubated sequentially in solutions of 70%, 
95%, and 100% ethanol as described above. Slides were then sealed using cover slips and 
mounting medium composed of a 1:3 (v/v) of PBS to glycerol, and imaged under bright 
field. Images of the entire ventral horn were captured, and every Nissl-positive cell body 
was measured and grouped into a category based on its length along its longest axis using 
Adobe Photoshop CS4 software. These categories included neurons that were <15µm, 
neurons that were 15-20µm, neurons that were 20-25µm, and neurons that were >25μm 
in length. Any neurons that were 20µm in size or larger were considered viable motor 
neurons (Guo et al. 2013); however the data for neurons that were at least 25µm in size 
was also analyzed as a more stringent evaluation of motor neuron presence and viability. 
This analysis was performed on at least 13 ventral horns per animal with three animals 
per each of the three treatment groups. 
 
3.3.6 Statistical Analysis 
Histological analyses were performed on at least three animals from each 
treatment group. Differences in GFAP fluorescence intensity, Nissl-stained cell number, 
and NMJ size were assessed using one-way analysis of variance (ANOVA) with post hoc 
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Tukey’s test to compare differences between groups. Kaplan-Meier curves were analyzed 
using a log rank test. PaGE and weight data were analyzed using one-way ANOVA with 
a post hoc Tukey’s test for each time point. For all analyses, differences were statistically 
significant when p<0.05.  
 
3.4 Results 
3.4.1 SAE Delays Disease Onset and Extends Survival in the hSOD1G93A Mouse 
Model of ALS 
We first examined the therapeutic benefit of anthocyanin supplementation in the 
hSOD1G93A mouse model of ALS by evaluating its impact on disease onset and 
progression. Mice were treated by oral gavage with an anthocyanin-enriched extract 
beginning at 60 days of age. This age is considered presymptomatic, as hSOD1G93A mice 
on an FVB background typically experience disease onset at approximately 90 days of 
age, although gait abnormalities in hSOD1G93A mice have been reported as early as 8 
weeks of age (Mancuso et al. 2011, Ross et al. 2014). Transgenic hSOD1G93A mice 
receiving SAE treatment displayed a dramatic delay in disease onset with a mean onset of 
109.4 ± 2.2 days of age (Fig. 3.2A). In comparison, transgenic mice that did not receive 
SAE treatment experienced a mean age of onset of 92.6 ± 1.5 days of age. In addition to 
this delay in disease onset, transgenic hSOD1G93A mice treated with SAE showed a  
statistically significant extension in survival (Fig. 3.2B). SAE-treated hSOD1G93A mice 
reached end-stage at an average age of 139.0 ± 2.7 days of age whereas untreated 





Figure 3.2. Presymptomatic administration of SAE delays disease onset and extends 
survival in the hSOD1G93A mouse model of ALS. A, Administration of SAE beginning 
at 60 days of age significantly delayed clinical onset of disease in comparison to 
untreated hSOD1G93A controls. Curves are significantly different as determined by a 
Mantel-Cox Log Rank test (p<0.001, n=9). B, Administration of SAE as in (A) 
significantly extended survival of hSOD1G93A mice in comparison to untreated 
hSOD1G93A controls. Curves are significantly different as determined by a Mantel-Cox 
Log Rank test (p<0.01, n=9). 
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3.4.2 SAE Preserves Hind Limb Grip Strength in the hSOD1G93A Mouse Model of 
ALS, But Does Not Affect Body Weight 
We next assessed the functional benefit of SAE treatment by evaluating grip 
strength and body weight loss in hSOD1G93A mice. Deficits in muscle strength and 
coordination were assessed twice weekly by the PaGE wire hang test. Hind limb grip 
strength was measured by allowing the mouse to hang from an inverted wire cage lid 
until its hind limbs detached from the wire. Mice receiving SAE supplementation showed 
a significant preservation of grip strength between 85 and 124 days of age when 
compared to hSOD1G93A mice that did not receive treatment (Fig. 3.3A). However, 
although muscle strength and function were maintained for a longer period of time 
throughout disease progression, SAE treatment did not significantly affect declines in 





Figure 3.3. Presymptomatic administration of SAE preserves hind limb grip 
strength in the hSOD1G93A mouse model of ALS. A, Paw grip endurance (PaGE) 
testing. PaGE testing was conducted twice weekly beginning at 80 days of age. Each 
mouse received three scored attempts for each time point, expressed as latency to fall. B, 
Body weight of WT and hSOD1G93A mice. Body weight was measured twice weekly 
immediately following PaGE testing, and is expressed as the percent of peak body weight 
for each time point. All data are expressed as mean ± SEM for each time point, n=8. *** 
indicates p<0.001, ** indicates p<0.01 and * indicates p<0.05 in comparison to non-
transgenic wild type (WT) controls. ††† indicates p<0.001, †† indicates p<0.01 and † 
indicates p<0.05 in comparison to untreated hSOD1G93A controls. All data were analyzed 
using one-way ANOVA with a post hoc Tukey’s test for each time point.  
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3.4.3 hSOD1G93A Mice Show a Trend Towards Decreased Numbers of Spinal Motor 
Neurons That is Prevented by SAE 
Given the significant clinical benefits produced by treatment with SAE in 
hSOD1G93A mice, we next assessed the effects of anthocyanin supplementation on 
histopathological indices of disease. Since motor neuron death is known to underlie ALS, 
we first evaluated the effects of SAE on preserving motor neuron populations in lumbar 
spinal cord. As the greatest difference in clinical manifestations of the disease was 
observed at approximately 105 days of age (see Fig. 3.3A), we selected this time point to 
evaluate spinal cord tissue for various markers of disease pathology. 
Mice were sacrificed at 105 days of age and spinal cord tissue was collected for 
further analysis. Sections of lumbar spinal cord were Nissl stained to visualize neuronal 
cell bodies and the number of viable alpha motor neurons in the ventral horns were 
quantified by measuring each cell body and counting the number of neurons that were 
either >20μm in size or those that were >25μm in size, a more stringent evaluation of the 
viable motor neurons. While no statistically significant differences were observed in the 
total number of motor neurons between the three groups for either size, untreated 
hSOD1G93A mice showed a trend towards a decreased motor neuron population (Fig. 3.4). 
This trend was reversed by treatment with SAE, which restored motor neuron numbers to 







Figure 3.4. Presymptomatic administration of SAE shows a trend towards 
preserving motor neurons in spinal cord tissue in the hSOD1G93A mouse model of 
ALS. A, Representative images of ventral horns in lumbar spinal cord isolated from non-
transgenic wild type controls (WT), untreated hSOD1G93A controls (G93A), and 
hSOD1G93A mice treated with SAE (SAE). Tissue was isolated at 105 days of age and 
Nissl stained to identify neuronal cell bodies. Nissl-positive cells were measured 
individually along their longest axis. Cells were considered viable alpha-motor neurons if 
they were >20μm in size, indicated by the red arrows. Scale bar =20μm. B, Quantitative 
assessment of Nissl-positive neurons >20μm in size. C, Quantitative assessment of Nissl-
positive neurons >25μm in size. Data are expressed as mean ± SEM. Motor neurons were 
counted in at least 13 ventral horns per animal, n=3 mice per group. All quantitative data 
were analyzed using one-way ANOVA with a post hoc Tukey’s test.  
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3.4.4 SAE Reduces Reactive Gliosis in hSOD1G93A Spinal Cord Tissue 
As glial-mediated inflammation is thought to be a major contributor to ALS 
disease progression and motor neuron death, we next examined lumbar spinal cord tissue 
for the presence of reactive astrocytes by GFAP staining. WT controls displayed very 
little evidence of reactive astrogliosis in the ventral horns; however, untreated 
hSOD1G93A mice demonstrated a dramatic increase in the number of astrocytes observed 
with GFAP staining (Fig. 3.5A). This increase was almost entirely attenuated by 
treatment with SAE (Fig. 3.5A). In good agreement with these observations, analysis of 
the total fluorescence intensity measured as green GFAP fluorescence was significantly 
enhanced in untreated hSOD1G93A controls. Treatment with SAE mitigated this effect, 







Figure 3.5. Presymptomatic administration of SAE reduces reactive astrogliosis in 
spinal cord tissue from the hSOD1G93A mouse model of ALS. A, Representative 
images of ventral horns in lumbar spinal cord isolated from non-transgenic wild type 
controls (WT), untreated hSOD1G93A controls (G93A), and hSOD1G93A treated with SAE 
(SAE). Tissue was isolated at 105 days of age and stained for GFAP (green) and Hoechst 
(Blue) to identify reactive astrocytes and nuclei respectively. Scale bar =20μm. B, 
Quantitative assessment of green GFAP intensity. Ventral horns were imaged using equal 
exposure times and the intensity of GFAP fluorescence was measured.  Data are 
expressed as mean ± SEM. *** indicates p<0.001 in comparison to WT controls. †† 
indicates p<0.01 in comparison to untreated mutant hSOD1G93A mice. Measurements 
were conducted on at least 13 ventral horns per animal, n=4 mice per group. All 
quantitative data were analyzed using one-way ANOVA with a post hoc Tukey’s test.  
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3.4.5 SAE Preserves the Size and Health of Neuromuscular Junctions in hSOD1G93A 
Gastrocnemius Muscle Tissue 
Dying back of motor axons, loss of muscle innervation, and subsequent muscle 
atrophy are among the first pathological features observed in ALS, becoming apparent 
even before clinical onset of disease (Pun et al. 2006). Since mice receiving SAE 
supplementation displayed an impressive retention of grip strength throughout disease 
progression, but did not display a significant enhancement in motor neuron survival over 
their untreated counterparts, we hypothesized that effects on grip strength might be 
explained by preservation of NMJ size and architecture. With this in mind, the area of 
each NMJ was measured and images were collected to compare morphology. Medial 
gastrocnemius muscle tissue was isolated from mice at 105 days of age as with spinal 
cord tissue, and stained with BTx to analyze the size and morphology of NMJs.  
WT controls displayed large and elaborate NMJ architecture with smooth 
margins, indicative of overall muscle health (Fig. 3.6A). In contrast, untreated 
hSOD1G93A mice possessed NMJs that were much smaller than those observed in WT 
animals (Fig. 3.6B). Fragmentation of NMJs was also observed, consistent with loss of 
innervation and muscle atrophy (Fig. 3.6A; Rudolf et al. 2014). This effect was 
substantially rescued by supplementation with SAE as complex NMJ morphology and 





Figure 3.6. Presymptomatic administration of SAE preserves the size and health of 
NMJs in muscle tissue from the hSOD1G93A mouse model of ALS. A, Representative 
images of neuromuscular junctions in medial gastrocnemius muscle tissue from non-
transgenic wild type controls (WT), untreated hSOD1G93A mutant controls (G93A) and 
hSOD1G93A mice treated with SAE (SAE). Tissue was isolated at 105 days of age and 
stained with fluorescently labeled α-bungarotoxin (red) and Hoechst (blue) to identify 
motor endplates and nuclei respectively. Scale bar =10μm. B, Quantitative assessment of 
NMJ size. The area of individual NMJs was measured for 50-150 NMJs per animal. *** 
indicates p<0.001 in comparison to WT controls, and †† indicates p<0.01 compared to 
untreated mutant hSOD1G93A controls, n=3 mice per group. All quantitative data were 






The complex nature of ALS disease pathology has proved to be a great obstacle in 
the effort to identify new and effective therapeutic strategies. With this in mind, it has 
become clear that novel treatments are vitally needed to improve the prognosis and 
quality of life for patients suffering from this insidious disease. Attention has recently 
turned towards identifying new therapeutic agents that target multiple factors contributing 
to ALS etiology and progression. Anthocyanins have garnered significant attention in this 
regard as a potential treatment for neurodegenerative diseases as they have been shown to 
exert pleiotropic effects on many of the factors thought to underlie these disorders 
(reviewed by Ross et al. 2013). Therefore, we explored the potential therapeutic benefits 
of an anthocyanin-enriched extract from strawberries in the preclinical hSOD1G93A mouse 
model of ALS. 
Until now, the potential of anthocyanins as therapeutic agents for ALS has not 
been examined, although their efficacy in other models of neurodegenerative disease has 
been described. In the MPTP mouse model of Parkinson’s disease, for example, an 
anthocyanin-rich mulberry extract conferred significant neuroprotection, preserving 
dopaminergic neurons in the substantia nigra and reducing Parkinsonian symptoms (Kim 
et al. 2010). Similar results were obtained in a study conducted by Roghani et al. (2010), 
in which the authors demonstrated that oral treatment with pelargonidin, the aglycon 
form of callistephin, significantly reduced neuronal loss and diminished lipid 
peroxidation in a 6-hydroxydopamine-lesioned rat model of hemi-Parkinsonism. Positive 
effects of anthocyanins have also been reported in models of Alzheimer’s disease and 
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aging. Indeed, in the mutant amyloid precursor protein/presenilin-1 (APP/PS1) mouse 
model of Alzheimer’s disease, anthocyanins isolated from bilberry and black currant 
prevented the deposition of amyloid beta peptides that is characteristic of this disease, 
and reduced associated cognitive impairments  (Vepsäläinen et al. 2013). Similarly, the 
anthocyanin, cyanidin-O-3-glucoside, was also found to modulate phosphorylation of tau, 
which is known to form neurofibrillary tangles in Alzheimer’s disease, by reducing 
activation of glycogen synthase kinase-3β following hippocampal injection of amyloid 
beta peptide (Qin et al. 2013). This reduction in tau phosphorylation was associated with 
enhanced learning and memory in comparison to rats that did not receive anthocyanin 
treatment.  
In agreement with these prior studies, our results demonstrate that anthocyanin 
supplementation shows significant preclinical efficacy for the therapeutic treatment of 
ALS. Administration of SAE at a presymptomatic age significantly delayed clinical 
disease onset and extended the lifespan of hSOD1G93A mutant mice in comparison to 
mice that did not receive anthocyanin treatment. In addition, SAE supplementation 
markedly preserved muscle strength and function in treated mice throughout disease 
progression as measured by PaGE testing. However, SAE did not affect weight loss in 
hSOD1G93A animals. This may be due to the fact that anthocyanins are known to enhance 
weight loss by decreasing fat content; thus SAE-treated mice may have shown a 
significant reduction in weight, but this could be due to loss of fat while lean muscle is 
largely preserved in comparison to untreated hSOD1G93A controls (Prior et al. 2008, 
Tsuda 2008). Further exploration is needed to test this hypothesis. These findings are 
 
137 
highly encouraging in that notable prior studies, such as those assessing the efficacy of 
vitamin E and Riluzole in this mouse model of ALS, have reported only modest benefits, 
such as uniquely delaying disease onset or extending lifespan, respectively (Gurney et al. 
1996). Furthermore, even when administered at a presymptomatic stage of disease, there 
is no evidence that either of these treatments is capable of preserving muscle function, 
which significantly impacts quality of life for ALS patients. Thus, anthocyanin 
supplementation may be a more efficacious treatment strategy than many of those that 
have been previously tested. 
In addition to improving clinical indices of disease, we also demonstrate that 
treatment with SAE significantly modulates several aspects of underlying ALS disease 
pathology. The death of motor neurons is a key pathological factor contributing to ALS 
etiology. Therefore, strategies aimed at preserving motor neuron populations by 
mitigating these factors are essential when considering potential therapeutic agents. With 
this in mind, we first examined the beneficial effects of SAE supplementation on motor 
neuron survival in the ventral horns of lumbar spinal cord isolated from hSOD1G93A 
mutant mice. Tissue was collected from mice at 105 days of age, the time point at which 
the greatest difference in clinical indices of disease were observed between untreated 
hSOD1G93A controls and mice receiving SAE supplementation. Untreated hSOD1G93A 
mice demonstrated a trend towards decreased numbers of viable motor neurons in spinal 
cord tissue, although this decrease did not reach statistical significance. This may be due 
to the fact that motor neuron viability was assessed at a relatively early time point in 
disease progression, as marked motor neuron loss is not observed until later stages of the 
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disease (Dal Canto and Gurney 1994). Nevertheless, it is noteworthy that mice receiving 
SAE supplementation displayed a trend towards preservation of viable motor neurons in 
spinal cord tissue, indicating that anthocyanins may display neuroprotective effects in this 
mouse model of ALS. Indeed, anthocyanins are unique in that they demonstrate a 
multiplicity of neuroprotective effects, including modulation of neuronal antioxidant 
status, prevention of perturbances in calcium homeostasis caused by excitotoxic insult, 
and attenuation of glial inflammation in vivo (Dani et al. 2008, Matsunaga et al. 2009, 
Wang et al. 2010, Poulose et al. 2016, Rehman et al. 2016). These varied effects may 
contribute to the observed trend towards a positive impact on motor neuron survival.  
Reactive astrogliosis plays a prominent role in several neurodegenerative 
diseases, and its role in ALS specifically is well established as astrocyte-specific 
knockout of mutant SOD1 has been shown to significantly alter disease progression in 
mouse models of ALS (Yamanaka et al. 2008, Wang et al. 2011). Here we report that 
anthocyanin treatment of hSOD1G93A mutant mice with SAE significantly reduced the 
presence of reactive astrocytes in lumbar spinal cord tissue, which correlates with the 
trend towards enhanced motor neuron survival observed with SAE administration. This is 
in good agreement with a very recent study demonstrating that anthocyanins extracted 
from black soybeans significantly attenuated astrogliosis in cortex and hippocampal 
tissue isolated from the D-galactose rat model of accelerated aging (Rehman et al. 2016). 
Furthermore, anthocyanins have been shown to significantly reduce oxidative stress in 
manganese-treated primary rat astrocytes, a condition that is known to contribute to the 
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transition of astrocytes from a neuroprotective to a neurotoxic state (da Silva Santos et al. 
2014).   
Lastly, we examined the impact of anthocyanin supplementation on the health of 
NMJs in medial gastrocnemius tissue. Since motor neuron loss in untreated hSOD1G93A 
did not reach statistical significance at 105 days of age, we hypothesized that the marked 
difference in grip strength observed between untreated hSOD1G93A mice and those 
supplemented with SAE at this time point was likely due to differences in the health of 
NMJs in muscles of the hind limbs. Our results show that untreated hSOD1G93A mice 
displayed a significant reduction in NMJ size and complexity, indicative of muscle 
atrophy and loss of function, whereas animals treated with SAE displayed NMJs of a size 
and complexity comparable to WT controls (Rudolf et al. 2014). Thus, it is likely that 
preservation of healthy NMJs and not preservation of motor neuron viability is 
responsible for the impressive preservation of grip strength observed in SAE-treated mice 
at 105 days of age. 
While anthocyanins appear to be promising therapeutics, impacting multiple 
aspects of ALS disease pathology, it is important to note that the results of this study are 
currently limited by the use of an anthocyanin-enriched extract and the presymptomatic 
administration of SAE. While widely used and important investigative tools, anthocyanin 
extracts are poor candidates for potential drug development due to the fact that they 
contain multiple compounds that may produce synergistic effects in vivo and confound 
the ability of investigators to determine the impact of any specific compound on human 
health. Additionally, the production of anthocyanin-rich extracts in large quantities would 
 
140 
be costly and difficult to standardize. It is also noteworthy that, presymptomatic 
administration of treatments in ALS mouse models, though common, represents an 
unrealistic paradigm for the treatment of human disease, as most ALS patients cannot 
seek treatment until after clinical disease onset.  
Nevertheless, the considerable benefit of SAE administration in the hSOD1G93A 
mouse model of ALS is highly encouraging, and provides proof of concept that the 
therapeutic efficacy of both anthocyanin extracts and pure anthocyanin compounds 
should be further investigated in preclinical models of ALS with administration started at 
later stages of disease. This is particularly true in light of our recent work demonstrating 
that different anthocyanin species display differential neuroprotective effects in vitro, 
with anthocyanins such as cyanidin-O-3-glucoside displaying broader neuroprotective 
activity than the closely related anthocyanin callistephin, the major component of SAE 
(Chapter 2, Section 2.4). With this in mind, it is possible that further preclinical 
assessment of anthocyanins in the context of ALS and other neurodegenerative diseases 
may identify anthocyanins with even greater therapeutic benefit than those examined 
here. Such studies will be of great value moving forward as they have the potential to 
reveal novel therapeutic agents in addition to defining new mechanisms of action of 








CHAPTER FOUR: COMPARISON OF THE DISTINCT NEUROPROTECTIVE 
AND ANTI-INFLAMMATORY EFFECTS OF THE PHENOLIC ACIDS, 
PROTOCATECHUIC ACID AND 4-HYDROXYBENZOIC ACID 
 
4.1 Abstract 
Neurodegenerative diseases are characterized by the death of specific neuronal 
populations in the brain and spinal cord. Polyphenols, and in particular, anthocyanins, 
have been increasingly investigated for their neuroprotective and anti-inflammatory 
effects in the context of neurodegenerative disease; however the overall bioavailability of 
many anthocyanins is relatively low. In contrast, phenolic acids, metabolites of many 
commonly consumed polyphenols, including anthocyanins, have been shown to 
accumulate in tissue at higher concentrations than those of parent compounds, suggesting 
that these metabolites may be the bioactive components of anthocyanin-rich diets. We 
examined the neuroprotective capacity of two common phenolic acids, 4-hydroxybenzoic 
acid (HBA) and protocatechuic acid (PCA), in primary cultures of cerebellar granule 
neurons. We demonstrate that both HBA and PCA are capable of mitigating oxidative 
stress induced by hydrogen peroxide, which is thought to contribute to neuronal cell 
death in neurodegeneration. Under conditions of nitrosative stress, which occur during 
inflammation in the central nervous system, only PCA was neuroprotective, despite 
similar structural characteristics between HBA and PCA. Intriguingly, this trend was 
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reversed under conditions of excitotoxicity, in which only HBA was neuroprotective. 
Lastly, we explored the anti-inflammatory activity of these compounds in the BV2 
microglial cell line stimulated with lipopolysaccharide. In this model, PCA proved to be 
an effective anti-inflammatory agent, reducing nitric oxide production and induction of 
inducible nitric oxide synthase, while HBA had no effect. These data indicate that 
phenolic acid anthocyanin metabolites possess distinct neuroprotective and anti-




With steady medical advances being made in recent decades, the human 
population has enjoyed a considerable increase in average life expectancy; however as 
the population ages, the incidence of neurodegenerative disease has also increased. 
Indeed, disorders including Alzheimer’s disease, Parkinson’s disease, and amyotrophic 
lateral sclerosis (ALS) have all seen a rise in positive diagnoses, prompting extensive 
research into the etiology and pathology of these diseases (Ingre et al. 2015). Despite 
these efforts, however, the treatments for these diseases remain scarce and are targeted 
primarily at reducing symptoms rather than at alleviating causes underlying disease 
pathology and progression.  
Neurodegenerative diseases are characterized by the death of specific neuronal 
populations within the brain, brain stem and spinal cord, producing significant cognitive 
and/or motor impairments. Although each disease is uniquely characterized by the type of 
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neurons that are ultimately affected, the underlying causes of neuronal death are thought 
to be remarkably similar. These include conditions such as oxidative stress, caused by the 
buildup of reactive oxygen species (ROS) within the cell that damage vital cellular 
components such as DNA and proteins, nitrosative stress, caused by damaging reactive 
nitrogen species (RNS) produced in the central nervous system (CNS) under 
neuroinflammatory conditions, and excitotoxicity, resulting from overstimulation of 
neuronal cells by excitatory neurotransmitters, causing massive calcium influx and 
subsequent activation of cell death signaling cascades (Calabrese et al. 2000, Lin and 
Beal 2006, Gu et al. 2010, Wang and Qin, 2010, Radi et al. 2014). The identification of 
agents targeting multiple aspects of neurodegenerative disease pathology, therefore, 
provides an appealing therapeutic avenue for treating multiple disorders.  
In this regard, polyphenols have emerged as promising therapeutic candidates due 
to their impressive antioxidant, anti-neuroinflammatory, and anti-apoptotic effects 
(reviewed by Ramassamy, 2006). In particular, anthocyanins, a unique class of flavonoid 
compounds, show significant potential as a treatment for neurodegenerative disease for 
these reasons in addition to the observation that they are among the most commonly 
consumed polyphenolic species around the world (Scalbert and Williamson, 2000). These 
compounds, responsible for producing the red, blue, and purple pigmentation of many 
fruits and vegetables, have received significant attention as neuroprotective agents both in 
vitro and in vivo; however, the efficacy of these compounds for the treatment of 
neurodegenerative diseases may be limited by their relatively low bioavailability in the 
brain following ingestion (Passamonti et al. 2005, Talavera et al. 2005). Indeed, 
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anthocyanins are rapidly absorbed, and have been shown to accumulate in several areas 
of the brain; however the levels at which anthocyanins accumulate are extremely low at 
only ~0.2nmol/g of tissue (Youdim et al. 2003, Andres-Lacueva et al. 2005, Passamonti 
et al. 2005, Talavera et al. 2005, El Mohsen et al. 2006).  
The low levels of circulating anthocyanins are thought to be due in part to 
extensive metabolism of the parent compounds by gut microflora to form various 
phenolic acid metabolites (Fleschhut et al. 2006, Woodward et al. 2009, Woodward et al. 
2011, Forester and Waterhouse, 2010). This phenomenon has been described by several 
studies, and it has been reported that incubation of anthocyanin aglycons with gut 
microflora results in complete degradation of the parent species to form phenolic acids 
and aldehydes (Woodward et al. 2011). Furthermore, circulating concentrations of 
phenolic acid metabolites derived from anthocyanin degradation such as protocatechuic 
acid (PCA), have been observed at up to eight times that of the parent anthocyanins 
(Azzini et al. 2010). It has also been reported that PCA remains in relevant tissues longer 
than its parent anthocyanin compounds (Tsuda et al. 1999).  Similarly, gallic acid, 
another phenolic acid metabolite of some anthocyanin compounds, has also been 
observed to accumulate in brain tissue at high levels with chronic consumption (Ferruzzi 
et al. 2009). Collectively, these observations have led investigators to suggest that 
phenolic acids and other anthocyanin metabolites are the bioactive components of 
anthocyanin-rich diets (Vitaglione et al. 2007). Studies assessing the neuroprotective and 
anti-inflammatory effects of these compounds are few in number, however, and have 
focused predominately on only two phenolic acids, PCA and gallic acid. Thus, the 
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distinct neuroprotective effects of other phenolic acids derived from anthocyanins have 
not been examined.  
We have previously reported that two structurally similar, but distinct 
anthocyanins, cyanidin-O-3-glucoside (kuromanin) and pelargonidin-O-3-glucoside 
(callistephin), display differential neuroprotective effects against a variety of neurotoxic 
insults. While both callistephin and kuromanin are capable of protecting primary 
cerebellar granule neurons (CGNs) from mitochondrial oxidative stress and 
excitotoxicity, only kuromanin is capable of defending neurons from nitrosative stress 
induced by the nitric oxide donor, sodium nitroprusside (SNP; Kelsey et al. 2011, 
Chapter 2, Section 2.4). In good agreement with these studies, it has also been reported 
that PCA and gallic acid display differential abilities to interact with lipid-rich 
environments and prevent lipid peroxidation dependent upon their relative lipophilicity 
(Brown and Kelly, 2007). These studies suggest that different anthocyanins, and likely 
their respective metabolites, may display distinct neuroprotective effects. 
Following the work of our previous study on the distinct neuroprotective effects 
of anthocyanins, we examine the differential neuroprotective effects of two phenolic 
acids, PCA, the primary metabolite of cyanidin-based anthocyanins, such as kuromanin, 
and 4-hydroxybenzoic acid (HBA), the primary metabolite of pelargonidin-based 
anthocyanins, such as callistephin. While the neuroprotective effects of PCA against a 
variety of stressors such as hydrogen peroxide and SNP have previously been 
investigated, the neuroprotective abilities of HBA have never been explored, and the anti-
inflammatory capabilities of these compounds have not yet been defined (An et al. 2006, 
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Guan et al. 2006a, Shi et al. 2006, Tarozzi et al. 2007). Moreover, to our knowledge, this 
is the first study to directly compare the neuroprotective and anti-inflammatory capacities 
of two distinct, but structurally similar phenolic acids (Fig. 4.1) in order to determine 
their potential efficacy for the treatment of neurodegenerative disease. Our results 
demonstrate that PCA and HBA display differential neuroprotective and anti-








Figure 4.1. Chemical structures of 4-hydroxybenzoic acid (left) and protocatechuic 






Protocatechuic acid was purchased from MP Biomedicals (Solon, OH). Potassium 
chloride, 4-hydroxybenzoic acid, glutamic acid, glycine, lipopolysaccharide (LPS) from 
E. coli, bovine serum albumin (BSA), paraformaldehyde, Hoechst 33258, and Tween 20 
were purchased from Sigma-Aldrich (St. Louis, MO). Sodium nitroprusside (SNP) was 
obtained from Calbiochem (San Diego, CA). Basal Medium Eagle’s solution, Dulbecco’s 
Modified Eagle’s Medium with glucose solution, L-glutamine solution, 
penicillin/streptomycin solution, and fetal bovine serum (FBS) were purchased from 
Invitrogen (Grand Island, NY) BCA protein assay kits, and Nitric Oxide Assay kits 
(EMSNO) were obtained from Thermo Scientific (Rockford, IL). Primary antibody to 
inducible nitric oxide synthase (iNOS) was purchased from Abcam (Cambridge, MA). 
Primary antibody to β-actin was purchased from Cell Signaling Technology (Danvers, 
MA). Secondary donkey anti-mouse and donkey anti-rabbit antibodies conjugated to 
horseradish peroxidase (HRP), polyvinylidene difluoride (PVDF) membranes and ECL 
reagents were purchased from Amersham Biosciences (Pittsburg, PA).   
 
4.3.2 Cell Culture 
CGNs were isolated from 7-day-old Sprague-Dawley rat pups of both sexes 
(Charles Rivers, location) as previously described (Linseman et al. 2001). Briefly, cells 
were plated in poly-L-lysine-coated 6-well plates (35mm-diameter) at a density of 
approximately 4.0x106 cells per well. Cells were maintained in Basal Medium Eagle’s 
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supplemented with 2mM L-glutamine, 25mM potassium chloride, 10% FBS, and 
penicillin/streptomycin (100U/mL/100μg/mL). After 24h, CGNs were treated with 
cytosine arabinoside at a concentration of 10μM to inhibit the growth of non-neuronal 
cells. CGN cultures were then maintained in 10% CO2
 at 37°C for 6-7 days before 
experiments were performed. This procedure produced cultures that were ~95% pure.  
BV2 microglia were maintained in Dulbecco’s Modified Eagle’s Medium 
containing 4.5g/L glucose and supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (100U/mL/100μg/mL). BV2 microglia were maintained in 5% 
CO2 at 37°C. For experiments, cells were plated in 6-well plates (35mm-diameter) and 
allowed to reach 80% confluency before treatment. 
 
4.3.3 Treatment of Cell Cultures 
Culture medium was removed and replaced with medium lacking fetal bovine 
serum to eliminate the neuroprotective effects of serum that might prevent neuronal 
apoptosis induced by neurotoxic insult. CGNs were then treated with 250μM hydrogen 
peroxide, 100μM SNP, or 100μM/10μM glutamate/glycine alone or in combination with 
the indicated doses of either PCA or HBA. CGNs were allowed to incubate under these 
conditions for 24h prior to assay of neuronal cell death. For all experiments, an untreated 
control in serum-free medium was used for comparison in assaying cell death. 
BV2 microglial cells were treated with LPS at a concentration of 1μg/mL alone or 
in combination with PCA or HBA at the indicated concentrations in cell culture medium. 
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Cells were allowed to incubate for 24h prior to cell lysis and assay of nitric oxide 
production. 
4.3.4 Assay of Neuronal Cell Death 
Following treatment, CGNs were washed twice with phosphate buffered saline 
(PBS, pH=7.4) and then fixed for 1h at room temperature with 4% paraformaldehyde. 
CGNs were then washed again with PBS and stained with Hoechst at a concentration of 
10μg/mL to visualize nuclear morphology. Cells were washed with PBS and imaged 
using a Zeiss Axiovert-200M epi-fluorescence microscope. Five bright field and five 
nuclear images per well were captured to assess cell death with duplicate wells for each 
treatment composing one experiment. Cells were counted and scored as either viable or 
apoptotic based on nuclear morphology using images showing decolorized Hoechst 
fluorescence. CGNs displaying nuclei with fragmented or condensed morphology were 
scored as apoptotic, with at least 100 cells per treatment per experiment being scored. 
 
4.3.5 Nitric Oxide Assay 
Nitric oxide production was assayed in cell culture medium from BV2 cells 
following treatment using a nitric oxide assay kit (EMSNO) from Thermo Scientific per 
the manufacturer’s instructions. This kit assays total concentrations of nitrite in solution, 
one of the major degradation products of nitric oxide, using the Griess method. The 
concentration of nitrite for each treatment was determined by comparison to a standard 
curve created using solutions of known nitrite concentrations, with each treatment being 




4.3.6 Cell Lysis and Western Blotting 
At 24h after treatment with LPS and either HBA or PCA, whole cell lysates from 
BV2 cells were prepared for Western blotting essentially as described by Loucks et al. 
(2006). Protein concentrations were determined for each lysate using a BCA protein 
assay kit from Thermo Scientific per the manufacturer’s instructions. SDS-PAGE was 
then performed using equal quantities of protein for each treatment, and proteins were 
then transferred to PVDF membranes for immunodetection. Membranes were then 
incubated in blocking solution composed of PBS with 0.1% Tween 20 (PBS-T) and 1% 
BSA for 1h at room temperature to block non-specific binding sites. Membranes were 
then incubated overnight in primary antibody prepared in blocking solution at 4°C. 
Following incubation, membranes were washed five times with PBS-T over the course of 
25min to remove excess primary antibody. Membranes were then incubated with the 
appropriate secondary HRP-conjugated antibodies prepared in PBS-T for 1h at room 
temperature. Excess secondary antibody was removed by washing the membranes with 
PBS-T as described above, and immunoreactive proteins were detected using enhanced 
chemiluminescence.  
 
4.3.7 Statistical Analysis 
All experiments in both CGNs and BV2 microglia were performed using 
duplicate wells with each experiment being performed at least three times. Data are 
represented as the mean ± standard error of the mean (SEM) for the total number of 
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experiments carried out (n). One-way analysis of variance (ANOVA) with a post hoc 




4.4.1 Both PCA and HBA Protect CGNs from Oxidative Stress Induced By 
Hydrogen Peroxide 
The role of oxidative stress has been extensively documented in several forms of 
neurodegenerative disease, and indices of oxidative damage have been observed in tissue 
from the brains and spinal cords of patients with Alzheimer’s disease, Parkinson’s 
disease and ALS (Lin and Beal 2006). Hydrogen peroxide (H2O2) in particular is thought 
to play a significant role in these diseases, as proteins such as amyloid beta, implicated in 
the pathogenesis of Alzheimer’s disease, and mutant SOD1, associated with familial 
forms of ALS, are known to mediate neuronal death in part through enhanced production 
of this toxic species (Tabner et al. 2005, Ferri et al. 2006). Therefore, we first evaluated 
the ability of PCA and HBA to protect CGNs from H2O2-induced toxicity.  
Alone, H2O2 induced significant levels of cell death, with approximately 80% of 
CGNs displaying fragmented and/or condensed nuclei as determined with Hoechst 
staining, which is consistent with apoptosis (Fig. 4.2A). Furthermore, H2O2 treatment 
caused significant degradation and fragmentation of neuronal processes in addition to 
shrinkage of neuronal cell bodies, also indicative of cell death.  This effect was abrogated 
by co-treatment of CGNs with either HBA or PCA, which preserved healthy nuclear 
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morphology comparable to that observed in untreated controls as well as preventing the 
degradation of neuronal processes (Fig. 4.2A). Quantification of these data revealed that 
these protective effects are dose dependent, with higher doses of both HBA and PCA 
offering greater neuroprotection (Fig. 4.2B, C).  Moreover, it was shown that PCA 
protects neurons more efficiently than HBA, demonstrating significant neuroprotection at 





Figure 4.2. Both HBA and PCA protect CGNs from H2O2-induced oxidative stress. 
A, Representative images of untreated control CGNs (Con), CGNs treated with H2O2 
alone (H2O2), and CGNs treated in combination with H2O2 and either 200μM 4-
hydroxybenzoic acid (HBA) or 200μM protocatechuic acid (PCA). Top panels show 
decolorized Hoechst fluorescence to visualize nuclei. Bottom panels show bright field 
images to visualize neuronal cell bodies and processes. Scale bar =10µm. B, Quantitative 
assessment of apoptosis in CGNs treated with H2O2 alone or in combination with various 
concentrations of HBA. C, Quantitative assessment of apoptosis in CGNs treated with 
H2O2 alone or in combination with various concentrations of PCA. For quantification, 
nuclear morphology was assessed, and cells displaying condensed or fragmented nuclei 
were scored as apoptotic. The percent of all total cells that displayed apoptotic 
morphology was then determined. Data are represented as mean ± SEM for n=3 
experiments. *** indicates p<0.001 in comparison to untreated controls, and ††† 
indicates p<0.001 and †† indicates p<0.01 in comparison to cells treated with H2O2 alone 





4.4.2 PCA, But Not HBA, Protects CGNs from Nitrosative Stress Induced by 
Sodium Nitroprusside 
Nitrosative stress is a condition similar to oxidative stress caused by a buildup of 
toxic RNS such as nitric oxide and peroxynitrite, which are capable of causing oxidative 
damage to many vital cellular components. S-nitrosylation of key cellular proteins 
involved in protein homeostasis and mitochondrial respiration have been described in the 
context of ALS and Parkinson’s disease respectively indicating a role for RNS in the 
underlying pathology of these diseases (Walker et al. 2010, Chinta and Andersen, 2011). 
Nitric oxide and peroxynitrite are produced in abundance during neuroinflammatory 
responses in the CNS by activated microglia and reactive astrocytes, which have been 
shown to play a critical role in the etiology and progression of several neurodegenerative 
diseases (Di Filippo et al. 2010). Thus, compounds that are effectively able to scavenge 
and detoxify RNS could be of significant therapeutic benefit for the treatment of 
neurodegeneration. Therefore, we next evaluated the ability of HBA and PCA to mitigate 
neurotoxicity induced by the nitric oxide donor, SNP. 
Treatment of CGNs with SNP alone produced substantial neuronal death, causing 
extensive nuclear condensation and almost complete obliteration of neuronal processes 
(Fig. 4.3A). Co-treatment with HBA was unable to attenuate this effect with these cells 
displaying nuclear morphology and fragmented processes similar to that of cells treated 
with SNP alone (Fig. 4.3A). In striking contrast to these results, PCA offered complete 
protection from this insult and preserved healthy nuclear morphology and neuronal 
processes (Fig. 4.3A).  Even at doses as low as 10μM, co-treatment with PCA provided 
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significant neuroprotection from nitric oxide-induced death, and this effect increased with 
PCA concentration, while HBA was unable to defend neurons from this insult at any of 






Figure 4.3. PCA, but not HBA, protects CGNs from nitric oxide-induced toxicity. A, 
Representative images of untreated control CGNs (Con), CGNs treated with SNP alone 
(SNP), and CGNs treated in combination with SNP and either 300μM 4-hydroxybenzoic 
acid (HBA) or 300μM protocatechuic acid (PCA). Top panels show decolorized Hoechst 
fluorescence to visualize nuclei. Bottom panels show bright field images to visualize 
neuronal cell bodies and processes. Scale bar =10µm. B, Quantitative assessment of 
apoptosis in CGNs treated with SNP alone or in combination with various concentrations 
of HBA. C, Quantitative assessment of apoptosis in CGNs treated with SNP alone or in 
combination with various concentrations of PCA. For quantification, nuclear morphology 
was assessed, and cells displaying condensed or fragmented nuclei were scored as 
apoptotic. The percent of all total cells that displayed apoptotic morphology was then 
determined. Data are represented as mean ± SEM for n=3 experiments. *** indicates 
p<0.001 in comparison to untreated controls, and ††† indicates p<0.001 and † indicates 
p<0.05 in comparison to cells treated with SNP alone by one-way ANOVA with a post 





4.4.3 HBA, But Not PCA, Protects CGNs from Glutamate-Induced Excitotoxicity 
Excitotoxicity is a process specific to neurons in which overstimulation by 
excitatory neurotransmitters, such as glutamate, causes massive calcium influx from the 
extracellular space, triggering the activation of a number of cell death cascades, such as 
calpain-dependent apoptosis (Wang and Qin, 2010). Additionally, disturbances in 
calcium homeostasis can cause membrane depolarization in mitochondria, resulting in 
enhanced production of ROS, and release of apoptogenic factors. Considerable evidence 
for the involvement of excitotoxicity in Alzheimer’s disease, Parkinson’s disease and 
ALS has accumulated and suggests that ameliorating excitotoxic effects could be a viable 
therapeutic approach to treating these diseases (Miguel-Hidalgo et al. 2002, Helton et al. 
2008, Parameshwaran et al. 2008, King et al. 2016). Thus, we examined the capacity of 
HBA and PCA to defend neurons from excitotoxic conditions induced by stimulation 
with the excitatory neurotransmitter, glutamate.  
When treated with glutamate alone, CGNs experienced approximately 50% cell 
death evidenced by nuclear condensation and fragmentation as well as moderate 
degradation of neuronal processes (Fig. 4.4A). HBA significantly protected CGNs from 
glutamate-induced excitotoxicity, preserving nuclear morphology and restoring neuronal 
processes (Fig. 4.4A). As with H2O2, this effect was dose dependent, with the greatest 
protection occurring with the highest dose of HBA examined in this experiment in direct 
contrast to PCA (Fig. 4.4B). Under these conditions, PCA displayed no neuroprotective 
effects, actually displaying a trend towards enhancing neuronal death induced by 
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glutamate excitotoxicity at higher concentrations, although this trend did not reach 






Figure 4.4. HBA, but not PCA, protects CGNs from glutamate-induced 
excitotoxicity. A, Representative images of untreated control CGNs (Con), CGNs treated 
with glutamate alone (G/G), and CGNs treated in combination with glutamate and either 
500μM 4-hydroxybenzoic acid (HBA) or 500μM protocatechuic acid (PCA). Top panels 
show decolorized Hoechst fluorescence to visualize nuclei. Bottom panels show bright 
field images to visualize neuronal cell bodies and processes. Scale bar =10µm. B, 
Quantitative assessment of apoptosis in CGNs treated with glutamate alone or in 
combination with various concentrations of HBA. C, Quantitative assessment of 
apoptosis in CGNs treated with glutamate alone or in combination with various 
concentrations of PCA. For quantification, nuclear morphology was assessed, and cells 
displaying condensed or fragmented nuclei were scored as apoptotic. The percent of all 
total cells that displayed apoptotic morphology was then determined. Data are 
represented as mean ± SEM for n=3 experiments. *** indicates p<0.001 and ** indicates 
p<0.01 in comparison to untreated controls, and ††† indicates p<0.001 in comparison to 




4.4.4 PCA, But Not HBA, Attenuates Lipopolysaccharide-Induced Microglial 
Inflammation in the BV2 Cell Line 
Microglia are the primary mediators of inflammatory immune responses in the 
CNS. While beneficial in the short term for neuronal protection and repair from foreign 
invaders, prolonged inflammation of these cells is neurotoxic and has been implicated as 
a major contributor to the neuronal death underlying neurodegenerative disease (Appel et 
al. 2011). Indices of microglial inflammation, such as enhanced production of 
inflammatory cytokines, induction of pro-inflammatory proteins such as COX-2 and 
inducible nitric oxide synthase (iNOS), and microglial proliferation have been described 
in Alzheimer’s disease, Parkinson’s disease, and ALS (Almer et al. 1999, Almer et al. 
2001, Hensley et al. 2003, Raoul et al. 2006, Heneka and O’Banion, 2007, Hirsch and 
Hunot, 2009, Di Filippo et al. 2010). Collectively these studies demonstrate that 
microglial inflammation is a significant feature of these diseases, making this facet of the 
neurodegenerative process an appealing therapeutic target. One of the many hallmarks of 
microglial inflammation is the up-regulation of iNOS and subsequent production of large 
quantities of nitric oxide (Brown and Neher, 2010). While the ability of potential 
therapeutic agents to directly scavenge nitric oxide is desirable, as discussed above for 
SNP, modulation of nitric oxide production and other inflammatory processes is likely to 
have greater therapeutic benefit overall. Therefore, we assessed the ability of HBA and 
PCA to alter nitric oxide production and iNOS induction in the BV2 microglial cell line 
following treatment with LPS. 
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LPS induced a significant inflammatory response in BV2 microglia marked by a 
considerable increase in nitric oxide production (Fig. 4.5A, C). This correlated with 
enhanced expression of iNOS in these cells (Fig. 4.5B, D). Co-treatment of BV2 cells 
with both LPS and PCA dose-dependently reduced nitric oxide production by a 
significant amount with corresponding decreases in iNOS protein levels (Fig. 4.5A, B). 
Co-treatment with HBA and LPS, however, did not produce a significant effect on 
microglial inflammation, with nitric oxide production and iNOS levels remaining largely 






Figure 4.5. PCA, but not HBA, attenuates inflammation induced by LPS in BV2 
microglia. A, Quantitative assessment of nitric oxide production in untreated, BV2 
microglia, and microglia stimulated with LPS alone or in combination with various 
concentrations of PCA. Nitric oxide production was determined using the Griess method 
to measure nitrite, a major degradation product of nitric oxide, in cell culture medium 
incubated with BV2 microglia. B, Representative western blots for iNOS (top panel) and 
β-actin loading control (bottom panel) in whole cell lysates from untreated BV2 
microglia, and microglia stimulated with LPS alone or in combination with various 
concentrations of PCA. C, Quantitative assessment of nitric oxide production by BV2 
microglia stimulated with LPS alone or in combination with various concentrations of 
HBA. Nitric oxide production was quantified as in (A). D, Representative western blots 
for iNOS (top panel) and β-actin loading control (bottom panel) in whole cell lysates 
from untreated BV2 microglia, and microglia stimulated with LPS alone or in 
combination with various concentrations of HBA. Data are represented as mean ± SEM 
for n=3 experiments for nitric oxide assay. iNOS blots represent n=1 experiment. *** 
indicates p<0.001, and * indicates p<0.05 in comparison to untreated controls, and † 
indicates p<0.05 in comparison to cells treated with LPS alone by one-way ANOVA with 






Diets rich in anthocyanins and other polyphenols are associated with a myriad of 
health benefits, including decreased risk of developing cancer, cardiovascular disease, 
and neurodegenerative disease, particularly Parkinson’s disease (Albarracin et al. 2011, 
Gao at al. 2012). As anthocyanins are known to mitigate multiple facets of the 
neurodegenerative process thought to contribute to neuronal cell death (reviewed by Ross 
et al. 2013), this finding is perhaps unsurprising; however current research suggests that it 
is likely anthocyanin metabolites produced after anthocyanin ingestion that are truly 
responsible for mediating these positive effects in vivo. We have previously compared the 
neuroprotective abilities of two anthocyanin species, callistephin and kuromanin, against 
mitochondrial oxidative stress, nitrosative stress, and excitotoxicity, and found that slight 
structural variances in anthocyanin structure significantly influence the neuroprotective 
capacity of these compounds against different neurotoxic insults (Kelsey et al. 2011, 
Chapter 2, Section 2.4).  Given these data in conjunction with the observation that 
phenolic acid metabolites from anthocyanins are likely responsible for mediating the 
beneficial effects of these compounds in vivo, it is equally important to determine if 
different anthocyanin metabolites display differential neuroprotective functions that may 
influence their overall effectiveness as potential therapeutic agents in neurodegenerative 
disease. However, while the neuroprotective capacity of some anthocyanin metabolites 
has been previously evaluated, a systemic comparison of the effects of phenolic acid 
metabolites from anthocyanins against a broad range of neurotoxic insults has never been 
conducted. Here, we evaluated the broad neuroprotective and anti-inflammatory effects 
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of two phenolic acid metabolites, HBA and PCA, which are derived from pelargonidin-
based and cyanidin-based anthocyanins respectively.  
Our results demonstrate that HBA and PCA display both similar and distinct 
neuroprotective effects against several neurotoxic stressors. While both compounds are 
capable of defending CGNs from H2O2-induced oxidative stress, consistent with previous 
studies conducted with PCA, their protective effects diverge in the context of nitrosative 
stress and glutamate excitotoxicity (An et al. 2006, Guan et al. 2006a, Shi et al. 2006, 
Tarozzi et al. 2007). In agreement with prior reports, PCA is a highly effective 
neuroprotective agent against nitric oxide-induced death following treatment with SNP 
(An et al. 2006). These results are in remarkable contrast to those observed for HBA, 
which demonstrate that this compound is incapable of mitigating nitric toxicity to any 
degree. Our previous work with kuromanin and callistephin, parent compounds of PCA 
and HBA respectively, also displayed this trend, with kuromanin protecting CGNs to a 
significant degree from SNP toxicity, while the closely related anthocyanin, callistephin, 
showed no effect on nitric oxide-induced death (Chapter 2, Section 2.4). This previous 
work also demonstrated that protection from nitric oxide by kuromanin appeared to be 
catechol-dependent, a structural feature that both kuromanin and its phenolic acid 
metabolite, PCA, share, but which is notably lacking from the structure of both 
callistephin and its metabolite, HBA (Fig. 4.1).  Thus, it is very likely that this slight 
structural difference between HBA and PCA that gives PCA a catechol moiety is 
responsible for their vastly different neuroprotective abilities against nitric oxide toxicity.  
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This trend appears to be reversed in the context of excitotoxicity. In CGNs 
stimulated with glutamate, HBA offered significant neuroprotection, while PCA 
treatment had no effect on neuronal viability against this insult. This result was 
unexpected as we have previously shown that both callistephin and kuromanin, two of the 
parent compounds of these phenolic acids, are potent inhibitors of excitotoxic cell death 
in CGNs (Chapter 2, Section 2.4).  Furthermore, it has been reported that PCA is capable 
of reducing increases in intracellular calcium concentrations in primary cortical neurons 
treated with amyloid-beta, which are thought to occur through activation of N-methyl-D-
aspartate (NMDA) receptors at the cell surface (Ban et al. 2007, Alberdi et al. 2010). As 
massive calcium influx through NMDA receptors is also a major feature of glutamate 
excitotoxicity, it is somewhat surprising that PCA does not protect CGNs from glutamate 
treatment. The possibility remains, however, that the protective effects of PCA on 
neuronal viability in the context of amyloid beta toxicity are due to mechanisms other 
than its ability to attenuate disruptions in calcium homeostasis. These mechanisms could 
be distinct from those observed under excitotoxic conditions, which could render PCA 
ineffective for alleviating excitotoxic stress. Alternatively, this could also suggest that the 
ability of PCA to regulate calcium homeostasis is not sufficient to protect CGNs from 
glutamate excitotoxicity. This then suggests two possible mechanisms to explain the 
ability of the closely related HBA to preserve neuronal viability following excitotoxic 
insult in contrast to PCA. One simple explanation for the differences observed between 
these compounds is that they may both regulate calcium homeostasis, but HBA may do 
so more effectively than PCA, which could in turn prevent activation of downstream pro-
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apoptotic signaling to a greater extent. Conversely, preservation of neuronal viability by 
HBA but not PCA could be reliant on the ability of HBA to activate pro-survival or 
inhibit pro-apoptotic signaling pathways involved in excitotoxic death, an ability that 
PCA may lack due to structural differences between these compounds. However, since 
neither PCA nor HBA has been examined for their neuroprotective effects against 
excitotoxicity until now, further exploration of this topic is needed to define the 
neuroprotective mechanism of HBA treatment under these conditions.  
Finally, we assessed the ability of these compounds to attenuate LPS-induced 
inflammation in the BV2 microglial cell line. Under inflammatory conditions, we again 
observed a stark difference between the abilities of HBA and PCA, with PCA acting in an 
anti-inflammatory capacity, while HBA treatment produced no effect on microglial 
inflammation. This was assessed by the ability of these compounds to reduce nitric oxide 
production and induction of iNOS, two hallmarks of microglia-mediated inflammation in 
the CNS (Brown and Neher, 2010). PCA effectively reduced nitric oxide production, 
which correlated with reduced protein levels of iNOS; however HBA had no effect on 
either nitric oxide production or iNOS expression. Intriguingly, another anthocyanin 
metabolite, gallic acid, has also been shown to reduce microglial inflammation in a 
similar manner, although the effects of PCA and HBA in BV2 microglia have not been 
evaluated until now. Reductions in inflammation by gallic acid were reported to prevent 
microglial-mediated toxicity in co-cultured neurons, suggesting that some anthocyanin 
metabolites may mediate neuroprotective effects in vivo through amelioration of 
microglial inflammation (Kim et al. 2011). Despite these observations, the mechanism 
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underlying PCA’s ability to attenuate neuroinflammatory responses in microglia is 
unknown; however, reductions in iNOS expression suggest that PCA may modulate 
regulators of the gene encoding iNOS, such as nuclear factor-κB. This phenomenon has 
been well-established in BV2 microglia treated with extracts rich in anthocyanins, which 
may share this ability with some phenolic acid metabolites. A lack of protection by HBA 
also suggests this mechanism as differences in structural features between HBA and PCA 
may allow them to regulate different signaling pathways, as suggested above.  
Nevertheless, further study is needed to confirm or refute this hypothesis.  
Collectively, these data highlight the intriguing neuroprotective and anti-
inflammatory differences in anthocyanin metabolites, while also indicating some 
limitations of these compounds to mitigate various factors involved in the 
neurodegenerative process. For example, while both HBA and PCA may effectively 
target toxicity induced by ROS, only PCA targets microglial inflammation and nitrosative 
stress, and only HBA targets excitotoxicity. However, the ideal therapeutic candidate for 
the treatment of neurodegeneration would target all four of these aspects of disease. It is 
interesting to note, then, that PCA and HBA display complimentary effects, suggesting 
that combination treatment with both of these agents may be an effective therapeutic 
strategy to target a broader range of factors involved in the neurodegenerative process, 
which could produce greater therapeutic effects in preclinical models of 
neurodegenerative disease than administration of either compound alone.  This is a 
particularly appealing strategy in light of several recent in vivo studies demonstrating that 
supplementation with PCA alone is an effective therapeutic treatment in mouse models of 
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Parkinson’s disease, Alzheimer’s disease, and D-galactose-induced accelerated aging 
(Zhang et al. 2010, Tsai and Yin, 2012, Song et al. 2014).  Finally, it is important to note 
that although they are discussed here in the context of anthocyanin metabolism, both 
HBA and PCA can be produced by the metabolism of other polyphenolic species. As the 
neuroprotective and anti-inflammatory effects of these compounds appear to be dose-
dependent, identifying parent compounds that can be metabolized to produce greater 
concentrations of PCA and HBA than anthocyanins in vivo could be an effective strategy 
for identifying new therapeutic candidates for testing in preclinical models of disease.  
In summary, both HBA and PCA display distinct neuroprotective effects in vitro 
in primary CGNs, suggesting that these compounds warrant further exploration both 
alone and in combination to further define their neuroprotective and anti-inflammatory 
mechanisms under diverse stress conditions.  Moreover, further exploration of these 
compounds in preclinical models of disease is warranted as both compounds target 
multiple aspects of neurodegenerative disease pathology. In particular, the use of HBA 
and PCA in combination could be of great therapeutic potential owing to the diverse and 
complimentary neuroprotective effects of these compounds against oxidative stress, 









CHAPTER FIVE: PROTOCATECHUIC ACID, AN ANTHOCYANIN 
METABOLITE, EXTENDS LIFESPAN AND PRESERVES GRIP STRENGTH IN 
THE HSOD1G93A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS 
 
5.1 Abstract 
Amyotrophic lateral sclerosis (ALS) is a malicious neurodegenerative disease 
characterized by the progressive loss of motor neurons in the brain and spinal cord. 
However, despite significant advances in our understanding of ALS pathology, the 
underlying cause of the disease remains unknown, and treatments for the disease are 
scarce. In recent years, abundant evidence demonstrating the complex nature of the 
disease has emerged, and several factors are thought to contribute to motor neuron death. 
Thus, therapeutic strategies for this disease have begun to focus on the identification of 
agents that target multiple facets of disease pathology. In particular, nutraceutical 
compounds, such as anthocyanins, have shown great promise as neuroprotective and 
therapeutic agents in preclinical models of neurodegenerative disease, stroke, and aging, 
which share common pathological features with ALS. However, the bioavailability of 
anthocyanins in vivo is relatively low, leading investigators to suggest that the beneficial 
effects of anthocyanin supplementation are likely due to the activity of anthocyanin 
metabolites, and not the parent compounds themselves. We have previously shown that 
an anthocyanin-enriched extract from strawberries produces significant therapeutic 
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benefits in the transgenic G93A mutant human Cu, Zn-superoxide dismutase 
(hSOD1G93A) mouse model of ALS; however the therapeutic potential of direct 
supplementation with anthocyanin metabolites has never been examined. Therefore, we 
evaluated the effects of supplementation with a major anthocyanin metabolite, 
protocatechuic acid (PCA), on ALS disease progression. We show that supplementation 
with PCA beginning at disease onset significantly extends lifespan and preserves skeletal 
muscle function in hind limbs of hSOD1G93A mice. These preliminary data suggest that 
PCA may be a viable therapeutic agent for the treatment of ALS and related diseases, 
although further research is needed to evaluate the effects of PCA administration on 
histopathological indices of disease. 
 
5.2 Introduction 
Amyotrophic lateral sclerosis (ALS) is the most common adult onset motor 
disease and is marked by progressive weakness, loss of motor function and coordination, 
muscle atrophy, and paralysis. These characteristics of the disease are due to the death of 
motor neurons in the brain, brain stem and spinal cord, leading to a loss of muscle 
innervation. ALS is inevitably fatal, and patients usually experience death 2-5 years 
following their diagnosis due to respiratory failure. While our understanding of ALS 
pathogenesis has grown, and genetic causes for familial forms of the disease have been 
identified, a cause for the vast majority of sporadic ALS cases is unknown. This has 
made designing effective therapeutic agents for ALS exceedingly difficult; however 
several factors contributing to the death of motor neurons in this disease have been 
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identified, and may represent effective therapeutic targets for future treatment 
development. Specifically, the roles of oxidative stress, nitrosative stress, excitotoxicity, 
and neuroinflammation are currently topics of intense focus in ALS research due to 
accumulating evidence that these factors all contribute to motor neuron death and disease 
progression (Carri et al. 2015, Hooten et al. 2015, King et al. 2016). Oxidative stress is a 
prominent feature of ALS and is thought to occur due to a combination of enhanced 
reactive oxygen species production by damaged mitochondria and reductions in 
endogenous antioxidant defenses (Carri et al. 2015). Accumulation of free radicals and 
other oxidative species then causes significant damage to vital cellular components such 
as lipid membranes and DNA. Similarly, nitrosative stress occurs when reactive nitrogen 
species generation is elevated, particularly under conditions of neuroinflammation, and 
contributes to nitrosative modification of important cellular components, such as those 
involved in protein homeostasis (Walker et al. 2010, Hooten et al. 2015). 
Neuroinflammation is mediated primarily by microglia surrounding motor neurons, 
which become chronically enflamed and adopt a neurotoxic phenotype as ALS 
progresses in which they secrete large quantities of pro-inflammatory cytokines, 
chemokines, and nitric oxide (Hooten et al. 2015). Lastly, excitotoxicity occurs as a result 
of over-stimulation with excitatory neurotransmitters, particularly glutamate, causing 
calcium influx into post-synaptic cells, activation of apoptotic signaling pathways, and 
ultimately neuronal death (King et al. 2016). Enhanced glutamate release, and impaired 
glutamate clearance from the synaptic cleft are observed ALS patients and mouse models 
of ALS, indicating a role for this phenomenon in ALS pathogenesis (Rothstein et al. 
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1995, Fray et al. 1998, Sasaki et al. 2000, Allaman et al. 2011, Milanese et al. 2011, 
Giribaldi et al. 2013). With the complexity of this disease in mind, a growing consensus 
has emerged that effective therapeutic strategies for disease treatment should target 
multiple facets of ALS disease pathology.  
Several trials have been conducted with agents, such as vitamin E, an antioxidant, 
olesoxime, a mitochondrial protectant, and Riluzole, an anti-glutamatergic, that target one 
significant aspect of disease pathology, and while these potential therapeutics showed 
promising results in preclinical trials, their effects in the clinic were only modest at best 
(Graf et al. 2005, Miller et al. 2012, Lenglet et al. 2014). Indeed, of these agents, only 
Riluzole has shown any true clinical efficacy, although its overall effect on disease 
progression is very small, extending lifespan by 2-3 months (Miller et al. 2012). The 
failure of these treatments highlights the need for new therapeutic agents that display 
pleiotropic effects and target multiple disease pathways. 
Recently, anthocyanins have emerged as novel therapeutic agents in preclinical 
studies of neurodegeneration, and clinical studies of mild cognitive impairment. These 
flavonoid compounds, found abundantly in many types of berries, have garnered 
significant attention for several reasons. First and foremost, anthocyanins are among the 
most commonly consumed polyphenolic species in the western diet, making them an 
appealing dietary supplement for a variety of health disorders (Scalbert and Williamson, 
2000). Secondly, anthocyanins have been shown to have impressive neuroprotective and 
anti-inflammatory properties that make them well-suited as potential therapeutics for 
neurodegenerative diseases (reviewed by Ross et al. 2013).  In vivo studies have revealed 
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that anthocyanins display significant antioxidant and anti-inflammatory activities in 
models of carbon tetrachloride-induced cognitive impairment and LPS-induced 
inflammation, respectively (Dani et al. 2008, Wang et al. 2010). Moreover, several 
studies have examined the neuroprotective effects of these unique compounds in the 
context of NMDA-induced excitotoxicity as well as models of Parkinson’s disease and 
Alzheimer’s disease and discovered that anthocyanins are capable of limiting oxidative 
damage and activating pro-survival signaling pathways in these paradigms (Matsunaga et 
al. 2009, Kim et al. 2010, Roghani et al. 2010, Shih et al. 2010, Qin et al. 2013, 
Vepsäläinen et al. 2013). However, while these studies are promising, they do not take 
into account that the relative bioavailability of anthocyanins in vivo is quite low due to 
the rapid metabolism of these compounds following ingestion (Fleschhut et al. 2006, 
Woodward et al. 2009, Woodward et al. 2011, Forester and Waterhouse, 2010). This has 
led investigators to speculate that anthocyanins themselves likely contribute very little to 
the beneficial health effects associated with an anthocyanin-rich diet, suggesting instead 
that anthocyanin metabolites are responsible for these positive findings (Vitaglione et al. 
2007). 
 Several phenolic acid metabolites are derived from anthocyanins by degradation 
of the parent compounds by gut microflora (Fleschhut et al. 2006, Woodward et al. 2009, 
Woodward et al. 2011, Forester and Waterhouse, 2010). Among these, the compound 
protocatechuic acid (PCA) has begun to garner recent attention as an effective 
neuroprotective agent. PCA is a prevalent anthocyanin metabolite, and is observed at 
concentrations up to eight times higher than that of its parent compounds in the blood 
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following anthocyanin ingestion (Azzini et al. 2010). It has also been shown to remain in 
tissue for longer periods of time than anthocyanins, suggesting that it may be among the 
bioactive components of an anthocyanin-rich diet (Tsuda et al. 1999). This is supported 
by reports that PCA displays potent neuroprotective abilities against oxidative stress 
induced by hydrogen peroxide and nitric oxide toxicity induced by sodium nitroprusside 
(An et al. 2006, Guan et al. 2006a, Shi et al. 2006, Tarozzi et al. 2007). We have also 
shown that PCA possesses anti-inflammatory effects in a microglial cell line treated with 
LPS, an in vitro model of neuroinflammatory microglia, which are observed in ALS 
(Chapter 4, Section 4.4.4).  Furthermore, our work demonstrated that higher doses of 
PCA offered greater neuroprotection against oxidative and nitrosative stress as well as 
microglial inflammation, suggesting that direct supplementation with PCA at higher 
concentrations than those observed following anthocyanin metabolism may be a more 
effective therapeutic strategy than treatment with the parent compounds (Chapter 4, 
Section 4.4). It is also important to note that PCA is a major metabolite of other 
polyphenols, such as procyanidins and other flavonoid species, making it a prevalent 
component of polyphenol-rich diets. Collectively, these data suggest that PCA 
supplementation may be a viable therapeutic strategy for the treatment of diseases like 
ALS for which conditions of oxidative and nitrosative stress, and neuroinflammation are 
major contributing factors. Thus, we examined the beneficial effects of PCA 
supplementation on the transgenic G93A mutant human Cu, Zn-superoxide dismutase 
(hSOD1G93A) mouse model of ALS. Our preliminary results indicate that PCA may be a 




5.3.1 hSOD1G93A  Mouse Model of ALS 
All procedures were performed in accordance with a protocol approved by the 
institutional animal care and use committee (IACUC) at the University of Denver. Mice 
harboring a human transgene coding for SOD1 with a glycine to alanine substitution at 
position 93 on an FVB/J background were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Mice were bred on an FVB/NJ background. Breeding and maintenance of 
all mice took place at the University of Denver animal facility. Mice were kept under a 
standard 12-hour night and day cycle with chow and water provided ad libitum. Mice 
were genotyped by a third party company, Transnetyx Inc. (Cordova, TN), to identify 
transgenic animals. 
Mice were divided into three groups: non-transgenic wild type controls (WT), 
untreated hSOD1G93A transgenic mice, and hSOD1G93A mice receiving PCA 
supplementation (MP Biomedicals, Solon, OH). Each group consisted of seven mice, 
with roughly equal numbers of males and females in each group. Each set of mice was 
composed of age and sex-matched littermates to ensure accurate comparison of clinical 
indices of disease and survival across the three groups. Those mice that received PCA 
supplementation were dosed once daily by oral gavage with 0.25mL of a PCA solution 
prepared in sterile drinking water at a dose of 100mg/kg beginning at 90 days of age, 
which coincides with the average age of disease onset for this model (Ross et al. 2014). 
Treatment with PCA proceeded until mice had reached end-stage of disease, at which 




5.3.2 Clinical Tests 
Hind limb grip strength was assessed using the paw grip endurance (PaGE) test as 
previously described by Weydt et al (2003). Mice were placed on top of a standard wire 
cage lid and allowed to acclimate before the lid was inverted in one smooth motion, 
prompting the mice to grip the wire with their fore and hind limbs. The lid was then 
suspended a few inches above the bench top, and the time at which mice released their 
grip on the cage lid with their hind limbs was determined using a stopwatch. Mice were 
monitored for a maximum of 30s, or until their hind limbs detached from the wire, and 
this time was recorded as latency to fall. Each mouse was given three scored attempts, 
and final scores are reported as the average of these attempts ± standard error of the mean 
(SEM) for each of the indicated time points. PaGE testing was performed twice weekly, 
and time points correspond to the age of the animals at testing. Time points are 
represented as a range of five days due to the fact that several groups of mice having 
slightly different ages were tested concomitantly. Body weight was also measured 
immediately following PaGE testing for each individual mouse.    
For the duration of the study, mice were monitored on a daily basis for signs of 
progressive motor deficits. When mice reached end-stage of disease, defined as the point 
at which a mouse placed on its side failed to right itself to a sternal position within 20s, 
they were euthanized. Euthanasia was performed by exposing the animals to inhaled 




5.3.3 Statistical Analysis 
Kaplan-Meier curves were analyzed using a Mantel-Cox log rank test. PaGE and 
weight data were analyzed using one-way analysis of variance (ANOVA) with a post hoc 
Tukey’s test for each time point. For all analyses, differences were statistically significant 
when p<0.05.  
 
5.4 Results 
5.4.1 Administration of PCA at Disease Onset Extends Survival in the hSOD1G93A 
Mouse Model of ALS 
The potential therapeutic efficacy of PCA supplementation was first examined by 
evaluating its effect on survival in the hSOD1G93A mouse model of ALS. Mice were 
administered PCA at a dose of 100mg/kg (assuming an average body weight of 25g) 
beginning at 90 days of age, which coincides on average with the first clinical signs of 
disease onset (Ross et al. 2014). At this age, hSOD1G93A mice typically display beginning 
signs of muscle weakness, presenting as trembling in the hind limbs and failure to fully 
extend one or both hind limbs when the mouse is suspended by its tail (Gurney et al. 
1994, Ludolph et al. 2007, Scott et al. 2008). Under this treatment paradigm, mice 
receiving PCA experienced a dramatic extension in survival over their untreated 
hSOD1G93A counterparts (Fig. 5.1). Indeed, PCA-treated mice displayed a mean survival 
of 140.5 ± 4.3 days while untreated hSOD1G93A mice experienced a mean survival of 
122.8 ± 2.9 days. While preliminary, these data represent a significant alteration in 






Figure 5.1. Administration of PCA at disease onset extends survival in the 
hSOD1G93A mouse model of ALS. Administration of PCA beginning at 90 days of age 
significantly extended the lifespan of hSOD1G93A mice in comparison to untreated 
hSOD1G93A controls. Curves are significantly different as determined by a Mantel-Cox 
Log Rank test (p<0.01, n=6).  
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5.4.2 Administration of PCA at Disease Onset Preserves Grip Strength, But Does 
Not Affect Body Weight in the hSOD1G93A Mouse Model of ALS 
In addition to studying the effects of PCA on survival, the effects of this 
compound on hind limb strength and function were also assessed as measures of quality 
of life. Intriguingly, at 90 days of age, both untreated and treated hSOD1G93A mice 
already displayed marked reductions in hind limb grip strength in comparison to WT 
controls. However, as the study progressed, untreated hSOD1G93A mice experienced 
continuing decline in grip strength as assessed by PaGE testing while mice receiving 
PCA maintained grip strength comparable to that observed at 90 days of age well into the 
disease course (Fig. 5.2A). Specifically, mice treated with PCA showed significantly 
higher grip strength than untreated hSOD1G93A mice from 95-114 days of age before 
experiencing declines in hind limb muscle strength and function.  
Declines in body weight beginning at disease onset are a major characteristic of 
the hSOD1G93A mutant mouse model of ALS, so we next evaluated the ability of PCA to 
attenuate weight loss in this model. Both untreated hSOD1G93A mice and mice receiving 
PCA supplementation displayed steady reductions in body weight as the disease 
progressed in comparison to WT controls (Fig. 5.2B). No significant differences were 





Figure 5.2. Administration of PCA at disease onset preserves hind limb grip 
strength in the hSOD1G93A mouse model of ALS. A, Paw grip endurance (PaGE) 
testing. PaGE testing was conducted twice weekly beginning at 90 days of age. Each 
mouse received three scored attempts for each time point, expressed as latency to fall. B, 
Body weight of WT and hSOD1G93A mice. Body weight was measured twice weekly 
immediately following PaGE testing, and is expressed as the percent of peak body weight 
for each time point. All data are expressed as mean ± SEM for each time point, n=7. *** 
indicates p<0.001, and * indicated p<0.05 in comparison to non-transgenic wild type 
(WT) controls. †† indicates p<0.01 and † indicates p<0.05 in comparison to untreated 
hSOD1G93A controls. All data were analyzed using one-way ANOVA with a post hoc 




Oxidative and nitrosative stress as well as neuroinflammation are major features 
of ALS disease pathology, and have been described in both patient tissue and several 
animal models of this disease. In particular, it has been noted that there are significant 
reductions in endogenous anti-oxidant defenses, such as glutathione, in patient blood and 
cortex, while lipid peroxidation and oxidative DNA damage are enhanced (Bogdanov et 
al. 2000, Simpson et al. 2004, Babu et al. 2008, Weiduschat et al. 2014). Furthermore, it 
has been reported that S-nitrosylation of key proteins involved in protein homeostasis, 
such as protein disulfide isomerase, are elevated in patient spinal cord tissue, highlighting 
the role of nitrosative damage in this disease (Walker et al. 2010). Elevations in oxidative 
damage are thought to be due in part to mitochondrial dysfunction, causing large 
increases in the production of toxic species such as superoxide, an assertion supported by 
the observation that mitochondrial redox status can be altered by mutant forms of SOD1 
(Ferri et al. 2006). Moreover, activity of pro-oxidant enzymes such as NADPH-oxidase-2 
(NOX-2) are increased in microglia from spinal cord tissue in both ALS patients and a 
mouse model of the disease, suggesting that oxidative damage in motor neurons can be 
attributed to both cell-autonomous and non-cell-autonomous mechanisms (Wu et al. 
2006). 
Markers of neuroinflammation are also observed at elevated levels in 
cerebrospinal fluid from ALS patients and spinal cord tissues from ALS mouse models. 
Pro-inflammatory cytokines such as tumor necrosis factor-α and Fas ligand have both 
been observed at elevated levels, as have pro-inflammatory enzymes such as 
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cyclooxygenase-2 and inducible nitric oxide synthase (iNOS; Almer et al. 1999, Almer et 
al. 2001, Hensley et al. 2003, Raoul et al. 2006). It has also been reported that glia-
specific knockout of mutant SOD1 in mutant mouse models of ALS, which attenuates the 
inflammatory phenotype of microglia and astrocytes, is neuroprotective, providing 
compelling evidence for the role of neuroinflammation in this disease (Beers et al. 2006, 
Boilée et al. 2006, Yamanaka et al. 2008, Wang et al. 2011).  
In light of the growing consensus that targeting multiple facets of ALS disease 
pathology may provide better clinical benefits than targeting any one aspect in particular, 
we previously explored the therapeutic efficacy of treating hSOD1G93A mice with an 
anthocyanin-enriched extract from strawberries (Chapter 3). Anthocyanins are best 
known for their high levels of intrinsic antioxidant activity, which has been used in part 
to explain their impressive neuroprotective effects, though recently, their anti-
inflammatory activity in microglia has also been described (Lau et al. 2007, Shih et al. 
2007, Zafra-Stone et al. 2007, Zhu et al. 2010, Hwang et al. 2011, Carey et al. 2013, 
Poulose et al. 2012, Jeong et al. 2013). In good agreement with these data, we found that 
anthocyanins displayed a marked trend towards preserving motor neuron viability in 
spinal cord tissue from hSOD1G93A mice. This trend correlated with significant reductions 
in the presence of reactive astrocytes in spinal cord and preservation of healthy 
neuromuscular junctions in hind limb muscle tissue. Moreover, mice receiving 
anthocyanin supplementation experienced both a significant delay in disease onset and 
corresponding extension in lifespan (Chapter 3, Section 3.4). This supports the idea that 
targeting multiple aspects of disease pathology, particularly oxidative stress and 
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neuroinflammation, is an efficacious therapeutic strategy. However, it is of utmost 
importance to note that the beneficial effects of anthocyanins in vivo are now generally 
believed to be due to activity of anthocyanin metabolites rather than the parent 
anthocyanin compounds. Indeed, one report indicated that up to 73% of cyanidin-based 
anthocyanins are converted to PCA shortly after human ingestion, and circulating 
concentrations of this compound far exceeded that of the parent anthocyanins (Vitaglione 
et al. 2007). Additionally, our previous work with PCA has indicated that this compound 
retains some of the neuroprotective and anti-inflammatory activity of its parent 
compounds in vitro, and that these effects are dose dependent (Chapter 4, Section 4.4). 
Thus, it was of great interest to assess the therapeutic benefit of direct PCA 
supplementation in the hSOD1G93A mouse model to determine if this compound shows 
similar or greater preclinical efficacy than its parent anthocyanin compounds. 
Our preliminary data indicate that administration of PCA at disease onset 
significantly extends the lifespan of hSOD1G93A mice in comparison to their untreated 
counterparts. Additionally, we found that PCA administration significantly preserved 
hind limb grip strength well into the disease course, consistent with a slowing in disease 
progression. However, PCA supplementation did not significantly impact alterations in 
body weight throughout the disease course. It has been reported that parent anthocyanins 
are capable of promoting weight loss in this manner, although the influence of PCA on 
weight has not been examined (Prior et al. 2008, Tsuda 2008). Thus, it is possible that the 
lack of effect on body weight by PCA could be due to reductions in overall body fat 
while lean muscle mass is preserved to some extent. While preliminary, these data are 
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very promising for the preclinical efficacy of this compound for treating ALS and support 
previous findings demonstrating that PCA is an effective therapeutic agent in other 
preclinical models of neurodegenerative disease and aging. In the MPTP mouse model of 
Parkinson’s disease, for example, PCA was shown to have neuroprotective effects on 
dopaminergic neurons in the substantia nigra (Zhang et al. 2010). Similarly, in mouse 
models of aging and Alzheimer’s disease, PCA was shown to decrease markers of 
oxidative damage in addition to reducing expression of several pro-inflammatory factors, 
likely associated with astroglial or microglial activity (Tsai and Yin, 2012, Song et al. 
2014). Together with our data, these findings suggest that PCA may show similar results 
to that of its parent anthocyanin compounds on motor neuron survival and proliferation of 
reactive astrocytes when histopathological indices of disease are measured, although 
further study is needed to confirm these hypotheses.  
Another important factor when evaluating the potential therapeutic efficacy of 
PCA is the timing of administration. While it is common place to perform preclinical 
studies in the hSOD1G93A mouse model of ALS using a presymptomatic dosing strategy 
so as not to rule out promising therapeutic candidates (Leitner et al. 2009), this paradigm 
does not translate well to clinical practices for ALS patients. Because the large majority 
of ALS patients cannot seek treatment until the onset of symptoms, administration of 
therapeutic agents is often impossible at presymptomatic stages of the disease. Thus, it is 
becoming a more common practice to test potential therapeutic candidates at disease 
onset, as this methodology more closely resembles clinical practices. However, many 
therapeutic candidates that show preclinical benefits in the hSOD1G93A mouse model at 
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presymptomatic stages of the disease are not effective when administered at disease 
onset. As such, it is very encouraging to note that PCA shows a relatively large effect on 
survival and grip strength when administered at disease onset, although these data are 
preliminary. In the future it will be of considerable interest to determine if this effect 
retains significance as more mice are assessed. It will also be of significant value to 
determine the effects of PCA supplementation on histopathological indices of ALS to 








CHAPTER SIX: CONCLUSIONS AND FUTURE DIRECTIONS 
The use of anthocyanins and their metabolites as therapeutic agents in several 
preclinical models of neurodegenerative disease and aging has grown substantially in 
recent years, and yielded promising results for the preclinical efficacy of these 
compounds. However, a systematic comparison of the neuroprotective effects of 
anthocyanins and their metabolites has not been conducted until now despite reports that 
distinct anthocyanins and phenolic acids display significant differences in their ability to 
act in various biological systems, such as lipid-rich environments and membranes 
(Youdim et al. 2003, Brown and Kelly, 2007, Faria et al. 2014). Furthermore, although 
positive results for the use of anthocyanins and their metabolites have been observed in 
other disease models, their preclinical efficacy in the context of ALS has not been 
explored until now. Thus, the principle goal of this dissertation was to examine the 
potential of anthocyanins and their metabolites as therapeutic candidates for the treatment 
of ALS. To accomplish this task, anthocyanins and anthocyanin metabolites were first 
examined in vitro to establish their neuroprotective characteristics before further 
evaluation in vivo in the hSOD1G93A mouse model of ALS. The major findings of these 




6.1 Summary of Major Findings 
Previous work in our lab studied the neuroprotective effects of two structurally 
similar but distinct anthocyanin species, callistephin and kuromanin, against 
mitochondrial oxidative stress induced by inhibition of the pro-survival protein, Bcl-2 
(Kelsey et al. 2011). These data demonstrated that both anthocyanins under investigation 
displayed similar neuroprotective effects under these treatment conditions. Given these 
encouraging results, we wished to elaborate upon these findings by further characterizing 
the neuroprotective effects of callistephin and kuromanin against other neurotoxic insults. 
Our results, detailed in Chapter 2, revealed that while both anthocyanins were able to 
potently inhibit the neurotoxic effects of glutamate excitotoxicity, only kuromanin was 
able to protect primary cerebellar granule neurons (CGNs) from nitric oxide toxicity. 
Further examination of the mechanism underlying this effect revealed that the 
neuroprotective abilities of kuromanin were dependent upon the catechol moiety located 
on the B-ring of this anthocyanin, which is notably lacking in the closely related 
anthocyanin, callistephin. Furthermore, we demonstrate that this effect is dependent on 
generation of superoxide through auto-oxidation and possible redox cycling of this 
catechol structure, defining a highly unique and novel mode of neuroprotection for 
kuromanin and its related compounds.  
Since we observed positive neuroprotective effects in both our previous studies, 
and those detailed in Chapter 2, we next assessed the therapeutic benefit of anthocyanin 
treatment in the hSOD1G93A mouse model of ALS. This study was the first to appraise the 
therapeutic efficacy of anthocyanin supplementation in a model of ALS, and yielded 
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highly encouraging results. Mice that received anthocyanin supplementation beginning at 
a presymptomatic age displayed a significant delay in disease onset with a corresponding 
extension in survival. Furthermore, testing of hind limb grip strength was used as a 
measure of muscle function, and by extension, quality of life. Testing showed that 
supplementation with anthocyanins preserved grip strength well into the disease course in 
comparison to hSOD1G93A mice that did not receive anthocyanins. These findings 
correlated with the observation that untreated hSOD1G93A mice showed a trend towards 
decreased numbers of viable motor neurons in addition to a marked increase in the 
number of reactive astrocytes in lumbar spinal cord tissue. These effects were reversed by 
treatment with anthocyanins. Lastly, the health of neuromuscular junctions (NMJs) was 
evaluated. Mice receiving anthocyanin supplementation displayed NMJs with an average 
size and morphology that was comparable to that of non-transgenic wild type (WT) 
controls, whereas untreated hSOD1G93A mice experienced marked reductions in the size 
of NMJs as well as fragmented morphology characteristic of NMJ deterioration. These 
results suggest that anthocyanins may be effective therapeutic agents for the treatment of 
ALS.  
Nevertheless, reports that the relative bioavailability of anthocyanins in vivo is 
quite low prompted us to consider the hypothesis that the beneficial effects of 
anthocyanin supplementation are due to the activity of anthocyanin metabolites, rather 
than the activity of the parent compounds. With this in mind, we next explored the 
neuroprotective and anti-inflammatory activity of the anthocyanin metabolites, 4-
hydroxybenzoic acid (HBA) and protocatechuic acid (PCA), derivatives of callistephin 
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and kuromanin, respectively. The results of this study, discussed in Chapter 4, 
demonstrated that, like their parent compounds, HBA and PCA displayed neuroprotective 
effects that were both similar and distinct. While both HBA and PCA protected primary 
CGNs from oxidative stress induced by hydrogen peroxide, only HBA was able to defend 
neurons from glutamate excitotoxicity. In contrast, under conditions of nitric oxide 
toxicity and neuroinflammation, HBA had no effect while treatment with PCA protected 
CGNs from nitric oxide generated by a nitric oxide donor, and reduced levels of nitric 
oxide and inducible nitric oxide synthase (iNOS) expression in BV2 microglial cells. 
These results were intriguing from the standpoint that these two compounds display 
complimentary effects against these various neurotoxic insults. Thus, although both are 
effective neuroprotective agents individually, HBA and PCA may display even greater 
neuroprotective effects when administered in tandem.  
As anthocyanin metabolites proved to be effective neuroprotective agents in vitro, 
we next sought to determine the preclinical value of these compounds in the treatment of 
ALS, which is discussed in Chapter 5. In particular, PCA was selected for further study 
as this compound is one of the most common anthocyanin metabolites generated in 
mammalian systems, and it has been shown to have a positive impact in animal models of 
Parkinson’s disease, Alzheimer’s disease, and aging (Zhang et al. 2010, Tsai and Yin, 
2012, Song et al. 2014). Preliminary data collection revealed that hSOD1G93A mice 
receiving PCA supplementation beginning at disease onset displayed a marked extension 
in survival. Moreover, PCA treatment appeared to halt declines in hind limb grip 
strength, maintaining muscle function at a relatively steady level well into the disease 
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course. In comparison, untreated hSOD1G93A mice experienced steady declines in grip 
strength throughout the disease course. Though preliminary, these data are incredibly 
promising for the preclinical efficacy of PCA, and are the first to demonstrate that this 
anthocyanin metabolite may show potential as a therapeutic agent for ALS. A complete 
summary of the therapeutic potetial of each treatment tested within the scope of this work 




Table 6.1. Summary of the Neuroprotective, Anti-inflammatory, and Therapeutic 
Effects of Anthocyanins and Their Metabolites. The in vitro neuroprotective and anti-
inflammatory effects and the in vivo preclinical benefits of treatment with the 
anthocyanins and anthocyanin metabolites discussed in this dissertation are summarized. 
+ indicates a positive/protective effect and – indicates no effect on the indicated stesses or 
clinical index of disease that were examined. ND (not determined) indicates that a 
particular insult or clinical index was not examined for a treatment. 
 









SAE ND - + ND 
BAE ND + + ND 
Callistephin ND - + ND 
Kuromanin ND + + ND 
HBA + - + - 
PCA + + - + 








SAE + + + - + 




6.2 Considerations for Anthocyanins and Their Metabolites as Therapeutic Agents 
in ALS 
Although the data presented herein are promising with regards to the use of both 
anthocyanins and their metabolites for ALS, several considerations must be taken into 
account when choosing a compound for further preclinical and clinical development. 
These include the relative neuroprotective abilities of these compounds, their availability 
and absorption in relevant tissues, and the timing and route of treatment administration. 
Additionally, other considerations beyond targeting neuroprotection in the CNS must also 
be evaluated when predicting the preclinical and clinical efficacy of these compounds. 
 
6.2.1 Implications of Differential Neuroprotective and Anti-inflammatory Effects of 
Anthocyanins and Their Metabolites 
The anthocyanins kuromanin and callistephin, as well as their metabolites PCA 
and HBA, are potent antioxidants that are able to defend primary cultures of CGNs from 
oxidative stress (Kelsey et al. 2011, Chapter 4, section 4.4.1). However, as illustrated in 
Chapters 2 and 4, subtle variations in the structure of anthocyanins and their metabolites 
have a significant impact on the chemistry of these compounds, and consequently, their 
interactions within biological systems under different contexts. Indeed, though these 
compounds may display similar activity under one condition encountered in the 
neurodegenerative process, such as oxidative stress, under other disease conditions, their 
activity may differ substantially from one another. This was most clearly demonstrated in 
vitro under conditions of nitrosative stress induced by nitric oxide.  
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While both kuromanin and its metabolite, PCA show impressive neuroprotective 
effects in CGNs insulted with the nitric oxide donor, sodium nitroprusside (SNP), 
callistephin and HBA offer no protection from nitric oxide toxicity (Chapter 2, Section 
2.4.3; Chapter 4, Section 4.4.2). However, when comparing the molecular structures of 
these compounds, it becomes readily apparent that both kuromanin and PCA possess a 
catechol moiety, a feature that both callistephin and its metabolite, HBA, lack. In Chapter 
2, we define the mechanism of neuroprotection against nitric oxide for kuromanin, and 
propose that this process is dependent upon auto-oxidation of the catechol moiety on the 
B-ring of this anthocyanin to generate superoxide. Superoxide then acts in turn as a 
scavenger of toxic nitric oxide radicals. Since callistephin lacks a catechol structure, it is 
incapable of participating in this reaction, and offers no neuroprotection. As PCA and 
HBA can be derived from the B-rings of kuromanin and callistephin respectively, and 
demonstrate the same neuroprotective capacities as their parent compounds against nitric 
oxide, it is reasonable to assume that the mechanism of PCA’s neuroprotective abilities in 
this context are similar to those of kuromanin. As nitric oxide toxicity plays a prominent 
role in the neurodegenerative process, the ability to mitigate nitrosative stress is a 
desirable feature in any potential therapeutic agent and makes kuromanin and PCA 
appealing in this regard. However, the complex nature of ALS pathology is also driven 
by other factors such as excitotoxicity. 
In the context of glutamate excitotoxicity, both callistephin and kuromanin acted 
as effective neuroprotective agents; however the neuroprotective abilities of their 
metabolites, HBA and PCA, are widely divergent. While HBA offers significant 
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protection from this insult, PCA does not significantly alter glutamate-induced toxicity 
(Chapter 4, Section 4.4.3). This again illustrates the significant contribution of chemical 
structure to differences in the neuroprotective effects of these compounds as HBA and 
PCA share a significant degree of structural homology, differing only by the presence of 
an additional hydroxyl group on the phenolic ring of PCA. While the mechanism 
underlying this effect has not been defined, the ability of anthocyanins and HBA to 
defend primary neurons from excitotoxic stress represents another desirable therapeutic 
feature in these compounds. Additionally, the differential neuroprotective abilities of 
PCA and its parent anthocyanin, kuromanin, highlight another vital consideration for 
identifying novel therapeutic agents for neurodegeneration in that the beneficial effects of 
parent compounds are not always retained by their metabolites. This consideration 
becomes particularly important when assessing the activity of these compounds in vivo, 
where extensive metabolism of parent compounds takes place, particularly with oral 
consumption. 
 Lastly, although the anti-inflammatory effects of parent anthocyanins were not 
evaluated in this work, we again observed substantially different results on the 
inflammatory phenotype of microglia treated with lipopolysaccharide (LPS) and either 
HBA or PCA. Indeed, PCA was able to attenuate microglial inflammation as measured 
through production of nitric oxide and iNOS; however HBA did not display this ability 
(Chapter 4, Section 4.4.4). While further investigation is needed to define the mechanism 
by which PCA mitigates iNOS induction and nitric oxide production, this example also 
highlights how similar compounds can act in very different ways depending on the 
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context of the disease. Anti-neuroinflammatory activity is yet another desirable trait of 
potential therapeutic candidates for neurodegeneration given the role of glial 
inflammation in ALS, making PCA an appealing therapeutic candidate in this regard.  
Based upon these considerations, kuromanin and PCA emerge as having the 
broadest range of neuroprotective activity against diverse sources of neurotoxicity among 
anthocyanins and their metabolites respectively. This makes them appealing therapeutic 
candidates for diseases such as ALS; however, while their in vitro activity is promising, it 
is of great import to consider how these compounds may behave in vivo before selecting 
a particular agent for preclinical development.  
  
6.2.2 Bioavailability, Metabolism and Absorption of Anthocyanins and Their 
Metabolites 
As previously discussed, the overall bioavailability of anthocyanins is quite low, 
particularly in comparison to their phenolic acid metabolites (Youdim et al. 2003, 
Andres-Lacueva et al. 2005, Passamonti et al. 2005, Talavera et al. 2005, El Mohsen et 
al. 2006, Vitaglione et al. 2007, Azzini et al. 2010). This is due in part to their extensive 
degradation in the intestinal tract; however other factors also affect the abundance of 
these compounds in relevant tissues. It has been described previously that anthocyanins 
interact in differing degrees with lipid membranes dependent upon the number of 
hydroxyl groups on the compound (Youdim et al. 2003, Brown and Kelly, 2007, Faria et 
al. 2014). The capacity to interact with membranes significantly affects the ability of 
anthocyanins to be absorbed across epithelial and endothelial cell layers in vitro, such as 
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those observed in the intestine and the blood brain barrier (Youdim et al. 2003, Faria et 
al. 2014).  Similar trends have been described for anthocyanin metabolites, which display 
an increasing ability to mitigate lipid peroxidation in direct correlation with their relative 
lipophilicity (Brown and Kelly, 2007). This study also demonstrated that phenolic acids 
like PCA were more effective at interacting with lipid-rich environments and preventing 
lipid peroxidation than their parent anthocyanins, strongly suggesting that these 
compounds may be taken up at a higher rate than parent anthocyanins. This data is 
supported by the observation that PCA accumulates in serum at levels significantly 
greater than that of parent compounds (Vitaglione et al. 2007, Azzini et al. 2010). 
However, it is important to note that to our knowledge, there are currently no studies 
directly evaluating the interaction of phenolic acid metabolites with lipid membranes, and 
the mechanism by which these compounds are absorbed in the gut after generation by 
microflora is undefined. Nevertheless, the findings discussed above suggest that parent 
anthocyanins may not be an ideal choice as therapeutic agents for neurodegeneration, 
though the relatively high absorption of metabolites like PCA is encouraging.  
Metabolism also significantly impacts bioavailability, as observed with 
anthocyanins, which are degraded in the gut to form phenolic acids and aldehydes in 
addition to forming methylated, sulfated, glucuronidated, and glycosylated conjugates 
(Gonthier et al. 2003, Manach et al. 2005, Fleschhut et al. 2006, Woodward et al. 2009, 
Forester and Waterhouse, 2010, Woodward et al. 2011). Thus, while we observed 
positive effects on disease onset and lifespan, as well as histopathological indices of 
disease in the hSOD1G93A mouse model of ALS, it is very likely that these effects were 
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mediated by anthocyanin metabolites formed in vivo after oral ingestion (Chapter 3). 
Thus, we next explored the therapeutic efficacy of direct supplementation with the 
anthocyanin metabolite, PCA. PCA administration significantly extended survival in 
hSOD1G93A mice, and preserved grip strength through the initial portion of the disease 
course, which provided encouraging results for the therapeutic efficacy of this compound 
in ALS. However, while the metabolism of anthocyanins has been studied extensively, 
metabolism of phenolic acids like PCA is less understood. It has been shown in vitro that 
incubation of PCA with liver microsomes forms glucuronidated conjugates of this 
compound, and a study in healthy human subjects administered cyanidin-O-3-glucoside 
found several PCA-derived metabolites in serum up to several hours after anthocyanin 
consumption (Woodward et al. 2011, de Ferrars et al. 2014). With this in mind, it will be 
of great interest in the future to determine how PCA is metabolized when administered 
directly as a purified substance, as extensive degradation or alterations to this compound 
could modify its activity and therefore its efficacy as a potential therapeutic for ALS and 
related diseases.  
 
6.2.3 The “Dying-Back” Phenomenon: Beyond the Neuroprotective Effects of 
Anthocyanins and Their Metabolites 
Since ALS is characterized by the selective death of motor neurons, most 
therapeutic strategies are designed with the goal of achieving neuroprotection, often 
measured by preservation of motor neuron cell bodies in spinal cord tissue. However, this 
assay of neuronal viability does not take into account the functional state of surviving 
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motor neurons with regards to muscle innervation. Indeed, it has been observed in ALS 
mouse models that nerve terminals and NMJs begin to degrade early on in the disease 
while neuronal cell bodies in the spinal cord remain largely intact, leading to the 
development of the “dying-back” hypothesis (Fischer et al. 2004). This suggests that 
motor neuron dysfunction begins with loss of axonal health and subsequent axonal 
retraction, which occurs long before indices of neuronal death are observed in the spinal 
cord. It is now widely accepted that the dying-back phenomenon precedes overt loss of 
motor function and neuronal death; however, until recently, many studies to identify 
novel treatment strategies have focused around physically preserving motor neurons in 
the spinal cord, but have given little regard to preserving the functionality of these cells 
for muscle innervation. 
Dying-back of motor neuron axons is thought to be the result of multiple intrinsic 
factors affecting motor neurons such as impaired axonal transport and mitochondrial 
dysfunction (reviewed by Dadon-Nachum et al. 2011). For example, previous work in 
our lab has demonstrated that members of the Rho family of GTPases, which play a role 
in neuronal survival and axonal outgrowth, are dysregulated in spinal cord motor neurons 
in the hSOD1G93A mouse model of ALS. Indeed, Rac1, which promotes neuronal survival 
and axonal outgrowth, is diminished in spinal motor neurons of hSOD1G93A mice in 
comparison to non-transgenic wild type (WT) controls. Conversely, RhoB, which plays a 
role in promoting neuronal death and axonal retraction, was found to be re-distributed to 
motor neuron axons in hSOD1G93A mice, while remaining localized in the cell body in 
WT controls (Stankiewicz, 2014). 
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Additionally, the role of non-cell autonomous mechanisms has also been 
implicated in the dying-back phenomenon as new evidence emerges to suggest that 
skeletal muscle may contribute to axonal dysfunction and subsequent neuronal death 
(reviewed by Loeffler et al. 2016). Like motor neurons, oxidative stress and 
mitochondrial dysfunction have been documented in skeletal muscle isolated from mice 
harboring mutant forms of SOD1. Moreover, several studies have emerged highlighting 
the beneficial role of targeting skeletal muscle for treatment on overall disease pathology. 
In particular, one study demonstrated that overexpression of insulin-like growth factor-1 
in muscle tissue of hSOD1G93A mice decreased inflammation and motor neuron death in 
spinal cord tissue in addition to diminishing muscle atrophy and preserving NMJs 
(Dobrowolny et al. 2005). In a related manner, increases in brain-derived neurotrophic 
factor (BDNF) in skeletal muscle caused by motor activity correlated with enhanced 
muscle re-innervation following nerve crush injury, suggestive of a role for muscle-
derived neurotrophic factors in muscle innervation (Sartini et al. 2013). Collectively, 
these data suggest that it is important to examine the effect of novel therapeutic 
compounds for ALS, such as anthocyanins and their metabolites, on both intrinsic factors 
and extrinsic muscle-derived factors involved in the retraction of motor axons from 
skeletal muscle.  
While the effects of anthocyanins and their metabolites on the activity and 
regulation of Rac and Rho have not been examined in neurons, PCA has been shown to 
modulate the activity of RhoB in melanoma cells (Lin et al. 2011). While PCA treatment 
increased expression of RhoB in this system, it is important to note that anthocyanins 
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display opposite effects on cellular signaling pathways in cancer cells and neurons, such 
as promotion of pro-apoptotic signaling in the former and diminished pro-apoptotic 
signaling in the latter (Ross et al. 2012). Thus, it is possible that PCA may modulate 
RhoB expression and activity in neurons in a manner opposite to that observed in 
melanoma cells. With this in mind, the Rho signaling pathway could represent an 
interesting point for future examination of therapeutic interventions with PCA to prevent, 
and perhaps reverse, the dying back phenomenon that is observed to precede motor 
neuron death in ALS. Furthermore, it has been previously reported that anthocyanins and 
PCA are capable of increasing BDNF levels in brain through activation of cAMP 
response element binding protein (Williams et al. 2008, Song et al. 2014) Although it is 
currently unknown if anthocyanins or their metabolites are also able to modulate BDNF 
levels in skeletal muscle tissue, this ability could potentially be used to stimulate re-
innervation by motor axons and prevent the dying-back phenomenon. This idea is 
supported by our data demonstrating that anthocyanin supplementation preserves NMJ 
size and architecture in skeletal muscle tissue from hSOD1G93A mice, which corresponds 
to preserved muscle function and grip strength (Chapter 3, Section 3.4). As PCA also 
appears to preserve grip strength in this model, it will be of great interest to evaluate the 




6.2.4 Timing and Standardization of Treatment with Anthocyanins and Their 
Metabolites 
Practical considerations must also be kept in mind when evaluating anthocyanins 
and their metabolites as potential therapeutic agents for ALS. Chief among these is the 
time at which these agents can be administered and still provide a measurable effect. Up 
to this point, many studies have identified potential therapeutic compounds by 
presymptomatic administration of these substances in ALS mouse models; however the 
translation of these agents into clinical settings has yielded incredibly poor results on a 
universal scale (Ludolph et al. 2007, Wilkins et al. 2011). Traditionally, studies have 
been conducted in this manner to ensure that promising therapeutic candidates are not 
inadvertently overlooked due to poor performance when administered at later disease 
stages in animal models displaying very aggressive forms of ALS, such as the 
hSOD1G93A mouse model (Leitner et al. 2009). Nevertheless, this treatment paradigm is a 
poor representation of clinical practices. Since the vast majority of ALS patients are 
diagnosed with the sporadic form of the disease, treatment in the clinic cannot begin until 
after the initial onset of symptoms. Thus, it is becoming a more common practice to 
evaluate potential therapeutic candidates at both presymptomatic ages and the time of 
disease onset, which represents a more clinically relevant time point for translational 
research. 
In the present work, we defined the therapeutic benefits of administering 
anthocyanins at a presymptomatic age and observed a significant shift in disease 
progression as well as positive impacts on grip strength and histopathological indices of 
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disease (Chapter 3). However, while these results are very encouraging, it is important to 
note that the poor correlation between the success of potential therapeutic agents in 
preclinical animal models and the success of these compounds in human patients 
necessitates evaluation of the therapeutic efficacy of anthocyanins at a later disease stage. 
However, given that the beneficial effects of anthocyanin treatment in the hSOD1G93A 
mouse model of ALS were likely mediated by anthocyanin metabolites rather than the 
parent compounds, we instead evaluated the therapeutic benefits of the anthocyanin 
metabolite, PCA, at disease onset. Preliminary data in this study demonstrated that PCA 
significantly slows disease progression in treated mice when administered at this later 
disease stage, providing further compelling evidence that PCA may be a viable 
therapeutic candidate for the treatment of ALS, particularly in light of its success at a 
clinically relevant time point in the disease.  
One more practical consideration for the use of anthocyanins and their 
metabolites for the treatment of ALS is the ability to standardize the production and use 
of these compounds. Currently, purified anthocyanins are very costly, one reason many 
investigators choose to evaluate the beneficial effects of these compounds using 
anthocyanin-enriched extracts. However, the success of anthocyanin extraction is 
dependent upon many factors such as temperature, solvent, and pH, which can 
significantly affect the anthocyanin content of the end product (Revilla et al. 1998, Lu 
and Foo, 2001, Kahkonen et al. 2003, Lapornik et al. 2005, Monrad et al. 2010). 
Furthermore, solvents that are safe for human consumption following extraction, such as 
ethanol and water, are less efficient for extracting anthocyanins from plant material than 
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solvents such as methanol that carry a risk of toxicity (Lapornik et al. 2005). Thus, the 
use of anthocyanin extracts on a large scale for the treatment of diseases such as ALS 
poses many challenges with regards to standardization and quality control, while the use 
of commercially available purified anthocyanins is cost prohibitive. Phenolic acids such 
as PCA, however, are commercially available as highly purified isolates for a relatively 
low cost, making this compound highly appealing for drug development and future 
clinical use. Thus, with these and the aforementioned considerations in mind, we 
conclude that PCA is the most promising therapeutic candidate of the compounds 
examined in this work, and suggest that this compound may be of significant therapeutic 
benefit for the treatment of ALS. Nevertheless, further study is required to more 
rigorously examine the effects of PCA administration on disease progression and muscle 
function, as well as to define its mechanisms of action in vivo in the preclinical 
hSOD1G93A mouse model. 
 
6.3 Future Directions for Therapeutic Development 
In the future, it will be of considerable interest to assess the effects of PCA 
supplementation on histopathological indices of disease in order to determine its 
mechanism of action. Given the very promising effects PCA administration has had on 
clinical indices of disease, such as survival and hind limb grip strength, we predict that 
we will observe positive effects on ALS disease pathology. Taken together with the 
considerations discussed above, we suggest that PCA may be of significant clinical 
 
205 
benefit to patients suffering from this devastating disease, and following further 
preclinical assessment, we hope to pursue a clinical trial with this compound.  
Additionally, it would be of significant clinical relevance to evaluate the potential 
additive or synergistic effects with other established and experimental treatments for 
ALS. For example, in vitro experiments demonstrated that PCA does not protect neurons 
from glutamate excitotoxicity. Therefore, combining this compound with Riluzole, an 
anti-glutamatergic drug, could have significant synergistic effects on ALS disease 
progression and pathology as it would target a broader array of factors contributing to 
motor neuron death.  
PCA may also be uniquely suited for administration in studies evaluating the 
efficacy of stem cell therapy for ALS. While these studies initially sought to replace 
dying motor neurons with those derived from healthy stem cells, this approach had many 
obstacles, and current research has now turned to protecting existing motor neurons by 
implanting neural progenitors into spinal cord tissue, which then differentiate into 
healthy, wild type astrocytes (reviewed by Haidet-Phillips and Maragakis, 2015). 
Astrocytes derived from this process are then thought to integrate into spinal cord tissue 
and secrete protective neurotrophic factors to support and repair injured motor neurons. 
This strategy has yielded promising results in rodent models of ALS, and recently, a 
Phase I clinical trial assessing the safety and feasibility of stem cell injection into the 
spinal cord of ALS patients was completed (Lepore et al. 2008, Glass et al. 2012, 
Feldman et al. 2014, Kondo et al. 2014, Chen et al. 2015). Concerns still exist, however, 
as to relative survival and differentiation of transplanted stem cells, and speculation as to 
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whether stem cell-derived astrocytes will become inflammatory upon encountering the 
toxic environment of the ALS spinal cord as arisen (Haidet-Phillips and Maragakis, 
2015). Recently, however, it was shown that PCA is able to enhance differentiation of rat 
neural progenitors into neurons in vitro in addition to decreasing cell death in 
differentiating cell populations of both neurons and glia (Guan et al. 2009, Guan et al. 
2011). While PCA modestly decreased the number of cells that differentiated into 
astrocytes in this paradigm, these studies also reported increases in antioxidant enzymes 
and decreased levels of reactive oxygen species in all differentiated cell types in the 
presence of PCA (Guan et al. 2011). This suggests that the overall health of the astrocytes 
derived from this process may be superior to that of astrocytes derived under standard 
differentiating conditions, which could prevent their transition to an inflammatory state. 
Taken together with our data demonstrating that PCA may be an effective anti-
inflammatory compound, this suggests that PCA administered in tandem with neural 
progenitors in ALS spinal cord may encourage stem cell differentiation and survival in 




In conclusion, this dissertation has established the therapeutic potential of two 
anthocyanins, callistephin and kuromanin, and their metabolites, HBA and PCA, for the 
treatment of ALS. Specifically, our work has defined the differential neuroprotective and 
anti-inflammatory capabilities of these compounds in vitro. In addition, this work is the 
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first to evaluate the use of an anthocyanin-enriched extract, and the anthocyanin 
metabolite, PCA, as therapeutic agents in the preclinical hSOD1G93A mutant mouse model 
of ALS. The results of this work provide important data highlighting the therapeutic 
efficacy of these compounds in vivo, and suggest that the use of anthocyanins and their 
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APPENDIX A: ABBREVIATIONS 
 6-OHDA: 6-hydroxydopamine 
AIF: Apoptosis-inducing factor 
ALS: amyotrophic lateral sclerosis 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA: analysis of variance   
APAF-1: apoptosis protease activating factor-1 
APP: amyloid precursor protein 
ASK1: apoptosis signal-regulating kinase 1 
BAE - blackberry anthocyanin extract  
BBB: blood brain barrier 
BDNF: brain derived neurotrophic factor  
BiP: binding immunoglobulin protein 
BSA: bovine serum albumin  
BTx: α-bungarotoxin 
CGN: cerebellar granule neurons  
CHOP: C/EPB homologous protein 
CNS: central nervous system  
COX-2: cyclooxygenase-2  
CytC: cytochrome c 
DMEM: Dulbecco’s Modified Eagle Medium 
DMSO: dimethyl sulfoxide 
DPPH: 1,1-diphenyl-2-picrylhydrazyl 
EAAT2: excitatory amino acid transporter-2 
EGFP: enhanced green fluorescent protein 
ER: endoplasmic reticulum 
ERK1/2: extracellular signal-regulated kinase 1/2 
FasL: Fas ligand 
FBS: fetal bovine serum 
FUS: fused in sarcoma 
GA: gallic acid 
γ-GCL: γ-glutamylcysteine ligase 
GFAP: glial fibrillary acidic protein 
GSH: glutathione 
GSSG: oxidized glutathione 
H2O2: hydrogen peroxide 
HBA: 4-hydroxybenzoic acid 
HO2: superoxide radical 
HRP: horseradish peroxidase 
hSOD1G93A: human Cu, Zn-superoxide dismutase with a glycine to alanine substitution at 
position 93 




iNOS: inducible nitric oxide synthase 
JNK: c-Jun-N-terminal kinase 
LPS: lipopolysaccharide 
MCLA: 2-Methyl-6-(4-Methoxyphenyl) -3,7-Dihydroimidazo[1, 2-A]pyrazin-O-3ne, 
Hydrochloride  
MCP-1: monocyte chemoattractant protein-1 
MPP+: 1-methyl-4-phenylpyridinium 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mTOR: mammalian target of rapamycin 
NF-κB: nuclear factor-κB  
NMDA: N-methyl-D-aspartate 
NMJ: neuromuscular junction 
NO: nitric oxide 
NOX-2: NADPH-oxidase-2 
Nrf2 : nuclear factor erythroid 2-related factor 2 
OCT: optimal cutting temperature 
ONOO-: peroxynitrite 
ORAC: oxygen radical absorption capacity 
p38-MAPK: p38-mitogen activated protein kinase  
PaGE: paw grip endurance 
PBS: phosphate buffered saline 
PCA: protocatechuic acid 
PDI: protein disulfide isomerase  
PEG-SOD: polyethyleneglycol-superoxide dismutase 1 
PERK: endoplasmic reticulum kinase 
PI3K: phosphoinositide-3-kinase 
PS1: presenilin-1 
PTEN: phosphatase and tensin homolog 
PVDF: polyvinylidene difluoride 
QR1: quinone oxidoreductase 1 
QR2: quinone oxidoreductase 2 
RNS: reactive nitrogen species 
ROS: reactive oxygen species 
SAE: strawberry anthocyanin extract  
SAMP8: senescence-accelerated mouse prone 8  
SEM: standard Error of the Mean 
SNP: sodium nitroprusside 
SOD1: Cu, Zn-superoxide dismutase 
SOD2: Mn-superoxide dismutase 
TDP-43: TAR DNA-binding protein-43  
TFA: trifluoroacetic acid  
TNF-α: tumor necrosis factor-α  
UPR: unfolded protein response 




APPENDIX B: LIST OF PUBLICATIONS 
 
 Chapter 2, entitled “Chemical Basis for the Disparate Neuroprotective Effects of 
the Anthocyanins, Callistephin and Kuromanin, Against Nitrosative Stress” is in revision 
for the Journal of Biological Chemistry. 
 
 Chapter 3, entitled “An anthocyanin-enriched extract from strawberries delays 
disease onset and extends survival in the hSOD1G93A mouse model of amyotrophic lateral 
sclerosis” is in preparation for submission to the Journal of Neuroscience. 
 
 Chapter 4, entitled “Comparison of the distinct neuroprotective and Anti-
Inflammatory effects of the phenolic acids, protocatechuic acid and 4-hydroxybenzoic 
acid” is in preparation for submission to the Journal of Neurochemistry. 
